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ADAMTS5 is a member of A Disintegrin-like and Metalloproteinase with 
ThromboSpondin Motifs (ADAMTS) family of secreted metalloproteinases 
with multiple proteoglycan substrates. Although this proteoglycanase is well 
characterized as the major aggrecanase and implicated in cartilage degradation 
in osteoarthritis, how it influences angiogenesis and cancer remains unclear. 
Our lab has previously shown that the first thrombospondin type 1 repeat 
(TSR1, the central TSR) but not TSR2 (the C-terminal TSR) of ADAMTS5 is 
anti-angiogenic in vitro. Coupled with prior reports that ADAMTS5 
expression is altered in several human cancers, we hypothesized that this 
proteoglycanase may play an important role in angiogenesis and cancer.  
This PhD thesis work reports a previously un-realized function of 
ADAMTS5 as an anti-angiogenic, anti-tumorigenic and anti-metastatic protein 
independent of its function as a proteoglycanase. In this work, I demonstrate 
that full-length ADAMTS5 and its autocatalytic N-terminal fragment (TS5-
p45) inhibit angiogenesis in vitro. TS5-p45 inhibits endothelial cell tube 
formation on Matrigel, cell proliferation and induced apoptosis through a 
caspase dependent pathway. The angiostatic function of ADAMTS5 is 
independent of its proteoglycanase function as TS5-p45 retained its angio-
inhibitory potential in the presence of ADAMTS5 inhibitor.  
I further showed that stable overexpression of the full-length ADAMTS5 
or its naturally existing autocatalytic fragments suppressed subcutaneous B16 
melanoma growth in mice. The reduced tumor growth is primarily a result of 
diminished tumor angiogenesis coupled with reduced tumor cell proliferation 
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and increased tumor cell apoptosis. The catalytic activity of ADAMTS5 is 
dispensable for its anti-tumorigenic function since the full-length active site 
mutant E411A presented similar tumor suppression activity. Domain mapping 
and mechanistic studies revealed that ADAMTS5 inhibits tumor growth 
through its TSR1 domain by suppressing tumor angiogenesis. 
To further elucidate the molecular mechanisms of anti-angiogenic/anti-
tumorigenic function of ADAMTS5, mouse angiogenesis antibody array was 
probed with total protein lysate of B16 mouse melanoma overexpressing 
ADAMTS5 and the corresponding vector control. Notably, no upregulation of 
any angiogenesis regulating proteins was observed. However, there was a 
significant down-regulation in the production of several pro-angiogenic factors 
such as vascular endothelial growth factor (VEGF) (~2 fold), placenta growth 
factor (PlGF) (~3 fold), platelet-derived endothelial growth factor (PD-ECGF) 
(~2 fold), insulin-like growth factor binding protein 3 (IGFBP-3) (~3 fold) and 
plasminogen activator inhibitor-1(PAI-1) (~2 fold) in the tumor milieu. This 
downregulation of pro-angiogenic factors is likely a major reason for the 
reduced tumor angiogenesis in ADAMTS5 overexpressing B16 melanoma. 
To explore the role of ADAMTS5 in human cancers, stable lines 
overexpressing ADAMTS5 were generated in A549, a human lung 
adenocarcinoma cell line. Nude mice xenograft studies showed that 
overexpression of ADAMTS5 suppressed subcutaneous tumor growth in nude 
mice. Suppression of tumor growth was coupled with reduced tumor 
vascularization and tumor cell proliferation plus enhanced tumor cell 
apoptosis. Thus, ADAMTS5 also suppresses human lung adenocarcinoma 
growth in mice and most likely plays a role in human cancer.    
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I further investigated the role of ADAMTS5 in metastasis using the mouse 
B16 cell line in an experimental pulmonary metastasis model. Overexpression 
of ADAMTS5 significantly suppressed B16 melanoma metastasis to lung. 
Two weeks after tail vein delivery of ADAMTS5-overexpressing B16 cells, an 
obviously reduced metastatic load in the lung were observed.  This 
suppression was independent of the catalytic function of ADAMTS5. 
Reduction in the tumor angiogenesis in these metastatic foci was also 
observed. Thus, ADAMTS5 inhibits mouse melanoma metastasis to lung 
likely by suppressing tumor angiogenesis.  
To investigate if ADAMTS5 also has anti-angiogenic function in normal 
physiology, I used zebrafish as a model. The expression pattern of zebrafish 
adamts5 gene was investigated during embryonic development as well as in 
adult tissues. Expression of adamts5 in zebrafish embryos correlated with the 
expression pattern of proteoglycans such as aggrecan and brevican. 
Morpholino antisense oligonucleotide based gene expression knockdown of 
adamts5 showed severe morphological defects during early embryogenesis 
such as distorted body axis, severely curled tail etc. However, no disturbance 
in embryological vasculogenesis or angiogenesis upon knockdown of adamts5 
in transgenic fish Tg(fli1:EGFP) were observed. These results suggest that 
either adamts5 is not important for developmental vasculogenesis and 
angiogenesis, or that there are redundant functions by other adamts members 
in zebrafish. Further research is required to clarify these possibilities in future.  
In summary, this study demonstrated a novel function of ADAMTS5 as an 
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CHAPTER 1: INTRODUCTION 
1.1 Angiogenesis 
Angiogenesis, the formation of new capillaries from the pre-existing ones, 
is an important process involved in various physiological as well as 
pathophysiological processes (Carmeliet, 2003; Folkman, 1995). Blood 
vessels are the constant source of nutrition, gas exchange and waste excretion 
from the cells and tissues. Mammalian cells require continuous source of 
oxygen supplied by the blood vessels in their vicinity. Every cell in the body is 
located very close to a blood vessel, the distance being 100 to 200 µm, which 
is the diffusion limit of oxygen (Carmeliet & Jain, 2000).  
 
Fig. 1.1 Origin and assembly of vasculature: The vertebrate 
vasculature comprises of vasculogenesis, angiogenesis and 
lymphangiogenesis that ensures efficient and simultaneous transport of 
gases, liquids, cells and signaling molecules. This is ensured by two 
tubular networks – blood vessels and lymphatic vessels, which are 
formed by ECs.(EPC- Endothelial Progenitor Cells, vSMC-vascular 
Smooth Muscle Cells, LEC – Lymph Endothelial Cells) (Adapted from 
(Adams & Alitalo, 2007)).  
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Angiogenesis differs from vasculogenesis that the former is formed from 
the pre-existing vessels whereas vasculogenesis is formation of new blood 
vessels (de novo) from precursor cells in the embryo or the circulating or 
tissue-resident angioblasts in adult (Patan, 2000). On the other hand, 
lymphangiogenesis is the formation of the lymphatic vessels from the pre-
existing lymph vessels, similar to angiogenesis (Adams & Alitalo, 2007) (Fig. 
1.1). 
 
Fig. 1.2 Types of angiogenesis: A. Sprouting angiogenesis. B. 
Intussusceptive angiogenesis. (Adapted from (Carmeliet & Jain, 
2011)). 
Angiogenesis can be classified into two types: i) Sprouting angiogenesis:  
This occurs in embryogenesis during which there is proteolytic degradation of 
the extracellular matrix (ECM) followed by the chemotactic migration and 
proliferation of the endothelial cells (ECs) leading to the formation of lumen 
resulting in capillary. The sprouting angiogenesis have a tip cell that is leading 
the ECs, which is a hallmark of sprouting angiogenesis (Risau, 1997). ii) 
Intussusceptive angiogenesis: Also referred to as non-sprouting angiogenesis, 
it involves splitting of the pre-existing vessels by transcapillary pillars of 
ECM. This is a sequential process involving establishment of a zone of contact 
between two opposing capillaries, formation of EC junction, perforation and 
formation of a lumen (Burri et al, 2004). There is also report of the insertion 
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of tissue pillars helping in splitting vessels leading to expansion of vessels 
(Djonov & Makanya, 2005) (Fig. 1.2).  
1.2 Angiogenesis in physiology and pathology 
Angiogenesis and vasculogenesis occur pre-dominantly during embryonic 
development. In adult physiology, angiogenesis is limited to reproductive 
cycle and wound repair (Carmeliet, 2005). In normal physiology, angiogenesis 
is tightly regulated involving a delicate balance between pro-angiogenic 
growth factors and inhibitors. The imbalance in this regulation is observed in 
various pathophysiological conditions. Both excessive and insufficient 
angiogenesis is detrimental (Folkman, 1995).  Insufficient angiogenesis results 
in pathogenesis of a variety of disorders such as stroke (Slevin et al, 2006), 
chronic wound (Tonnesen et al, 2000), ulceration (Jenkinson et al, 2002), 
ischemia (Friehs et al, 2004; Ye et al, 2004), hair loss (Yano et al, 2001), 
hypertension (Sica, 2006) etc. Excessive angiogenesis is implicated in cancer 
(Folkman, 1995), rheumatoid arthritis (Marrelli et al, 2011), diabetic 
retinopathy (Antonetti et al, 2012), psoriasis (Heidenreich et al, 2009), 
atherosclerosis (Slevin et al, 2009), endometriosis (Taylor et al, 2009), age 
related macular degeneration (Bressler, 2009) etc.  
1.3 Pro-angiogenic regulatory factors 
Angiogenesis is a complex process regulated by many soluble growth 
factors. Numerous inducers of angiogenesis have been discovered and are 
continuing to be discovered. They have been classified in various ways. Some 
of the most important growth factors can be classified as either heparin 
binding or non-heparin binding peptides. Some other belong to the class of 
inflammatory mediators, membrane bound factors, enzymes, hormones, 
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oligosaccharides, hematopoietic factors and others (Table 1.1) (Liekens et al, 
2001; Otrock et al, 2007).  
Inducers References 
Heparin binding peptide growth factors  
Vascular endothelial growth factor (VEGF) (Ferrara et al, 2003) 
Fibroblast growth factor 1 and 2 (FGF-1 and FGF-2) (Beenken & 
Mohammadi, 2009) 
Placenta growth factor (PlGF) (Ribatti, 2008) 
Platelet derived growth factor (PDGF) (Andrae et al, 2008) 
Non-heparin binding peptide growth factors  
Transforming growth factor - β (TGF-β) (Massague, 2012; ten 
Dijke & Arthur, 2007) 
Epidermal growth factor (EGF) (van Cruijsen et al, 
2005) 
Inflammatory mediators  
Tumor necrosis factor (TNF) – α (Nakao et al, 2003) 
Interleukin (IL) - 3 and 8 (Dentelli et al, 1999; 
Li et al, 2003) 
Membrane bound factors  
Integrins (Avraamides et al, 
2008) 
Vascular endothelial cadherin (VE cadherin) (Carmeliet & Collen, 
2000) 
Enzymes  
Cycloxygenase (COX-2) (Toomey et al, 2009) 
Matrix metalloproteinases (van Hinsbergh & 
Koolwijk, 2008) 
Oligosaccharides  
Hyaluronan Oligo‘s (Savani et al, 2001) 
Others  
Nitric oxide (Donnini & Ziche, 
2002) 
Table 1.1. List of endogenous angiogenesis regulators. 
A few of the key factors that orchestrate angiogenesis is discussed below:  
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1.3.1 Vascular endothelial growth factor (VEGF)  
Eventhough angiogenesis is a multi-step, complex process; it is remarkable 
that VEGF, a single growth factor is such a key regulator. VEGF is a family of 
homodimeric growth factors belonging to the platelet-derived growth factor 
family. It has at least 7 members namely –VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, PlGF and snake venom-derived VEGFs (Shibuya, 2008). 
The founding member VEGF-A is the best characterized growth factor. Vegf-
A gene is comprised of 8 exons that undergo alternative splicing resulting in 
different isoforms (Tischer et al, 1991) (Fig. 1.3). Different isoforms have 
different affinity towards ECM because of the net charge of the homodimer. 
VEGF165 is a heparin-binding glycoprotein of 45 kDa. However, VEGF121 is 
an acidic protein that does not bind heparin (Ferrara et al, 2003). 
 
Fig. 1.3 VEGF-A isoforms: Human VEGF-A comprises of 8 exons. It 
undergoes alternative splicing between exon 5 and 8 resulting in the 
multiple isoforms. Monomeric precursor of each isoform is represented 
here (Modified from (Ferrara, 2010)). 
VEGF regulates angiogenesis through its cell surface receptors.  VEGF 
binds to two highly related transmembrane receptor tyrosine kinase receptors, 
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VEGFR1 and VEGFR2. In lymphatic ECs, VEGFR3 is known to be the 
receptor for VEGF-C and VEGF-D (Lohela et al, 2009). These receptors are 
selectively expressed on ECs of vascular and lymphatic system. Neuropilin 1 
and 2 (NRP-1 and NRP-2) are the co-receptors of VEGF expressed on neurons 
and vascular endothelium (Ferrara, 2004). Both VEGFRs have seven 
immunoglobulin domains in the extracellular region, a single transmembrane 
region and a consensus tyrosine kinase sequence in the cytoplasmic region 
(Terman et al, 1991). Upon VEGF and VEGFR binding, a cascade of 
downstream signaling is initiated after the dimerization and 
autophosphorylation of the cytoplasmic domain of VEGFRs. This will finally 
lead to EC proliferation, sprouting, tube formation, migration, vasodilation etc. 
(Fig. 1.4) (Ferrara et al, 2003).  
 
Fig. 1.4 Interaction between isoforms of VEGF and VEGFRs: The 
diffusible isoforms that are not ECM bound are released and activate 
ECs through VEGFRs and NRPs (Modified from (Ferrara et al, 2003)). 
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VEGF plays an important role in both physiological and 
pathophysiological angiogenesis. Its role in neonatal and embryological 
vasculogenesis/angiogenesis was demonstrated by knockout mice studies. 
Inactivation of even a single allele of Vegf in mice resulted in embryonic 
lethality due to several developmental anomalies including defective 
vascularization (Carmeliet et al, 1996; Ferrara et al, 1996).  VEGFR-1 and 
VEGFR-2 knockout mice also showed embryonic lethality confirming the 
importance of VEGF mediated signaling during embryonic development 
(Fong et al, 1999; Shalaby et al, 1995). Administration of soluble VEGFR1 
systemically into the mice peritoneum for three successive days resulted in a 
significant inhibition of VEGF-induced angiogenesis causing growth arrest 
and kidney failure resulting in lethality suggesting its role in renal 
development (Gerber et al, 1999).  
VEGF also plays prominent roles in various human pathologies including 
cancer, diabetic retinopathy, inflammation, rheumatoid arthritis etc. 
(Carmeliet, 2005). The majority of human cancers are known to overexpress 
VEGF which plays a key role in tumor angiogenesis (Carmeliet, 2003). 
Increase in VEGF in the aqueous and vitreous humor of the eyes in patients 
suffering from diabetes mellitus is the primary cause for diabetic retinopathy 
(Aiello et al, 1994). VEGF also functions as a potent vascular permeability 
inducer (Dvorak et al, 1995a). Elevated level of VEGF and hence enhanced 
vascular permeability has been reported in psoriasis, edema and other kinds of 
inflammations (Dvorak et al, 1995b). In summary, VEGF plays a 
quintessential role in various embryological, physiological and pathological 
roles that includes angiogenesis.   
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Several VEGF inhibitors have been used or are in clinical trials for neo-
vascular diseases. These include monoclonal antibody to VEGF, anti-
VEGFR2 antibody, small molecules inhibiting downstream signaling of 
VEGF etc. (Carmeliet & Jain, 2011). Bevacizumab (Avastin), a monoclonal 
antibody targeting VEGF-A and all of its isoforms have been approved for 
metastatic colorectal cancer as a part of combinatorial approach with 
chemotherapy (Hurwitz et al, 2004).  Bevacizumab has also been approved for 
metastatic non-squamous non-small-cell lung cancer, metastatic breast cancer, 
recurrent glioblastoma multiforme and metastatic renal cell carcinoma (RCC) 
(Carmeliet & Jain, 2011). Sorafenib is a classic example of small molecule 
receptor tyrosine kinase inhibitor that inhibits VEGFR. This drug is approved 
for metastatic RCC and unresectable hepatocellular carcinoma (Escudier et al, 
2007). Two anti-VEGF compounds — intravitreous injection of the VEGF 
aptamer pegaptanib (Macugen) and the anti-VEGF Fab antibody ranibizumab 
(Lucentis) — have been approved for treatment of the wet (neovascular) form 
of age-related macular degeneration (Chakravarthy et al, 2006; Gragoudas et 
al, 2004). 
1.3.2 Fibroblast growth factor (FGF) 
FGF-2 was the first pro-angiogenic growth factor to be discovered (Shing 
et al, 1984). At present, 22 different types of FGFs have been reported in 
humans and have been encoded by 22 different genes (Itoh & Ornitz, 2004). 
They share a sequence homology of around 30-70% in their amino acid 
sequence. The FGF-1 and FGF-2 are the most studied classical FGFs. 
However, unlike other FGFs they lack a sequence for the extracellular export 
required for the secretion of growth factors. The apparent lack of regulated 
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FGF export signal has been a hindrance in accepting its role in regulating 
angiogenesis. However, there are other alternative working models reported 
for the FGF transport (Dow & deVere White, 2000).  
FGF-2, also known as the basic fibroblast growth factor is one of the most 
well studied and potent angiogenesis regulators in the FGF family. An unusual 
feature of this member (as well as FGF-3) is that they have multiple isoforms 
as a result of alternative translation start site rather than alternative splicing 
(Florkiewicz & Sommer, 1989; Prats et al, 1989) (Fig. 1.5).  FGF-2 is 
expressed in almost all organs and high expression was observed in brain and 
pituitary. It is expressed by different cell types such as fibroblast, endothelial, 
smooth muscle and glial cells (Coumoul & Deng, 2003).  
 
Fig. 1.5 FGF-2 isoforms resulting from alternative initiation 
during translation: Human FGF-2 mRNA consists of four non-
canonical CUG translation start sites upstream resulting in high 
molecular weight (Hmw) 34, 24, 22.5 and 22 kDa isoforms. The 
shorter low molecular weight (Lmw) isoform (18 kDa) is translated by 
the conventional AUG start codon. All possess nuclear localization 
signals (NLS) that imports the FGF after translation into the nucleus. 
(Adapted from (Sorensen et al, 2006)).  
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FGFs have high affinity towards heparin sulfate and their interactions with 
the heparin cell surface proteoglycan interaction are very critical for its 
receptor binding and downstream signaling (Vlodavsky et al, 1991). FGF 
receptors (FGFRs) are receptor tyrosine kinases that contain an extracellular 
ligand-binding domain, a transmembrane domain and a cytoplasmic tyrosine 
kinase binding domain. The extracellular domain contains two or three 
immunoglobulin like domains and a heparin binding domain. FGFs binds to 
FGFRs through a two-step process involving binding of FGF to heparin 
sulfate proteoglycan which further activates FGF-FGFR interaction to trigger 
the cytoplasmic signal transduction pathways resulting in endothelial cell 
proliferation, migration, differentiation, protease production and angiogenesis 
(Fig. 1.6) (Liekens et al, 2001; Sorensen et al, 2006).  
 
Fig. 1.6 FGFR receptor and FGF-FGFR interaction: A. Domain 
structure of the FGFRs. (Modified from (Bottcher & Niehrs, 2005)) B. 
FGF induced angiogenesis that involves interaction of FGF and FGFR 
with the help of heparin binding sulfate proteoglycans (HSPG). 
(Adapted from (Rak & Weitz, 2003)). 
 
There are a variety of functions attributed to FGFs in development and 
adult physiology (Bikfalvi et al, 1997; Liekens et al, 2001). FGF is known to 
be involved in hematopoiesis. FGF-2 stimulates myeloid progenitors and 
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stromal cells (Bruno et al, 1993; Harada et al, 1994). FGF is also known to be 
critical for wound healing. FGF-1 and FGF-2 has been shown to be involved 
in granulation tissue formation during wound healing. This involves 
macrophage and fibroblast migration towards the wound and EC proliferation 
helping in wound closure. FGF-1 is a chemoattractant for both ECs and 
fibroblasts (Ashton et al, 1995; Liekens et al, 2001). FGF-2 knockout mice 
shows delayed wound healing which further supports the role of FGF-2 in 
wound repair (Ortega et al, 1998). FGF-2 is also produced by various tumors 
thus signifying its role in tumor vascularization (Carmeliet, 2005; Carmeliet & 
Jain, 2000). 
1.4 Endogenous angiogenesis inhibitors 
As early as in 1971, Dr. Judah Folkman proposed that angiogenesis is a 
critical step in tumor progression and a tumor cannot grow beyond 2 mm in 
diameter without recruiting its own blood supply through secreting angiogenic 
factors. This implied that inhibition of angiogenesis can suppress tumor 
growth (Folkman, 1971). Since then, many research groups have been 
extensively investigating angiogenesis inhibition. As a result, many 
endogenous angiogenic inhibitor proteins were discovered such as 
Thrombospondin-1 (TSP-1), pigment epithelial derived factor (PEDF) etc. 
(Canfield & Schor, 1995; Dawson et al, 1999). Another class of endogenous 
anti-angiogenic peptides is the proteolytic fragment of parent proteins which 
themselves do not have any anti-angiogenic activity.  This group includes 
angiostatin (fragment of plasminogen) (O'Reilly et al, 1994), endostatin 
(fragment of collagen XVIII) (O'Reilly et al, 1997), tumstatin (fragment of 
collagen IV) (Maeshima et al, 2002) and many others (Folkman, 2004; 
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Nyberg et al, 2005; Ribatti, 2009; Sato, 2006).  Over the years, more and more 
endogenous angiogenic inhibitors have been identified and the list continues to 
grow (Kumar et al, 2009). Most notably, microRNAs have been identified to 
regulate angiogenesis directly or indirectly (Bonauer et al, 2009; Dews et al, 





Thrombospondin-1 and -2 (Good et al, 1990) 
Pigment epithelial derived factor (Dawson et al, 1999) 
Vasohibin-1 (Watanabe et al, 2004) 
Interleukin-10 and -18 (Cao et al, 1999; Silvestre et al, 
2000) 
Tissue inhibitors of 
metalloproteinases-1, -2 and -3 
(Ikenaka et al, 2003; Qi et al, 
2003; Seo et al, 2003) 
Maspin (Zhang et al, 2000) 
Interferons (Sidky & Borden, 1987) 
Platelet factor-4 (Hagedorn et al, 2001) 
Vascular endothelial growth 
inhibitor 
(Zhai et al, 1999) 
Chondromodulin (Hiraki et al, 1997) 
A Disintegrin and 
metalloproteinase with 
thrombospondin motifs 1, 2, 5, 8, 
9, 12, 
(Kumar et al, 2012a; Kumar et 
al, 2009) 
Isthmin (Xiang et al, 2011) 
Fragments: 
Endostatin (O'Reilly et al, 1997) 
Angiostatin (O'Reilly et al, 1994) 
Tumstatin (Maeshima et al, 2000) 
Vasostatin (Pike et al, 1998) 
Arrestin (Colorado et al, 2000) 
Canstatin (Kamphaus et al, 2000) 
Parstatin (Duncan & Kalluri, 2009) 
Angiostatin (O'Reilly et al, 1994) 




MicroRNAs -221/222, -15, -16, -
21, -34a, -519c, -107, -17~92 
cluster 
(Felli et al, 2005; Hua et al, 
2006; Suarez et al, 2007) 
2-methoxyestradiol (Pribluda et al, 2000) 
Table 1.2 List of endogenous angiogenesis inhibitors. 
Since the list of endogenous regulators of angiogenesis are ever-growing, 
it is evident that all have a specific role in different cell/tissues regulated 
spatio-temporally to maintain hemostasis and is deregulated in pathological 
conditions such as cancer and other angiogenesis related disorders. Thus, 
better understanding of the endogenous angiogenesis inhibitors in terms of 
their target and mechanism will lead us to design better drugs that might 
ultimately lead in combating angiogenesis related complications. 
1.4.1 Gene products 
Thrombospondins (TSPs): Thrombospondin family comprises a group of 
5 members, out of which, only TSP-1 and TSP-2 are known to have angio-
inhibitory function. Their structure has a N-terminal globular motif, a pro-
collagen region, followed by three very conserved thrombospondin repeats 
(TSR), three EGF repeats (also referred to as type 2 repeats), five calcium-
binding repeats (type 3 repeats) followed by a globular C-terminal end (Fig. 
1.7). TSP-1 and TSP-2 differ significantly in their expression as shown by 
murine expression pattern studies (Iruela-Arispe et al, 1993). In situ 
hybridization showed that TSP-1 is expressed during embryonic development 
in the brain and kidney and in megakaryocytes of liver. TSP-2 was mainly 
expressed in connective tissues such as pericardium, ligaments etc. TSP-2 was 




Fig. 1.7 Domain structure of TSP-1: Sequences of the motifs 
involved in various angio-inhibitory and other functions have been 
listed (Adapted from (Lawler, 2002)). 
TSP-1 regulates various biological functions that include cell adhesion, 
proliferation, survival, protease activation, TGF-β activation etc. (Chen et al, 
2000). The regulation of angiogenesis by TSP-1 is complex and involves both 
direct and indirect effects on ECs. Both pro- and anti-angiogenic role of TSP-1 
has been reported and it is thought to have a dual function, which is context 
and cell type dependent (Iruela-Arispe et al, 2004). The direct effects of TSP-1 
on ECs are mediated through the EC receptor CD36 (Dawson et al, 1997). The 
type 1 repeats of the TSP-1 (TSR) have been shown to be involved in its 
interaction with the receptor. Binding of TSR by TSP-1 results in activation of 
downstream pathway that include activation of cytoplasmic tyrosine kinase, 
caspase and p38 mitogen-activated protein (MAP) kinase resulting in EC 
apoptosis (Fig. 1.8)  (de Fraipont et al, 2001; Jimenez et al, 2000). Several 
synthetic peptides that include TSR sequences have been shown to inhibit 
angiogenesis both in vitro and in vivo (Iruela-Arispe et al, 1999; Tolsma et al, 
1993). The synthetic peptides those have anti-angiogenic function are not 
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over-lapping and not necessarily include the CD36 binding region suggests 
that multiple mechanisms exist (Fig. 1.8). CSVTCG sequence of TSP-1 is the 
CD36 binding site and the peptide is shown to inhibit VEGF or FGF mediated 
angiogenesis (Iruela-Arispe et al, 1999). By contrast, WSPWSHW sequence is 
known to inhibit FGF mediated angiogenesis (Guo et al, 1997). The efficacy 
of TSP-1 or its derived peptides have been tested in various tumor types and 
have been shown to be a promising anti-angiogenic and anti-tumorigenic agent 
(Bocci et al, 2003; Lawler & Detmar, 2004). Xenograft tumorigenesis studies 
in TSP-1 null mice have been shown to enhance tumor growth and 
angiogenesis as compared to wild type mice reconfirming its anti-angiogenic 
and anti-tumorigenic effect (Lawler et al, 2001). 
 
Fig. 1.8 CD-36 receptor mediated EC apoptosis by TSP-1: TSP-1 
binds to CD-36 through its TSR domain resulting in activation of 
caspase and MAPK pathway resulting in EC apoptosis and inhibition 
of angiogenesis (Adapted from (de Fraipont et al, 2001)). 
TSP-2 is also anti-angiogenic like TSP-1 in vitro (Noh et al, 2003). TSP-2 
overexpressing squamous cell carcinoma suppressed tumor growth in nude 
mice and was more potent compared to TSP-1 overexpressing tumor 
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inhibition. Cells overexpressing both TSP-1 and TSP-2 completely inhibited 
tumor growth (Streit et al, 1999).  
Pigment epithelial derived factor (PEDF): PEDF is a 50 kDa secreted 
protein first isolated from cultured pigment epithelial cells of the human fetal 
retina (Steele et al, 1993). PEDF is a non-inhibitory member of the serpin 
superfamily and was discovered to be the factor responsible for the angio-
inhibitory effect in ocular compartments (Volpert et al, 2002). The serpins 
(serine proteinase inhibitors) are structurally similar but functionally diverse 
proteins that fold into a conserved structure and employ a unique suicide 
substrate-like inhibitory mechanism. The non-inhibitory members lack this 
function. In addition to its angio-inhibitory function, PEDF is also known to 
help in growth, survival and maturation of neurons both in retina and central 
nervous system (Tombran-Tink & Barnstable, 2003).  PEDF‘s anti-angiogenic 
function is limited to the proliferating ECs as they do not affect the pre-
existing vessels (Bouck, 2002). PEDF is also known to inhibit angiogenesis in 
vivo in the retina induced by ischemia (Stellmach et al, 2001) and in tumor 
inhibition by suppressing angiogenesis (Crawford et al, 2001; Mahtabifard et 
al, 2003).  
Vasohibin-1 (VASH1): Sato‘s lab discovered this angiogenesis inhibitor 
while fishing for endogenous regulators of angiogenesis secreted by ECs upon 
VEGF stimulation (Abe & Sato, 2001). VASH1, a 42 kDa protein, was shown 
to be anti-angiogenic in vitro by inducing EC apoptosis and inhibition of EC 
proliferation (Watanabe et al, 2004). VASH1 was expressed in ECs in the 
developing mouse and human embryos (Shibuya et al, 2006) but is reduced 
post neonatal stage and observed in various tissues and organs such as brain, 
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lungs, liver, heart etc., during chick development (Nimmagadda et al, 2007). 
VASH1 was also detected in bone marrow hematopoietic stem cells (Naito et 
al, 2009). 
Tumors implanted into VASH1
-/-
 null mice was shown to be suppress 
tumor growth as a result of lack of maturation of vessels (Hosaka et al, 2009). 
Exogenous addition of VASH1 resulted in anti-angiogenesis in the sprouting 
zone but not in the termination zone of the vessels (Heishi et al, 2010). 
VASH1 was also shown to inhibit lymphangiogenesis in cornea as well as in 
tumor lymphangiogenesis (Heishi et al, 2010).  
In addition to those discussed above, number of angiogenesis inhibitors 
which are gene products have been discovered to date. Few of these include 
interleukin-1, interleukin-8, interferons, tissue inhibitors of metalloproteinase, 
platelet factor-4, vascular endothelial growth inhibitor etc. (Table 1.2).  
1.4.2 Protein fragments 
A few examples of protein fragments function as angiogenic inhibitors are 
described below: 
Arresten: Arresten is a 26 kDa protein fragment, which is a derived from 
C-terminal non-collagenous domain of the α1 chain of the type IV collagen 
(Colorado et al, 2000). Type IV collagen is the main component of vascular 
basement membrane. Arresten inhibits FGF-2 mediated EC proliferation and 
migration and induces EC apoptosis (Colorado et al, 2000). Arresten 
suppressed tumor growth and inhibited tumor vascularization in vivo in mice 
(Sudhakar et al, 2005). Arresten was shown to inhibit the expression of 
hypoxia inducible factor-1α (HIF-1α) and VEGF during hypoxia through 
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ERK1/2 and p38 pathway (Sudhakar et al, 2005). Inhibition of HIF-1α of 
arresten is most likely mediated through integrin α1β1. 
Canstatin: Canstatin is a peptide fragment of 24 kDa fragment of the α2 
chain of type IV collagen. Canstatin dose-dependently inhibited EC capillary 
tube formation and apoptosis (Kamphaus et al, 2000). Canstatin inhibits tumor 
growth and angiogenesis in vivo (Petitclerc et al, 2000). Canstatin also inhibits 
the phosphorylation of Akt, focal adhesion kinase (FAK), mammalian target 
of rapamycin (mTOR) and activation of caspases thus initiating cell death 
(Panka & Mier, 2003).  
Endorepellin: Endorepellin is an 85 kDa laminin-like domain derived 
from the C-terminus of the proteoglycan perlecan. Perlecan is a basement 
membrane heparin sulfate proteoglycan that plays key role in vascular growth. 
Endorepellin inhibits EC tube formation, migration in vitro and blood vessel 
growth in vivo (Mongiat et al, 2003).  
Endostatin: Endostatin is one of the most well studied potent 
angiogenesis inhibitor discovered in 1997 by O‘Reilly in Judah Folkman‘s 
laboratory. This 20 kDa peptide is a C-terminal cleavage fragment of collagen 
XVIII that was purified from hemangioendothelioma cell line (O'Reilly et al, 
1997). Endostatin inhibits angiogenesis directly by inducing EC apoptosis, 
inhibiting migration and proliferation (Dhanabal et al, 1999a; Dhanabal et al, 
1999b). It also affects angiogenesis indirectly by interfering with VEGF and 
VEGFR interaction and inhibition of matrix metalloproteinase 2 (MMP-2) 
activities (Kim et al, 2002; Kim et al, 2000). Recombinant endostatin was also 
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able to efficiently inhibit tumor growth and angiogenesis in vivo in various 
cancers (Boehm et al, 1997; Sund et al, 2005).  
1.4.3 Other angiogenesis regulators 
MicroRNAs: MicroRNAs are small non-coding RNAs that regulate gene 
expression by degrading the target mRNA (Pillai et al, 2007). In recent years 
more and more evidence are emerging that link miRNAs and angiogenesis. 
Dicer and Drosha are the two key enzymes involved in processing of miRNA. 
Knockdown of these two enzymes showed that angiogenesis genes were 
affected resulting in the discovery of a link between angiogenesis and 
miRNAs that led to further detailed investigations in this field (Kuehbacher et 
al, 2007; Poliseno et al, 2006; Yang et al, 2005). 
Detailed expression profiling of all the miRNAs in ECs showed that miR-
221/222, miR-21, the let-7 family, the miR-17-92 cluster, the miRNA-23-24 
cluster and miR-126 are highly expressed(le Sage et al, 2007; Sabatel et al, 
2011). Many studies have recently identified several anti-angiogenic miRNAs 
(Refer to Table 1.2). This long list includes miR-221/miR222, miR-15, miR-
16, miR-21, miR-34a, miR-519c, miRNA-107 and the miR 17-92 cluster.  
2-methoxyestradiol: This is a natural metabolite of estradiol and is an 
angiogenesis inhibitor (Fotsis et al, 1994). 2-methoxyestradiol is known to 
destabilize microtubules with nuclear accumulation and activity of hypoxia-
inducible factor 1α leading to significant reduction in VEGF levels. The 
endogenous role of this metabolite in regulating angiogenesis physiologically 




1.5 Tumor progression 
Tumorigenesis is a multi-step process during which normal cells acquire 
genetic alterations eventually resulting in neoplasm and malignancy. This has 
been supported by various studies showing that the genomes of tumor cells are 
altered at various sites, having suffered disruption such as point mutation, 
chromosomal translocation etc. (Futreal et al, 2004). Hanahan and Weinberg 
had initially characteristically described the 6 famous hallmarks of cancer cells 
that dictate cancer progression, invasion and metastasis (Hanahan & 
Weinberg, 2000). They are i) self-sufficiency in growth signals ii) insensitivity 
to anti-growth signals iii) evasion of apoptosis iv) non-stop cell proliferation 
v) vascularization for tumors and vi) ability to invade and metastasize (Fig. 
1.9A). A recent review in 2011 by the same authors have incorporated two 
new hallmarks as a result of the conceptual progress in the last decade – vii) 
reprogramming of energy metabolism and viii) evading immune destruction 





Fig. 1.9 Conventional and the emerging hallmarks of cancer: A. 
Six famous hallmarks employed by cancer for its growth and 
metastasis. B. Recent discoveries have led to the new pair of emerging 
hallmarks in cancer (Adapted from (Hanahan & Weinberg, 2011). 
Arguably, the most important step in cancer growth is its ability to 
continuously divide and it requires the mitogen signals that are dysregulated 
during cancer by continuous activation of the pathway by either producing the 
factors themselves, or inducing the normal stromal cells to do so (Cheng et al, 
2008; Lemmon & Schlessinger, 2010). Continuous growth of cancer cells  is a 
result of various somatic mutations it accumulates over the time leading to the 
activation of downstream pathway (Davies & Samuels, 2010; Jiang & Liu, 
2009).  
Cancer cells have also been observed to disrupt the negative-feedback 
mechanisms that dampen proliferation of cells (Mosesson et al, 2008). This is 
done through de-activating the various tumor-suppressors that are critical for 
the cell-cycle checkposts (Burkhart & Sage, 2008). In normal cells, cell to cell 
contact inhibition is one of the key cell division check points that have to be 
overcome if the cell has to grow limitlessly. This is taken care by primarily 
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two mechanisms involving inactivation of proteins such as merlin and LKB1 
epithelial polarity protein that are responsible for the contact inhibition (Curto 
et al, 2007; Partanen et al, 2009). Another primary hallmark of cancer is to 
resist cell death by apoptosis. Tumor cells evade death by deactivating tumor 
suppressor genes, down-regulating pro-apoptotic factors or by short-circuiting 
the extrinsic ligand-induced death (Junttila & Evan, 2009). Enabling 
replicative immortality is one more important feature of cancer that is 
achieved by overcoming cell senescence and overexpression of telomerase and 
its stabilization (Artandi & DePinho, 2010). 
When the cancer cells grow limitlessly, they face an unchangeable space 
constraint. In order to overcome this, they resort to invade and metastasize to 
other parts of the body where the cell growth and homing is easier. Metastasis 
is a sequential process involving local invasion, intravasation into the blood or 
lymphatic stream followed by extravasation into a distant site and colonization 
(Talmadge & Fidler, 2010). A developmental regulatory program –―epithelial-
mesenchymal transition‖, has been implicated in the process of invasion and 
metastasis that involves transformed epithelial cells invasion, apoptosis 
resistance and dissemination (Klymkowsky & Savagner, 2009). Recent 
discoveries have shown that in addition to all the above hallmarks there are 
more and more emerging characteristics of cancer cells such as genomic 
instability in the cancer cells resulting in mutation, silencing etc. (Negrini et 
al, 2010). This helps the cancer cells to deregulate the processes that limit 
their growth and survival. The other hallmark is the ability of the cancer cells 
to evade the immune destruction by disabling the immune system (Teng et al, 
2008). The cancer cells due to their rapid cell division rates, reprogram the 
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energy metabolism to suit their need which has become one hallmark of 
cancer (Jones & Thompson, 2009). 
1.6 Tumor angiogenesis 
Tumor angiogenesis is one of the most important hallmarks of cancer 
(Hanahan & Weinberg, 2011). Similar to normal tissues which require a 
continuous supply of nutrients, oxygen as well as removal of carbon dioxide 
and waste, tumor tissues face the same needs but with a greater demand due to 
their higher metabolic rate and cell division rate. This transition from pre-
vascular hyperplasia to highly vascularized and progressively growing tumors 
is referred to as the ―angiogenic switch‖. In adulthood, the normal vasculature 
becomes largely quiescent. Angiogenesis is turned on only under special 
circumstances such as wound healing or female reproductive cycling, but only 
transiently. On the contrary, during tumor progression, an ―angiogenic switch‖ 
is almost always activated and turned on, to fulfill the need of the actively 
dividing tumor cells (Bergers & Benjamin, 2003; Ribatti et al, 2007).   
The concept of ―angiogenic switch‖ was first formulated by the late Judah 
Folkman who spearheaded the discovery of the first angiogenic factors and 
first to demonstrate the angiogenesis induction mediated by secreted factors. 
Spontaneously arising tumors lack angiogenesis during the initial phase. In the 
pre-vascular phase, the tumor cells proliferate but the rate of tumor cell death 
counterbalances the cell division and thus limits tumor size. In order to turn on 
the ―angiogenic switch‖, the tumors modify the balance of angiogenesis 
regulators by increasing activator gene expression, changing the bio-
availability of the inducer proteins, reducing the concentration of endogenous 
inhibitors etc. (Hanahan & Weinberg, 2008) (Fig. 1.10). The tumor cells 
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switch to the angiogenic type, which is accomplished later, by the induction of 
new capillaries that converge towards the tumor. These new capillaries perfuse 
the tumor with nutrients and oxygen. The tumor ECs respond to tumor 
paracrine signals and also produce a spectrum of growth factors by themselves 
resulting in the growth of tumor cells (Baeriswyl & Christofori, 2009). 
―Angiogenic switch‖ depends on the production of one or more positive 
mediators of angiogenesis such as VEGF, FGF-2, IL-8, TGF-β, PDGF etc. 
The origin or source of these positive regulators may be tumor cells itself or 
can be mobilized from the tumor stroma or ECM. In addition, the switch 
might also be a result of downregulation of endogenous inhibitors such as 
TSP-1. Further, several other mediators such as integrins, proteases and other 
factors are also known to be altered during the vascular phase (Baeriswyl & 
Christofori, 2009). One more characteristic feature of the tumor vasculature is 
that their vessels are aberrant. It is marked by convoluted and excessive 
branching, excessive capillary sprouting leading to erratic blood flow, 





Fig. 1.10 The angiogenic switch in cancer: A. The tumor remains 
dormant at the initial phase due to the lack of blood vessels supplying 
them with nutrients and O2. B. The tumor cells initiate the process of 
angiogenesis by secreting factors resulting in vessel dilation. C. This 
results in the angiogenic sprouting. D. Angiogenesis is followed by the 
stabilization of new vessels. E. The complete functional tumor 
vascularization that is efficient in transporting nutrients and waste 
(Bergers & Benjamin, 2003). 
1.7 Anti-angiogenic cancer therapy 
Anti-angiogenic cancer therapy targeting tumor ECs offer a series of 
advantages compared to other conventional therapies such as chemo-therapy 
or radiation-therapy. Firstly, ECs are diploid, homogenous and genetically 
stable targets unlike their counterpart tumor cells that are non-homogenous, 
multiploid and genetically unstable. Secondly, the turnover of ECs in tumor 
vasculature is at least 50 fold higher than ECs in normal adult tissues. These 
active ECs express specific markers on them such as integrin αVβ3, E-selectin, 
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Tie and VEGF receptors that could be used for the development of new 
targeted therapies. Thirdly, due to the close proximity of the ECs and the 
blood vessels, the systemic administration will be feasible and very effective 
(Gasparini, 1999). Finally, since the blood vessels are in vicinity of all the 
tumor heterogeneity that is present, same approach can be used to treat 
different kind of tumor cell types (Quesada et al, 2006). 
There are different approaches for the anti-angiogenic intervention. Some 
angiogenic regulators may act on the angiogenic signals, or on one or more 
specific functions of ECs such as proliferation, apoptosis, differentiation, 
migration. Alternative methods would involve targeting mural cells in the 
vessels and other stromal cells in tumor (Fig. 1.11) (Carmeliet, 2005). All 
these agents can be classified further based on their targets. Most promising 
agents include those acting on VEGF such as anti-VEGF antibodies, or its 
receptors VEGFR. There are also small molecule inhibitors that interfere with 
downstream signaling such as MEK/ERK inhibitors. Many of these anti-




Fig. 1.11 Strategies targeting ECs and non-ECs in anti-angiogenic 
cancer therapy (BV – Blood vessel, PC - Pericytes, DC - Dendritic 
cells, LV –Lymphatic vessels, CC – Cancer cells, Ma – Macrophages, 
MC – Monocytes, CAF – Carcinoma activated fibroblasts, EPC/HPC – 
Embryonic or Hematopoietic stem cells ( Adapted from (Carmeliet, 
2005)). 
Drug Target Cancer type 
Avastin 
(Bevacizumab) 
VEGF Metastatic colorectal cancer 
(mCRC), Non-Small Cell Lung 







































EGFR Lung cancer 
Table 1.3 List of anti-angiogenesis drugs approved for clinical use 
(Modified from (Ribatti, 2010)). 
Eventhough there has been a vast progress in the discovery of 
angiogenesis inhibitors and they showing therapeutic promise in mouse 
models and some human cancers, however, in the pre-clinical and clinical 
stage anti-angiogenic cancer therapy benefits are transitory and there is a 
restoration of the tumor growth and metastasis. This is thought to be mainly 
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due to evasive resistance by the tumor to circumvent the limited vascular 
supply and intrinsic pre-existing differences in the tumors against the 
angiogenic inhibitors (Bergers & Hanahan, 2008). Further explorations to 
understand these extrinsic and intrinsic pathways and combinatorial 
approaches involving anti-angiogenic therapy combined with radiotherapy or 
chemotherapy will be more promising in the near future (Ma & Waxman, 
2008).    
1.8 Cancer metastasis 
Cancer metastasis can be defined as the spread of cancer from its primary 
site to another non-adjacent organ or part. When the cancer is detected at the 
early stage, before it has spread, it can be resected or irradiated and cured in 
most of the cases. However, once the cancer has metastasized, treatments are 
much less effective (Chambers et al, 2002). To complicate the matter further, 
for many patients who had no metastatic lesion diagnosed at the early stage 
have shown to possess metastatic foci at the later stages. This latency of the 
circulating or dormant metastasized cancer cells can take years or even 
decades to be detected (Talmadge & Fidler, 2010). Thus, cancer metastasis is 
a potential health concern for the human population.  
Carcinomas mostly arising from the epithelial tissues progress towards 
local invasion and further metastasize into distant places. Metastasis is a 
sequential process having distinct steps. Firstly, as the primary tumor grows to 
a relatively large size that restricts its further growth, the cancer cells use the 
leaky tumor vasculature to migrate to distant places. This process is known as 
intravasation. This process is also possible through the alternate channel of 
lymphatic system. The cancer cells will adapt so that they can survive in 
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circulation until they extravasate into a distant organ. Once the cells 
extravasate into the new site, cells initiate and form micrometastases and 
finally maintain growth to form macroscopic tumor that becomes clinically 
detectable (Chambers et al, 2002; Talmadge & Fidler, 2010).  
 
Fig. 1.12 Dissemination and growth of cancer cells in metastatic 
state: A. The cancer cells escape from the primary tumor site and 
arrest in secondary sites during which they remain dormant. B. 
Possible cancer cell state once they home into a secondary site where 
they remain dormant initially and later actively proliferate to form a 
tumor. (Modified from (Chambers et al, 2002)). 
These sequential steps also have distinct molecular mechanisms. In the 
initial phase during which the cancer cells are trying to intravasate to the 
tumor vessels, it involves the loss of E-cadherin, a key cell to cell adhesion 
molecule (Berx & van Roy, 2009). It is also thought that ―the epithelial-
mesenchymal transition‖ of the cancer cells helps them to successfully invade 
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and overcome the harsh condition in the blood circulation (Klymkowsky & 
Savagner, 2009). Increasing evidences also suggests a role of stromal cells in 
rendering the cancer cells invasive through cross-talk (Qian & Pollard, 2010). 
1.9 ADAMTS family 
A Disintegrin-like And Metalloproteinase with ThromboSpondin motifs 
(ADAMTSs) belong to a multi-domain, secreted, extracellular zinc 
metalloproteinase family with 19 members in humans. These extracellular 
metalloproteinases are known to cleave a wide range of substrates in the ECM 
(Stanton et al, 2011). They have been implicated in various physiological 
processes such as ECM turnover, melanoblast development, interdigital web 
regression, blood coagulation, ovulation, etc. (Apte, 2009). ADAMTSs are 
also critical in pathological processes such as arthritis, atherosclerosis, cancer, 
angiogenesis, wound healing, etc. In the past few years, there has been an 
explosion of reports concerning the role of ADAMTS family members in 
angiogenesis and cancer (Kumar et al, 2012a; Kumar et al, 2009; Wagstaff et 
al, 2011). 
1.9.1 Domain organization 
ADAMTSs have the following domains in the order from N-terminus (Fig. 
1.13): i) A signal peptide that directs the protein into endoplasmic reticulum 
and secretary pathway; ii) a prodomain which helps in maintaining enzyme 
latency (with the exception of ADAMTS7 and ADAMTS13) (Majerus et al, 
2003; Somerville et al, 2004). This prodomain is mostly cleaved by furin 
and/or other proprotein convertases (Longpre & Leduc, 2004). iii) a 
metalloproteinase domain with a zinc ion bound to conserved histidines and an 
aspartate residue in the catalytic pocket. This is characteristic of reprolysin-
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type zinc binding motif (Bode et al, 1993). In addition, this domain possesses 
a ‗met-turn‘ downstream of these histidines, characterized by the presence of a 
methionine residue. This turn helps in maintaining the structural integrity of 
these metzincins (Tallant et al, 2010). The domains C-terminal of the 
metalloproteinase domain are referred to as ancillary domains. These domains 
regulate the interaction of ADAMTS with its substrate in the ECM. They 
comprise of - iv) a disintegrin-like domain that shares sequence similarity with 
the disintegrin domain of the ADAM family known to interact with integrin. 
However, in the case of ADAMTS this is a misnomer. There is no evidence to 
date of any ADAMTS interaction with integrin through its disintegrin-like 
domain. This is because ADAMTS lacks the signature RGD integrin 
recognition sequence (Tortorella et al, 2009). v) a central thrombospondin 
type 1 repeat (TSR). This domain possesses sequence similarity of type 1 
repeats of TSP1 and TSP2. vi) a cysteine-rich region which, as the name 
suggests, is rich in cysteine residues. vii) the spacer region. The cysteine rich 
and spacer regions are the main domains binding to ECM. viii) At the C-
terminal end of the ADAMTS, there are variable numbers of TSRs. 
ADAMTS4 lacks this C-terminal TSR whereas ADAMTS9 and ADAMTS20 
have 14 TSRs (Porter et al, 2005) (Fig. 1.13). 
1.9.2 Expression  
ADAMTSs have been reported to be expressed in a wide range of tissues 
depending on its function. The expression of some ADAMTSs has also been 
characterized in the fetal tissues and embryos. All human tissues showed 
ADAMTS1 mRNA expression with high expression in heart, adrenal, 
placenta, skeletal muscle, thyroid and stomach as well as embryonic kidney 
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(Vazquez et al, 1999). ADAMTS2 mRNA was expressed at high levels in 
type-I collagen rich tissues such as skin, bones, tendons and aorta and trace 
amounts in brain and thymus (Colige et al, 1997).  
 
Fig. 1.13 Domain structures of the ADAMTS family members. 
ADAMTS4 mRNA expression was reported in brain, lung and heart along 
with very low levels in placenta and skeletal muscle (Tortorella et al, 1999). A 
recent study showed high expression of Adamts4 in murine kidney, with 
highest expression in 15.5 dpc embryos (Boerboom et al, 2011). ADAMTS8 
was found to be expressed mainly in the adult human tissues such as lung, 
brain, heart and placenta by Northern blot (Vazquez et al, 1999). Highest 
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expression of ADAMTS9 was observed in human adult tissues such as heart, 
placenta and skeletal muscle (Somerville et al, 2003). 
No ADAMTS12 expression was detected in human adult tissues by 
Northern blot. In fetal tissues, expression was restricted to fetal lung (Cal et al, 
2001). ADAMTS13 was first isolated from human plasma. ADAMTS13 was 
found to be mainly synthesized and expressed in liver. Hepatic stellate cells 
are thought to be the primary source of plasma ADAMTS13 (Fujikawa et al, 
2001; Gerritsen et al, 2001; Uemura et al, 2005).  Analysis of ADAMTS15 
expression in human fetal and adult tissues revealed that expression was 
evident only in fetal liver and kidney, while none of the adult tissues tested 
showed any presence of ADAMTS15 transcript (Cal et al, 2002). ADAMTS18 
mRNA was found to be widely expressed in all normal human tissues in high 
amounts (Jin et al, 2007). In human fetal tissues, ADAMTS18 mRNA 
expression was found in lung, liver and kidney (Cal et al, 2002). 
1.9.3 Regulation  
ADAMTSs are regulated at both transcriptional and translational level by 
various factors. At the transcriptional level, several of the catabolic agents, 
growth factors, cytokines and hormones regulate ADAMTSs (Porter et al, 
2005). For instance, ADAMTS1, ADAMTS4, ADAMTS8, ADAMTS12 
expression is regulated by cytokines and inflammatory stimulators such as 
interleukin-1 (IL-1), bacterial lipopolysaccharide (LPS) and tumor necrosis 
factor – α (TNF-α), (Kumar et al, 2012a).  
Post-translationally they have been observed to undergo zymogen cleavage 
and activation of the proteinases in most of the cases except for ADAMTS7 
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and ADAMTS13 (Majerus et al, 2003; Somerville et al, 2004). Some of the 
ADAMTS members like ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS9, 
ADAMTS12, etc. undergo auto-catalytic cleavage at their C-terminal region 
which is known to regulate the metalloproteinase function. The cleavage 
might also be a result of other proteases (Cal et al, 2001; Flannery et al, 2002; 
Zeng et al, 2006).  
1.9.4 Functions  
ADAMTS family members can be sub-divided into groups based on their 
functions.  
1.9.4.1 Proteoglycanases 
Proteoglycans are proteins that are heavily glycosylated. They consist 
of a core protein backbone with glycosaminoglycan chains attached to it 
(Hacker et al, 2005). Many of the ADAMTSs cleave one or more 
proteoglycan substrates - versican, aggrecan, brevican, neurocan etc. They 
include ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS9, ADAMTS12, 
ADAMTS15 and ADAMTS20 (Apte, 2009; Stanton et al, 2011). Aggrecan is 
the major proteoglycan in the cartilage that helps to resist compressive loads 
thus preventing joint injury leading to arthritis (Kiani et al, 2002). ADAMTS4 
and ADAMTS5 have been mainly implicated in arthritis due to their 
overexpression in arthritic cartilage. They are the most efficient aggrecanases 
and knockout studies in mice have shown that ADAMTS5 is the main 
aggrecanase (Glasson et al, 2005; Stanton et al, 2005). Versican is a main 
proteoglycan in most of the myogenic tissues and provides a loose and highly 
hydrated matrix (Wight, 2002). ADAMTS1, ADAMTS4, ADAMTS5, 
ADAMTS9 and ADAMTS20 are known to degrade versican (Stanton et al, 
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2011). Due to their role in versican degradation, ADAMTSs have been 
implicated in ovulation (Russell et al, 2003) and tissue morphogenesis 
(McCulloch et al, 2009b). 
1.9.4.2 Procollagen N-propeptidases 
Collagens comprise the major structural proteins of ECM composed of 
triple helical domains. ADAMTS2, ADAMTS3 and ADAMTS14 are involved 
in processing of procollagens to collagen by the removal of N-terminus 
propeptides (Fernandes et al, 2001). Adamts2 knockout mice develop fragile 
skin due to lack of processing of type I collagen fibrils in skin (Li et al, 2001). 
1.9.4.3 Cartilage oligomeric matrix protein degrading enzymes 
Cartilage oligomeric matrix protein (COMP) is a 534 kDa pentameric, 
multi-domain large glycoprotein found in cartilage. COMP is thought to play a 
key role in maintaining structural integrity of the cartilage by binding 
proteoglycans such as aggrecan (Tseng et al, 2009). Functional genetic assay 
based on yeast two-hybrid system revealed interaction between COMP and 
ADAMTS7 or ADAMTS12 (Liu et al, 2006a; Liu et al, 2006b). The last C-
terminal module of 4 TSRs serves as a COMP binding domain for these two 
ADAMTSs. They degrade COMP and thus affect the stability of the cartilage 
ECM. 
1.9.4.4 von Willebrand factor-cleaving protease 
ADAMTS13, popularly known as von Willebrand factor (vWF) 
cleaving protease, is one unique member of the ADAMTS family. vWF is a 
multimeric glycoprotein that mediates the tethering of platelets to vascular 
subendothelium during vessel wall damage (Denis & Lenting, 2012). 
36 
 
ADAMTS13 is of immense therapeutic interest because it is the target gene in 
thrombotic thrombocytopenic purpura (TTP). TTP is characterized by 
intravascular destruction of blood cells such as platelets and erythrocytes 
which might result in major complications such as anemia, renal failure or 
neurological dysfunction. TTP is caused due to the decreased ADAMTS13 
function as a result of mutations in ADAMTS13 gene or autoantibody 
production against ADAMTS13  (Sadler, 2008).  
1.9.4.5 Orphan ADAMTSs 
Eventhough there are 19 family members of ADAMTS, the physiological 
functions of many of them are still elusive or have not been explored. These 
include ADAMTS6, ADAMTS10, ADAMTS17, ADAMTS18 and 
ADAMTS19.  
1.9.5 ADAMTSs in angiogenesis and cancer 
Although ADAMTSs have been extensively studied for its catalytic 
function, more and more reports on their role in angiogenesis and cancer have 
emerged in recent years, with 10 out of 19 members reported so far. Many 
ADAMTS members have been shown to negatively regulate angiogenesis in 
the past decade, thus making it into the list of endogenous angiogenesis 
inhibitors (Kumar et al, 2009). It is also interesting to note that even though 
these 10 ADAMTS – ADAMTS1, ADAMTS2, ADAMTS4, ADAMTS5, 
ADAMTS8, ADAMTS9, ADAMTS12, ADAMTS13, ADAMTS15 and 
ADAMTS18 have emerged as important players in angiogenesis and/or 
cancer, their mechanisms of action are distinct. Notably, not all ADAMTS 








Role in Angiogenesis 
ADAMTS1 Yes (Pro-angiogenic) 
(Fu et al, 2011) 
Yes (Anti-
angiogenic)(Iruela-
Arispe et al, 2003) 
No (Anti-angiogenic) 
(Obika et al, 2012) 
Yes (Anti-
angiogenic)  
(Liu et al, 
2006c) 
Anti-angiogenic  
- Suppresses EC proliferation in a cell-specific, dose dependent manner (Iruela-Arispe et 
al, 2003; Vazquez et al, 1999) 
- Disrupts growth factor induced angiogenesis in vivo in a CAM model and matriplug 
assay (Vazquez et al, 1999). 
- Suppresses tumor angiogenesis in T47D human breast carcinoma  (Iruela-Arispe et al, 
2003) 
- Inhibits angiogenesis in ischemic myocardium (Nakamura et al, 2004) 
- Suppresses tumor angiogenesis in HT-1080, DU145 and CHO-K1 tumors (Obika et al, 
2012). 
- Alters blood vessel morphology in prostate tumors (Gustavsson et al, 2010) 
- Induced by VEGF in ECs and ischemia induced retinal neovascularization (Xu et al, 
2006) 
Pro-angiogenic 
- Induction of ADAMTS1 to degrade basement membrane versican in VEGF-induced 
pathological angiogenesis (Fu et al, 2011). 
- Promotes tumor angiogenesis in TA3 mammary carcinoma and Lewis lung carcinoma 
(Liu et al, 2006c) 
- Induces endothelial-like phenotype in plastic tumor cells (Casal et al, 2010) 
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ADAMTS2 No (Anti-angiogenic) 
(Dubail et al, 2010) 
Yes (Anti-
angiogenic) 
(Dubail et al, 
2010) 
Anti-angiogenic 
- Suppressed VEGF-stimulated EC proliferation in a cell-specific manner, induces 
apoptosis and inhibits capillary network formation of HUVEC (Dubail et al, 2010). 
- Increased blood vessels in vivo in a CAM model in ADAMTS2 knockout mice (Dubail et 
al, 2010). 





(Rao et al, 2012) 
Yes (Anti-
angiogenic)  
(Rao et al, 
2012) 
Anti-angiogenic 
- Anti-angiogenic peptide from ADAMTS4 TSR suppresses EC proliferation and VEGF-
induced HUVEC migration (Karagiannis & Popel, 2007). 
- Truncated ADAMTS4 fragment inhibits HuDMEC differentiation and migration in a 
scratch wound healing assay (Hsu et al, 2012). 
- ADAMTS4 C-terminal ancillary regions inhibit tumor angiogenesis (Rao et al, 2012). 
Pro-angiogenic 
- Full-length ADAMTS4 promotes tumor angiogenesis (Rao et al, 2012). 
ADAMTS5 No (Anti-angiogenic) 
(Kumar et al, 2012b) 
Yes (Anti-
angiogenic)  
(Kumar et al, 
2012b; 
Sharghi-
Namini et al, 
2008) 
Anti-angiogenic 
- ADAMTS5 is anti-angiogenic in vitro and in vivo (Kumar et al, 2012b; Sharghi-Namini 
et al, 2008). 








al, 1999) - Disrupts growth factor induced angiogenesis in vivo in a CAM model and matriplug 
assay (Vazquez et al, 1999). 
ADAMTS9 Yes (Anti-




(Koo et al, 
2010) 
Anti-angiogenic 
- Knockdown of ADAMTS9 in cultured ECs suppresses in vitro capillary network 
formation and migration (Koo et al, 2010). 
- Increased corneal neovascularization and tumor vascularization in Adamts9+/- mice 
compared to the wild type mice (Koo et al, 2010). 
- Suppresses oesophageal and nasopharyngeal carcinoma angiogenesis (Lo et al, 2010) 
ADAMTS12 No (Anti-angiogenic) 




et al, 2007) 
Anti-angiogenic 
- Inhibits capillary network formation by BAE-1 cells in 3D collagen gels (Llamazares et 
al, 2007). 
- Adamts12-/- mice showed increased sprout density in both ex vivo and in vivo models of 
angiogenesis (El Hour et al, 2010). 
ADAMTS13 Not known Yes (Anti-
angiogenic)  
(Lee et al, 
2012) 
Anti-angiogenic 
- ADAMTS13 inhibits VEGF-mediated angiogenesis - mediated HUVEC proliferation, 
migration and capillary network formation (Lee et al, 2012). 
Pro-angiogenic 
- Full-length ADAMTS13 promoted HUVEC tube formation, induces EC proliferation 
and migration in vitro (Lee et al, 2012). 
ADAMTS15 Not known Not known Not known 
ADAMTS18 Not known Not known Not known 





Protein Cancer type Regulation 
ADAMTS1 Lung cancer Down-regulation of ADAMTS1 mRNA in NSCLC cell lines and epigenetic regulation via 
hypermethylation of its promoter (Choi et al, 2008) 
Pancreatic cancer ADAMTS1 mRNA expression significantly lower in pancreatic cancer compared to 
noncancerous pancreas (Masui et al, 2001). 
Enhanced expression of ADAMTS1 mRNA in lymph node metastasis or severe retroperitoneal 
invasion (Masui et al, 2001). 
Prostate cancer Markedly low protein levels in prostate cancer cells (Gustavsson et al, 2009). 
Chondrosarcoma Transcriptional up-regulation in response to TNF-α (Hatipoglu et al, 2009). 
ADAMTS2 Osteosarcoma 8-fold increase in ADAMTS2 mRNA levels (Wang et al, 2003). 
ADAMTS4 Breast cancer Enhanced mRNA expression in breast cancer compared to normal breast tissue (Porter et al, 
2004). 
Head and neck squamous cell 
carcinoma 
Enhanced expression of ADAMTS4 mRNA (Demircan et al, 2009). 
Glioblastoma Increased expression of ADAMTS4 mRNA (Held-Feindt et al, 2006b). 
Ewings sarcoma Enhanced protein levels serving as a tumor-specific marker (Minobe et al, 2010). 
ADAMTS5 Breast carcinoma Down-regulation of ADAMTS5 transcript (Porter et al, 2004). 
Colorectal cancer Epigenetically silenced by promoter methylation (Kim et al, 2011). 
Prostate cancer Down-regulation of ADAMTS5 mRNA in prostate cancer cell lines (Cross et al, 2005). 




ADAMTS8 Lung cancer Down-regulation of ADAMTS8 at the mRNA level in NSCLC (Heighway et al, 2002). 
Down-regulation due to epigenetic silencing (Dunn et al, 2004). 
Brain Down-regulation due to promoter hypermethylation (Dunn et al, 2006). 
ADAMTS9 Breast carcinoma Down-regulation of ADAMTS9 transcript (Porter et al, 2004). 
Esophageal squamous cell 
carcinoma 
Hypermethylation of ADAMTS9 in esophageal tumors (Lo et al, 2007). 
Nasopharyngeal carcinoma Promoter hypermethylation and association of lower levels of ADAMTS9 protein with lymph 
node metastasis in NPC (Lung et al, 2008). 
Gastric cancer Epigenetic silencing by promoter hypermethylation (Zhang et al, 2010). 
Inhibition through Akt/mTOR pathway (Du et al, 2012). 
Pancreatic and colorectal cancer Epigenetic silencing by promoter hypermethylation (Zhang et al, 2010). 
ADAMTS12 Colorectal cancer Epigenetic silencing by promoter hypermethylation (Moncada-Pazos et al, 2009). 
ADAMTS13 Prostate, renal, testicular, head and 
neck squamous, colorectal, rectal, 
NSCLC, gastric, melanoma, 
adenocarcinoma and breast 
carcinoma. 
Correlation of presence or absence of tumor metastasis with lower or higher vWF cleaving 
respectively (Oleksowicz et al, 1999). 
Colon cancer, leukemia, multiple 
myeloma, breast, stomach cancer,  
non-Hodgkin‘s lymphoma 
Decreased activity of ADAMTS13 in plasma of malignant patients (Koo et al, 2002). 
Brain and prostate cancers Mild reduction in ADAMTS13 activity but no correlation with malignancy and metastasis 
(Böhm et al, 2003). 






2008; Viloria et al, 2009). 
Colorectal cancer Loss of heterozygosity in ADAMTS15 locus (Connolly et al, 1999). 
Breast cancer Grade-specific down-regulation of ADAMTS15 transcript in breast cancer (Porter et al, 2004). 
Prostate cancer Down-regulation of ADAMTS15 mRNA linked to poor prognosis in prostate cancer (Cross et 
al, 2005). 
ADAMTS18 Breast cancer Down-regulation of ADAMTS18 transcript (Porter et al, 2004). 
Pancreatic, gastric and colorectal 
cancers 
Hypermethylation of ADAMTS18 promoter (Li et al, 2010) 
Kidney and colorectal cancers Inactivation of ADAMTS18 via somatic mutations (Wood et al, 2007). 
Melanoma Somatic mutations in ADAMTS18 linked to higher transformation ability and increased 
metastases in vivo (Wei et al, 2010). 




Fig. 1.14 Role of ADAMTSs in angiogenesis and cancer: A. Many 
ADAMTS members have been shown to be down-regulated in cancer. 
This down-regulation is mostly through epigenetic silencing 
(ADAMTS1, ADAMTS5, ADAMTS8, ADAMTS9, ADAMTS12 and 
ADAMTS18). Somatic mutations in ADAMTS gene have also been 
reported (ADAMTS13, ADAMTS15 and ADAMTS18). B. ADAMTS 
members regulate angiogenesis and cancer in a complex manner that 
involves multiple mechanisms. Both proteinase-dependent and 
independent anti-angiogenic/anti-tumorigenic mechanisms have been 
revealed. On the other hand, proteinase-dependent pro-angiogenic/pro-
tumorigenic functions have also been reported. C. Illustrations of 
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molecular mechanisms by various ADAMTS members in angiogenesis 
and cancer. Examples include pro-angiogenic/pro-tumorigenic function 
through cleaving extracellular matrix substrates such as versican or 
brevican (e.g., ADAMTS1); help in releasing pro-angiogenic growth 
factors such as HB-EGF; proteinase-dependent release of anti-
angiogenic fragments from ECM (ADAMTS1 releasing TSP1 and 
TSP2); proteinase-independent sequestration of pro-angiogenic factors 
(ADAMTS1); TSR-mediated (ADAMTS5) anti-angiogenesis and 
receptor mediated cell death (ADAMTS2) (Adapted from (Kumar et 
al, 2012a)). 
Some ADAMTS members have been well established as tumor 
suppressors without any reported roles in angiogenesis (Kumar et al, 2012a). 
All the reports of ADAMTSs in angiogenesis and cancers till date have been 
tabulated (Table 1.4 and Table 1.5).  
It is important to note that the anti-angiogenic function of different 
ADAMTS members differ in their mechanism of action (Fig. 1.14). The 
angiostatic function might be broadly classified as proteolytic-dependent or -
independent. Proteolytic-independent function of ADAMTS can be a result of 
its anti-angiogenic TSRs or TSRs together with the ancillary domains involved 
(Table 1.4). Most ADAMTSs are down-regulated in cancers due to promoter 
hypermethylation (Table 1.5). Other ADAMTSs are also reported to be pro-
angiogenic and pro-tumorigenic (ADAMTS1, ADAMTS4). A paradox is 
ADAMTS13 which was shown to promote angiogenesis on its own but inhibit 
VEGF-mediated angiogenesis (Lee et al, 2012). In addition, not all ADAMTS 
family members regulate cancer through influencing angiogenesis. Since 
ADAMTSs are ECM metalloproteinases, cleavage of their substrates also 
might promote cancer cell invasion and metastasis as in the case of 
ADAMTS1 (Keightley et al, 2010; Ricciardelli et al, 2011). In addition, 
ADAMTS9 acts as a tumor suppressor by directly inhibiting tumor cell 
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proliferation and inducing tumor cell apoptosis through inhibition of Akt 
signaling pathway (Du et al, 2012). Thus, direct impact on tumor cells in 
addition to its anti-angiogenic function is also an important mechanism for 
ADAMTS members to regulate cancer. 
Several ADAMTS members share similar physiological functions and act 
through a cooperative manner such as role of ADAMTS5, ADAMTS9 and 
ADAMTS20 in morphogenesis during embryonic development (McCulloch et 
al, 2009b). Similar functional studies using double or triple knockout mice in 
cancer and angiogenesis may shed light into any cooperative role of 
ADAMTS members in this area. More mechanistic studies are also needed to 
fully understand how each member functions in human cancer. It is clear that 
members of this family are important players in angiogenesis and cancer. 
ADAMTS proteins or their peptide derivatives can serve as prototypes or 
targets towards the development of clinically relevant cancer therapeutics. 
1.10 ADAMTS5 
ADAMTS5 (also named aggrecanase-2) is a major cartilage aggrecanase 
responsible for joint arthritic diseases. In recent years there has been 
considerable research of this protein, thanks to the generation of Adamts5 
knockout mice and the crystal structure elucidation of its catalytic domain. 
These, together with biochemical and molecular cell biology approaches, have 
led to the elucidation of ADAMTS5‘s roles in tissues other than cartilage such 
as versicanase and brevicanase. Hence, this proteinase has an important role to 
play in extracellular remodeling in various tissues during development and 
pathology as a versicanase, in addition to its much studied role in cartilage 
homeostasis and pathophysiology by aggrecan degradation. 
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The determination of the crystal structure of catalytic site of ADAMTS5 
(Mosyak et al, 2008; Shieh et al, 2008) has promoted for the search for 
potential ADAMTS5 enzyme inhibitors for treating arthritis-related diseases 
using rational drug design approach. However, ADAMTS5 is the major 
aggrecanase in mice (Glasson et al, 2005; Stanton et al, 2005), it is still not 
clear whether ADAMTS5 is the major player in human cartilage degradation. 
Nevertheless, knockdown studies in cultured human cell cells accredit 
ADAMTS5 with the role of an important player in cartilage degradation (Song 
et al, 2007).   
1.10.1 Domain structure 
Like all other ADAMTS members, ADAMTS5 is a multi-domain protein, 
with the molecular mass of 100kDa (Gendron et al, 2007) which includes 
several distinct domains. From the N-terminus it comprises of: i) a 17aa long 
signal peptide; ii) N-terminal prodomain; iii) a catalytic metalloproteinase 
domain. This is followed by the ancillary domains: iv) Disintegrin-like 
domain; v) Thrombospondin type I-like repeat (TSR1); vi) Cysteine rich 
domain; vii) Spacer region; viii) a C-terminal Thrombospondin type I-like 
repeat (TSR2) (Fig. 1.15). 
Signal peptide directs the ADAMTS5 through endoplasmic reticulum to 
the secretary pathway. This is followed by the prodomain that is 245aa long in 
humans. Prodomain plays an important role in maintaining the latency of the 
metalloproteinase in ADAMTS5 (Longpré et al, 2009). Three pro-protein 







(Hurskainen et al, 1999) which have a 
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consensus sequence comprising of basic amino acids RX(K/R)R that is 
recognized by the furin.  
The catalytic domain is highly conserved in all ADAMTS members. The 
ADAMTS5 active site has the amino acid sequence HEIGHLLGLSHD which 
is a reprolysin type zinc binding motif (HEXXHXXGXXH). The 3 conserved 
histidines interact with the zinc ion which results in the formation of catalytic 
site and the conserved glycine allows flexibility, resulting in the correct 
orientation of the third histidine residue in the catalytic site. Also, the aspartate 
residue is conserved only in ADAM and ADAMTS whereas is lacking in other 
metalloproteinases. It helps in polarizing a water molecule, which in turn is 
required for the nucleophilic attack on the peptide bond resulting in cleavage. 
In addition, ADAMTS possess a conserved ‗met turn‘ downstream to the zinc 
binding signature and thus earns the name ‗metzincins‘ (Bode et al, 1993). In 
ADAMTS5 met turn has the amino acid sequence LMS. It helps in creating a 
hydrophobic environment near the zinc atom and histidine residues. The 
crystal structure of the catalytic domain of ADAMTS5 was solved by two 
different groups independently. One with a resolution of 2.8 Aº (Mosyak et al, 
2008) and the other with a resolution of 1.4 Aº, both deduced as an apo 
enzyme and as a complex with its inhibitor (Shieh et al, 2008). It was revealed 
that the catalytic site mainly comprises of α/β structure as seen in 
metalloproteinase of the metzincin family, funnel shaped and the structure of 
ADAMTS5 is comparable to that of ADAMTS1 which shares high sequence 
identity. The catalytic domain has a calcium cluster site, which interact with 
oxygen ligands of peptide and solvent which is unique to ADAMTS5 (Mosyak 
et al, 2008; Shieh et al, 2008).  
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The metalloproteinase domain is followed by several ancillary domains 
and first comes the disintegrin-like domain, called so due to its sequence 
similarity to the disintegrin family. It is a family of cysteine rich proteins that 
bind to the cell surface integrin receptors and are extensively found in the 
venom of vipers, where they act as fibrinogen receptor antagonists and prevent 
platelet aggregation (Eble, 2010). The interaction between the integrin and 
disintegrin is mainly through the RGD sequence of the latter. However, it‘s 
interesting to note that the ADAMTS family lacks this consensus sequence 
and there are no reports of this interaction. Nevertheless, the interaction 
between integrin and disintegrin cannot be ruled out completely as there are 
reports of RGD independent mechanism in a disintegrin and 
metalloproteinases (ADAM) and matrix metalloproteinases (MMPs) (Brooks 
et al, 1996; Cal et al, 2000). The disintegrin-like domain is also thought to 
interact with the Glycosaminoglycans (GAG). It has a GAG binding motif 
(BXXXXXXXB) in the disintegrin domain (KGRICLQGK
552
) (Zeng et al, 
2006). The structural studies have also revealed that disintegrin-like domain is 
in close proximity to the catalytic site and thus might play a role of an exosite 
and enhancing binding with the substrate (Mosyak et al, 2008). 
The ADAMTS5 has two TSRs – a central TSR (TSR1) and a C-terminal 
TSR (TSR2). It possesses the conserved regions as in TSR1 of 
thrombospondins consisting of 6 cysteine residues, the pentapeptide sequence 
CSR(T/S)C and few conserved amino acids such as glycine and tryptophan in 
TSR (GSWGSWGQ) (Hurskainen et al, 1999). This is particularly important 
because the Thrombospondin 1 (TSP1) TSR pentapeptide sequence CSVTC is 
known to interact with CD36 cell surface receptor of endothelial cells and the 
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tryptophan rich SHWSPWSS peptide containing WSXW motif can bind to 
heparin of ECM (Iruela-Arispe et al, 1999). Unlike TSP1 TSR or other 
ADAMTS such as ADAMTS 1, ADAMTS4 and ADAMTS6, ADAMTS5 
lacks the other potential heparin binding motif BBXB sequence (where B is 
the Basic amino acid, ADAMTS5 has KRAI) (Hurskainen et al, 1999). 
However, ADAMTS5 interacts with the negatively charged GAG of ECM 
such as heparin through its cysteine rich domain, present next to the TSR1 
(Gendron et al, 2007). As the name suggests, it contains 10 cysteine residues. 
It is followed by the spacer domain which in contrast lacks cysteine residues 
and hence thought to be relatively flexible (Fosang et al, 2008).   
1.10.2 Processing and post-translational modifications  
The theoretical molecular mass of the ADAMTS5 is 101.717 kDa. 
However, the molecular mass determined by western blotting of the full length 
ADAMTS5 was 120 kDa (Longpre et al, 2009). ADAMTS5 is predicted to 
possess 4 N-glycosylation sites (NXS/T) – one each in disintegrin (N498) and 
cysteine rich domain (N
728




) (Zeng et 
al, 2006) (Fig. 1.15). Presence of N-glycosylation was confirmed by treating 
the ADAMTS5 with peptide N-glycosidase and observing the gel shift 
compared to the untreated ADAMTS5 (Zeng et al, 2006). Recent studies have 
shown that the central TSR of ADAMTS5 also undergoes C-mannosylation 





) and one O-fucosylation (S
582
) has been identified using mass 
spectrometry (Wang et al, 2009). This post-translational modification is 
thought to play a critical role in secretion of the protein to the outside of the 
cell into the extracellular milieu. 
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C-terminal processing is also observed in ADAMTS5. This might be 
attributed to the autocatalytic cleavage by its metalloproteinase domain or by 
other proteases in physiological conditions. Two such isoforms of molecular 
weight 45 kDa and 60 kDa were identified (Zeng et al, 2006) (Fig. 2.1). The 
autocatalytic cleavage sites were predicted to be in cysteine rich domain and 




 at the spacer 
domain has been identified using the neoepitope antibody anti-RIPE
753
 (Zhu et 
al, 2007). The C-terminal processing plays a key role in regulating the 
functional activity of the metalloproteinase domain. This is because the 
ancillary domains affect substrate specificity, ECM binding which in turn 
affects the metalloproteinase activity (Gendron et al, 2007; Zeng et al, 2006). 
 
Fig. 1.15 Domain structure of ADAMTS5 
 
Presence of disintegrin-like and TSR1 domain is a must for the 
metalloproteinase activity of ADAMTS5. Sequential deletion of N-terminal 
domains has suggested that the cysteine rich domain plays a key role in 
binding of ADAMTS5 to the cell surface (Zeng et al, 2006). By generating 
chimeras between various domains of ADAMTS4 and ADAMTS5 (Gendron 
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et al, 2007), it was convincingly demonstrated that the ancillary domains play 
a key regulatory role in aggrecanase activity of ADAMTS5. They showed that 
the C-terminal domains are involved in both increasing the binding affinity 
towards chondroitin sulfate rich region of aggrecan and augmenting the 
enzymatic activity. 
1.10.3 Expression  
Real time analysis of ADAMTS5 in human tissues showed that the highest 
expression in cervix followed by the uterus and cartilage tissue (Abbaszade et 
al, 1999). Expression of ADAMTS5 was also observed in human decidual 
stromal cells that plays a crucial role in implantation of the embryo to the 
uterus (Zhu et al, 2007). Detailed study on Adamts5 expression profile in 
embryonic as well as adult mice was performed using beta galactosidase (β-
gal) histochemistry, in situ hybridization and immunohistochemistry in a 
genetically engineered mice containing reporter LacZ gene introduced into the 
catalytic domain of Adamts5 thus rendering it inactive (McCulloch et al, 
2009a). mRNA expression of Adamts5 was observed only in embryos that 
were either 9 days old or more. During this early embryogenesis, β-gal 
staining was observed only in the floor plate of the developing central nervous 
system. This was subsequently followed by the expression in neuromuscular 
structures and smooth muscles in the adult mice. It is quite surprising to note 
that there was no overlap between Adamts5 expression and developing 
cartilage. Adamts5 expression was well observed in arterial, bronchi and 
pancreatic smooth muscle cells. Also, the neuronal cells such as Schwann cells 
and dorsal root ganglia showed constitutive expression of the Adamts5. These 
studies clearly hint at the role of ADAMTS5 in degrading the extracellular 
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proteoglycan-versican and brevican because its abundance overlaps with the 
Adamts5 expression pattern in mice and has been recently shown to be the 
substrate for Adamts5 (Longpre et al, 2009) .  
1.10.4 Regulation  
Mainly the expression and regulation of human ADAMTS5 is extensively 
studied in the tissues related to joints such as cartilage and synovium due to its 
role in aggrecan cleavage and pathophysiology of arthritis. Transcript analysis 
by various groups have suggested that there is a significant upregulation of 
ADAMTS5 mRNA level and aggrecanolysis in chondrocytes upon treatment 
with catabolic agents such as IL-1α (Fushimi et al, 2008; Stanton et al, 2005) 
oncostatin M (East et al, 2007), IL-1β (Bau et al, 2002; Song et al, 2007; 
Young et al, 2005), retinoic acid (Cortial et al, 2006), TNF-α  (East et al, 
2007) and thyroid hormone (LaVallie et al, 2006). However, the synovium did 
not respond in the same way as chondrocytes. The expression of ADAMTS5 
in synovium remained constitutive and remained unchanged on catabolic 
stimulation by IL1, TNF-α and TGF-β (Makihira et al, 2003). Even in 
chondrocytes, TGF β failed to bring about an upregulation of ADAMTS5 
(Moulharat et al, 2004). Also, one note of caution is that upregulation of 
mRNA of ADAMTS5 not necessarily brings about an increase in the aggrecan 
loss. However, the intricate complexities of studying the aggrecanase activity 
and the lack of correlation between the mRNA level and the function of 
aggrecanase is well explained in the review by Fosang and colleagues (Fosang 
& Rogerson, 2010). Very few studies have been undertaken to understand the 
regulation of the ADAMTS5 in tissues other than cartilage.  
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Expression profile analysis of all the 19 members of ADAMTS family 
showed the down-regulation of the ADAMTS5 and few other ADAMTS such as 
ADAMTS1, ADAMTS3, ADAMTS8, ADAMTS9, ADAMTS10 and ADAMTS18 
mRNA in the case of breast cancer tumor tissue compared to the non-
neoplastic control (Porter et al, 2004). One more study has showed that the 
ADAMTS5 is silenced at the gene level by methylation of the promoter in the 
case of T-cell acute lymphoblastic leukemia (Roman-Gomez et al, 2005). 
These studies are quite important because it hints at the role of ADAMTS5 as 
a tumor suppressor. Real time PCR results showed an upregulation of 
ADAMTS5 in glioblastoma tissue compared to normal brain sample in humans 
(Talmadge & Fidler, 2010). This could be due to the metalloproteinase activity 
of ADAMTS5 catalytic domain that will help in ECM remodeling and tumor 
cell invasion.  
1.10.5 Physiological and pathophysiological functions 
1.10.5.1 Aggrecanase activity:  
Aggrecan is the major proteoglycan of the articular cartilage, also referred 
to as hyaline cartilage, a glistening white connective tissue that encapsulates 
the surface of all the diarthroidal joints. These movable joints can withstand a 
great amount of compressive load and reduce friction between the joints. This 
unique property is attributed to the type II collagen and aggrecan. The former 
provides strength and rigidity and the latter provides the ability to withstand 
compression and heavy weight (Pratta et al, 2003). Aggrecan is a very large 
protein which has 3 globular domains, 2 at the N terminal end (G1 and G2) 
and one at the C terminal end (G3) (Fig. 1.15).  
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Two biochemical properties of aggrecan play vital roles in it‘s afore 
mentioned physiological function. Firstly, G1 interacts with the hyaluronic 
acid, forms huge aggregates inside the collagen network. Secondly, negatively 
charged sulfate rich regions attract cations which in turn lead to the hydration 
and swelling of the tissue, acting as a shock absorber and thus resisting 
compression (Pratta et al, 2003). 
 
Fig. 1.16 Domain structure of proteoglycan substrates of 
ADAMTS5: Black arrow marks show the substrate cleavage site of 




In normal physiological condition, a balance is maintained between the 
rate of synthesis and degradation of the aggrecan. However, in pathological 
conditions like osteoarthritis and rheumatoid arthritis, aggrecan degradation 
takes over. ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS8, ADAMTS9, 
ADAMTS12, ADAMTS15, ADAMTS16 and ADAMTS18 have been shown 
to have aggrecanase activity (Porter et al, 2005). However, ADAMTS5 is 
found to be the major aggrecanase, complemented by ADAMTS4 in mice 
(Glasson et al, 2005; Stanton et al, 2005). Human aggrecan core protein is 





















 (Tortorella et al, 2002). However, the 




 in the IGD because this 
releases the sulfated proteoglycan part and thus affecting the cartilage 





plays a vital role in disturbing the cushion property of the cartilage and leading 
to arthritis, it is the least cleavage preference of ADAMTS5 (Tortorella et al, 
2002). Recent studies have also shown the relevance of aggrecanase function 
of ADAMTS5 in wound healing process. Adamts5 knockout mice showed 
impaired contraction and dermal collagen deposition in an excisional wound 
healing. Thus, it was evident that ADAMTS5 deficiency in fibrous tissues 
results in an accumulation of aggrecan and thus effecting normal wound 
healing (Velasco et al, 2011).  
1.10.5.2 Versicanase activity: 
Versican (also referred to as VCAN) gets its name derived from two words 
- ‗versatility‘ and ‗proteoglycan‘. The gene comprises of 15 exons and has a 
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size of over 90kbp (Naso et al, 1994). The versican consists of a multi-domain 
core protein, similar to aggrecan, comprising of an N-terminal globular 
domain (G1) which is subdivided into a immunoglobulin like domain and a 
hyaluronan binding domain followed by GAG binding domain which is 
heavily glycosylated with chondroitin sulfate side chains (LeBaron et al, 
1992) (Fig. 1.16). The C-terminal region comprises of G3 domain which can 
be further subdivided into 4 domains namely two epidermal growth factor 
(EGF) domains followed by a C-type Lectin domain and a terminal 
complement regulatory region (LeBaron et al, 1992; Zimmermann & 
Ruoslahti, 1989). Versican possess 4 isoforms, namely V0, V1, V2 and V3, 
resulting from all the combinations of the alternative splicing of the mRNA of 
two exons, which either incorporates or excludes exon7 and exon 8 (Naso et 
al, 1994; Wight, 2002).  Versican has a widespread distribution, expressing in 
various tissues including epithelia of prostate and liver, connective tissue of 
most of the internal organs such as spleen, kidney, heart etc. (Bode-
Lesniewska et al, 1996). This proteoglycan is thought to play a key role in 
development, like formation of the heart and neural cell migration (Wight, 
2002). 
Several MMPs and ADAMTSs have been shown to cleave versican (Kern 
et al, 2006; Passi et al, 1999; Sandy et al, 2001). Recently, versican was 
discovered as a substrate for ADAMTS5 which, is able to cleave versican 
(V0/V1 isoforms) efficiently in the GAG β domain of V1 to generate a N-
terminal versican 70kDa fragment as detected by the anti-DPEAAE antibody 
(Longpre et al, 2009). This catalytic function was inhibited when the assay 
was performed with E411A catalytic domain mutant of ADAMTS5 or the full 
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length ADAMTS5 in its zymogen form. The expression pattern studies of 
ADAMTS5 in mice also revealed co-localization of ADAMTS5 and versican 
expression (McCulloch et al, 2009a). During the discovery of ADAMTS5, 
northern analysis of mouse Adamts5 (also referred to as implantin) revealed 
that this gene is expressed in higher levels in placenta and in peri-implantation 
period of 7 day old embryo (Abbaszade et al, 1999; Hurskainen et al, 1999). 
Versican is present in the mouse endometrium and thought to play a role in 
embryo implantation, which might explain the physiological function of the 
implantin (Salgado et al, 2009; San Martin et al, 2003). Spatio-temporal 
expression pattern studies in human placenta also confirmed the presence of 
the ADAMTS5 both in vitro and in vivo in decidualized stromal cells of the 
human endometrium. It is known that versican is expressed moderately in the 
human stroma of the normal endometria and is upregulated during endometrial 
cancer (Hanekamp et al, 2003; Kodama et al, 2007). Also researchers have 
showed Adamts5 in cooperation with Adamts1 and Adamts9 regulate the 
mechanism of web regression during development in mice (Demircan et al, 
2009). Thus, it would be very relevant to study in detail the correlation 
between ADAMTS5 and versican, given the fact that the expression pattern 
overlap significantly and the vast role of versican in maintaining ECM 
homeostasis and pathological conditions such as cancer and atherosclerosis.  
Atherosclerosis, also known as the arteriosclerotic vascular disease, is a 
condition which involves thickening of the artery wall due to the deposition of 
lipids such as cholesterol and fibrous elements which might lead to 
cardiovascular diseases such as heart attack or stroke (Lusis, 2000). 
Interestingly, immunohistochemical studies of human atherosclerotic plaques 
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showed a strong expression of ADAMTS5, in addition to ADAMTS4 and 8 
(Wagsater et al, 2008). The expression was observed to be colocalized with 
macrophage rich areas suggesting that the monocytes differentiating into 
macrophages might be the possible source of this protease. Thus, ADAMTS5 
might be involved in the cleavage of versican, which is abundantly present in 
the plaque. The protease might have a protective role by clearing the ECM and 
thus helping in clearing the plaque or degrading roles involving ECM 
remodeling and generating active versican cleavage fragments in order to 
strengthen the plaque, which needs further investigation. Consistent with this 
hypothesis, ADAMTS5 was reported to be reduced in atherosclerotic aortas of 
apoE
-/-
 mice thus limiting versican clearance from the plaques (Didangelos et 
al, 2012).  
1.10.5.3 Brevicanase Activity 
Brevican, also known as the brain enriched hyaluronan binding (BEHAB) 
is a brain specific chondroitan sulfate proteoglycan of the lectican family 
(Yamada et al, 1994).  ECM of central nervous system comprises of lecticans 
which include brevican, neurocan, versican and aggrecan (Yamaguchi, 2000). 
The structure of the brevican, like all the lecticans, comprises of the globular 
domains on either end of the core protein. The core protein of the brevican is 
relatively shorter compared to aggrecan and versican (Fig. 1.16). Brevican is 
highly expressed in the adult brain and the expression of brevican increases as 
the brain develops (Yamaguchi, 1996). The role of the brevican in brain is to 
regulate neuronal cell adhesion, migration and outgrowth. Brevican is known 
to play two mutually exclusive roles of promoting and inhibiting cell adhesion 
and neurite outgrowth (Yamaguchi, 2000) (Fig. 1.16).  
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Brevican is a marker for gliomas as it is upregulated in brain cancer (Gary 
et al, 1998b; Gary et al, 2000; Giordana et al, 1994; Jaworski et al, 1996; 
Viapiano et al, 2005). The cleavage of the brevican is observed to be a critical 
step during glioma invasion (Viapiano et al, 2008). Under physiological 
conditions, ADAMTSs cleaves 145 kDa full length brevican resulting in the 
50 kDa N-terminal fragment that confers the glial cells with invasive property 
and 70 kDa C-terminal fragment (Matthews et al, 2000).The cleavage site is 




 (Yamada et al, 1995), which is a conserved site for 
cleavage by ADAMTSs (Nakamura et al, 2000). Further studies to identify 
other ADAMTS members that can cleave brevican led to the discovery of 
brevicanase activity by ADAMTS5 (Nakada et al, 2005). Nakada and 
colleagues also reported that ADAMTS5 is the only ADAMTS member which 
gets upregulated during glioblastomas compared to the normal tissue in brain. 
The expression studies of the ADAMTS5 in the normal brain tissue and 
gliomas have shown that there is upregulation of ADAMTS5 transcriptionally 
in solid human glioblastomas, thus reemphasizing its role in invasiveness 
(Held-Feindt et al, 2006b). Given the fact that ADAMTS5 is catalytically 
more active as a proteoglycanase than ADAMTS4 or ADAMTS1 (Kintakas & 
McCulloch, 2011).  
1.11 Zebrafish – a model organism for investigating physiological 
angiogenesis and gene function. 
Zebrafish (Danio rerio) is a small tropical fresh-water fish. They are 
commonly found in rivers of countries of South Asia such as northern India, 
northern Pakistan, Nepal and Bhutan. Characteristic strips running along the 
body of the fish gave this species its name. Zebrafish has become a favorite 
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model organism for studying various processes in embryology, physiology and 
pathology due to the numerous advantages it has. Firstly, the development of 
the zebrafish is very similar to the embryogenesis in higher vertebrates such as 
mammals, including humans. But, unlike most mammals, the fertilization and 
development of the embryo is external. Secondly, the egg and the subsequent 
embryos are completely transparent, making it possible to observe developing 
embryos in their natural environment. Zebrafish females can give a large 
number of embryos – around 200 embryos once a week. Also, they have a 
rapid life cycle and within the first 24 hpf, all the major organs would have 
already formed and within 3-4 months, they are ready for spawning. In 
addition, there are other advantages such as sequenced genome, range of 
genomic tools for knockdown, overexpression and somatic mutation studies. 
There are also multiple transgenic lines available to study specific functions or 
cell fate (Alestrom et al, 2006; Goldsmith, 2004). These and many more 
advantages have led to its application in studying various human diseases such 
as cancer (Berghmans et al, 2005), immune diseases (Yoder et al, 2002), 
metabolic diseases (Elo et al, 2007). The zebrafish embryo is a useful model 
to study vascular morphogenesis in vivo. The vasculature can be easily 
visualized using a variety of labeling techniques, such as endothelial specific 
expression of fluorescent protein or transgenic fish line or by 
microangiography (Fig. 1.17) (Ellertsdottir et al, 2010). 
Vascular development in zebrafish includes a series of cellular and 
molecular events beginning with specification of endothelial progenitors, then 
differentiating into arterial and venous cells, finally resulting in assembly and 
patterning of axial and intersegmental vessles (ISV). Angioblasts – the 
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endothelial precursors are the cells that express certain markers (Vegfr2) and 
characteristics of ECs but have not yet formed a lumen. They arise and 
segregate from the lateral plate mesoderm at the 5 somite stage (Thompson et 
al, 1998). These angioblasts gives rise to the primordial of the dorsal aorta 
(DA) and cardinal veins (CV) or the ISVs (Childs et al, 2002).  
 
Fig. 1.17 Vascular system of 72 hpf zebrafish embryo: The vascular 
system in a 3-day-old zebrafish embryo visualized by reporter gene 
analysis [Tg(flk1:EGFP) in green] and by microangiography using 
quantum dots (red in panels B and C). AA: aortic arches (1–6); CV: 
caudal vein; CCV: common cardinal vein; DA: dorsal aorta; PCV: 
posterior cardinal vein; PHS: primary head sinus; SA: segmental 
artery; SV segmental vein (Adapted from (Ellertsdottir et al, 2010)).  
Differentiation of arterial and venous ECs is regulated by various signaling 
pathways. Delta-notch signaling, VEGF signaling have been indicated in 
regulating arterial-venous differentiation and vascular development (Zhong, 
2005). First step in the tubulogenesis is the assembly of the DA and CV. This 
results from the migration of arterial and venous angioblasts to the midline, 
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leading to the formation of endothelial cords. Subsequently, these cords 
elaborate into lumens of the DA and the CV.  At the 22-somite stage, arterial 
and venous angioblasts gradually segregate from each other to occupy distinct 
domains and align in the form of rudimentary tubes (Blum et al, 2008).  
While the primary axial vessels are formed by vasculogenesis, the 
formation of secondary vessels occurs via angiogenesis. Formation of ISVs 
involves two distinct angiogenic sprouting steps. Firstly, ECs sprout to form 
the segmental arteries (SA). At ~22 hpf, the ECs sprout from the DA and grow 
dorsally and connect with their neighbors from anterior and posterior segments 
to form the future dorsal longitudinal anastomotic vessel (DLAV). Second 
phase is initiated that starts at 32 hpf by the ECs of pericardinal vein (PCV). 
These sprouts will connect to an existing SA, thereby transforming it into a 
segmental vein (SV) (Fig. 1.18) (Ellertsdottir et al, 2010).  
Several models have been postulated for the SA morphogenesis. Earlier 
model by Childs and colleagues suggested that SA is made up of 3 cells that 
are arranged in head to tail fashion (Childs et al, 2002). However, recent 
studies have shown that SAs are composed of 4-6 cells that extensively 
overlap along the proximodistal axis of the vessel (Blum et al, 2008). Thus, 
the new SA morphogenesis model suggests that one or two cells initially 
migrate out of the epithelium of the DA forming the sprout. During dorsal 
outgrowth, this sprout will become 3-4 cells, one tip and two or three stalk 
cells. Once the tip cell has made contacts with its anterior or posterior 




Fig. 1.18 Model for SA morphogenesis that leads to the formation 
of ISV and DLAV of the trunk: A. At 22 hpf, two leading cells (in 
blue and purple) grow along the somite boundaries to the dorsal roof 
of neural tube. B. & C. At the dorsal side of the embryo, the tip cells 
send extensions toward their anterior and posterior neighbors to 
establish connections. During this phase, the ECs establish a scaffold 
consisting of a vascular cord that is not yet lumenized. D. Further cell 
rearrangements and cell division lead to formation of a continuous 
apical surface that may surround initial luminal spaces (yellow). At 
around 32 hpf, a secondary wave of angiogenic sprouts emerges from 
the PCV. These sprouts connect with the adjacent primary vessel (D, 
on the right), which will become a segmental vein. E. Blood flow in 
ISVs commences after SA, SV and DLAV have been established 
(Modified from (Ellertsdottir et al, 2010)). 
 
Patterning of the ISVs takes place once the DA and CV form in the 
midline of the zebrafish embryos. ISVs grow from and sprout from the DA 
and CV to form the trunk vascular system. At 36 hpf, ISVs sprout and 
elongate dorsally up and their tips anastamose longitudinally to form a right 
and left pair of dorsal longitudinal anastamotic vessels. ISVs connect ventrally 
to either the DA or PCV respectively and run dorsally between and adjacent to 
the notochord-neural tube interface and the somites. Blood flow in these ISVs 
can be seen at around 48 hpf. By 72 hpf, nearly all ISVs are functioning, 
leading to the end of development of major trunk vessels. Because of their 
metameric arrangement and relative anatomical simplicity, ISVs are ideally 
suited to study the cues and mechanisms of the ordered formation of new 
blood vessels (Blum et al, 2008). 
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1.12 Aim & objectives of this study 
Hypothesis:  
ADAMTS5 plays an important role in angiogenesis, tumor progression 
and metastasis.  
Objectives:  
The overall objective of my project is to investigate the role of ADAMTS5 
in angiogenesis, tumor progression and metastasis. 
Specific objective would be as follows: 
A. To determine whether ADAMTS5 and its auto-catalytic fragment is 
anti-angiogenic in vitro 
 Our lab has previously shown that the first thrombospondin type 1 repeat 
(TSR1, the central TSR) but not TSR2 (the C-terminal TSR) of ADAMTS5 is 
anti-angiogenic in vitro suggesting a role for this proteoglycanase in 
angiogenesis (Sharghi-Namini et al, 2008). Thus, first objective of this project 
is to investigate if ADAMTS5 or its N-terminal catalytically active auto-
catalytic fragments containing TSR1 possesses anti-angiogenic function in 
vitro. 
B. To evaluate whether ADAMTS5 influence tumor growth and tumor 
angiogenesis in vivo 
Coupled with previous reports that ADAMTS5 expression is altered in 
several human cancers, ADAMTS5 may play an important role in cancer and 
angiogenesis. Using B16 mouse melanoma xenograft model, the effect of 
ADAMTS5 overexpression on tumor growth and vascularization would be 
investigated.   
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C. To decipher the role of autocatalytic fragments of ADAMTS5 in 
tumor growth and angiogenesis 
ADAMTS5 is shown to undergo auto-proteolytic cleavage at the C-
terminal ancillary domains resulting in at least two truncated N-terminal 
fragments of 60 kDa and 45 kDa. The C-terminal ancillary domains of 
ADAMTS5 are known to act as exosite helping the metalloproteinase to bind 
the substrates and to localize to the ECM and enhancing its endopeptidase 
activity. The functions of these truncated protein forms in angiogenesis and 
cancer would be investigated in mouse B16 melanoma model. 
D. To determine the role of the catalytic activity of ADAMTS5 in tumor 
growth and angiogenesis 
 Traditionally, matrix proteinases function as promoters of angiogenesis 
and tumor progression by digesting ECM molecules and facilitate cell 
migration and morphogenesis. On the other hand, the anti-angiogenic TSR1 
domain in ADAMTS5 may confer anti-angiogenic functions to this rpteonase. 
Hence, the function of the catalytically inactive point mutant (ADAMTS5 - 
E411A), its role in tumorigenesis would be investigated using similar mouse 
models described above.  
E. To determine the domain(s) responsible for its anti-tumorigenic and 
anti-angiogenic function 
ADAMTS5 is a multi-domain protein with a metalloproteinase and an 
anti-angiogenic TSR1. Both catalytic-dependent and catalytic-independent 
mechanisms of angioinhibition have been reported in other ADAMTS 
members that are anti-angiogenic. Using domain deletion analysis, the basis of 
angio-inhibitory action of ADAMTS5 would be investigated in vivo.  
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F. To study the role of this proteoglycanase in tumor metastasis 
Matrix metalloproteinases are well known for the cancer progression and 
metastasis by increasing cell growth, invasion and migration. ADAMTS5 is 
known to be upregulated in gliomas and overexpression of this brevicanase 
leads to increased invasion of the gliomal cells in vitro. However, the role of 
this proteinase in other tumors is still unknown. In this work, the role of this 
proteoglycanase in B16 melanoma metastasis to lung will be investigated. 
G. To investigate the role of adamts5 in embryonic angiogenesis using 
zebrafish as a model organism 
Zebrafish is a vertebrate model organism advantageous for studying gene 
function. Thus, I will use transgenic zebrafish line Tg(fli-1: EGFP) in which 
all blood vessel ECs are labeled green to study the role of adamts5 in 




CHAPTER 2. MATERIALS AND METHODS 
2.1 Cell lines and culture conditions 
2.1.1 Isolation of human umbilical vein endothelial cells (HUVECs) 
HUVECs used in this work were obtained from the freshly isolated human 
umbilical vein (Jaffe et al, 1973). Fresh umbilical cords were collected from 
consented maternal ward patients at the National University Hospital 
(Singapore) according to the protocol (DSRB C/00/553) which is approved by 
the Singapore National University Health care Group‘s Domain Specific 
Review Board (DSRB) ethics approval committee. Umbilical cord was placed 
in 1X Phosphate buffered saline (PBS) (8 g/L NaCl, 0.2 g/L KCl, 1.44 g/lL 
Na2HPO4, 0.24 g/L KH2PO4, pH7.4) after being severed from the placenta 
soon after birth. HUVECs were immediately isolated whenever possible and 
in other cases stored at 4ºC in 1X PBS until overnight before HUVEC 
isolation.  Briefly, the cord was opened inside the sterile biosafety cabinet, 
washed at least three times with 1X PBS to remove blood clot and both the 
ends of the cord were cut transversely. This was done in order to make a clear 
cut to insert the adaptor and to distinguish the vein from the rest of the two 
arteries. Umbilical vein has the largest diameter and more flexible than the 
arteries. The adaptors were cannulated into both the ends and tied tightly with 
the sterile suture thread. The umbilical vein was washed thrice with 1X PBS to 
remove coagulated blood. Sterile 20 ml of 0.2% collagenase (Sigma-Aldrich, 
USA) in 1X PBS was flushed into the vein through one of the adaptor using a 
sterile 50 ml syringe (Terumo, Philippines). Both the ends were clamped using 
clamping scissors on the adaptors and incubated for 15 min at room 
temperature for the collagenase to act on the HUVECs. The cord was kneaded 
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(i.e. massaged and squeezed) gently to help cell detachment. The HUVECs 
along with the collagenase was flushed into a sterile 50 ml falcon tube. The 
umbilical vein was rinsed with 20 ml of 1X PBS once to flush all the residual 
HUVECs. The cells were spun down at 1,500 rpm for 5 min. The cells were 
resuspended in 5 ml of CSC complete medium (Cell System Corporation, 
USA) or Endogro-LS complete media (Millipore, Singapore) supplemented 
with 1% Gentamicin (Sigma-Aldrich, USA) in a T-25 culture flask (NUNC, 
Denmark) pre-coated with 0.2% gelatin in PBS at 37ºC in an incubator with 
5% CO2. The medium was replaced with fresh medium after 3-4 h once the 
HUVECs have attached.  
2.1.2 HUVEC cell culture  
The HUVECs were cultured in CSC complete medium (Cell System 
Corporation, USA) or Endogro-LS complete media (Millipore, USA) 
supplemented with 1% Gentamicin (Sigma-Aldrich, USA) in a T-25/T-75 
culture flask (Biofil, China) or 10 cm dishes (NUNC, Denmark) pre-coated 
with 0.2% gelatin in 1X Phosphate buffered saline (PBS) at 37ºC in a 
humidified incubator (Thermo Scientific, Singapore) with 5% CO2. Cell 
culture medium was replaced once every two days. When they reach 80-90% 
confluence, the cells were washed once with 1X PBS and rinsed with 1X 
Trypsin-EDTA solution (Sigma-Aldrich, USA). The dish/flask was incubated 
at 37ºC incubator for 2-3 min till the cells have disassociated from the 
dish/flask. The trypsin-EDTA was neutralized using complete media and split 
with a passage ratio of 1:2 into new gelatin pre-coated dishes/flasks and 
incubated at 37ºC in a humidified incubator with 5% CO2. HUVECs from only 
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passage 3 to passage 8 were used for all the experiments after which the 
HUVECs differentiate.  
2.1.3 Tumor cell culture and routine maintenance 
All the mouse and human cancer cell lines used in this study were obtained 
from American type culture collection (ATCC) – B16F1, B16F10 (mouse 
melanoma), 4T1 (mouse mammary carcinoma), Lewis lung carcinoma (LLC), 
NIH-3T3 (mouse embryo fibroblast), HT-1080 (human fibrosarcoma), A549 
(human lung adenocarcinoma), G401 (human kidney tumor), JAR (human 
choriocarcinoma), PC3 (human prostate cancer), U87 (human glioblastoma), 
HeLa (human cervical cancer). All the cell lines were cultured in Dulbecco‘s 
minimal essential medium (DMEM) (Sigma-Aldrich, USA) with 5-10% Fetal 
bovine serum (FBS) (Biowest, France) and 1% Penicillin-Streptomycin (PS) 
antibiotic solution (Life technologies, USA). The cells were maintained at 
37ºC in a humidified CO2 incubator with 5% CO2.  Upon reaching 80-90% 
confluence, cells were trypsinized as explained above with 0.25% Trypsin 
(Life technologies, USA) and passaged in 1:4 ratios for further maintenance. 
2.1.4 Cell number quantification 
HUVEC or cancer cell lines were trypsinized and resuspended in a 
minimum volume of 1-5 ml of DMEM + FBS (10%) + PS (1%). Cell number 
quantification was done using Nucleocounter NC-100 (Chemometec, 
Denmark).Cell suspension of 100 µl was mixed with an equal volume of 
Reagent A (Cell lysis buffer) and Reagent B (Stabilization buffer) in a 1.7 ml 
microcentrifuge tube (Axygen, USA). The lysate solution was mixed and 
loaded onto a nucleocassette by immersing the tip of the cassette into the 
solution and pressing the piston. The nucleocassette was later inserted into the 
70 
 
instrument slot and the program was run. The cell number is displayed on the 
screen which was multiplied by 3 to obtain the cell number per ml of cell 
suspension.  
2.1.5 Cryopreservation and recovery of cell lines 
80-90% confluent HUVECs or the cancer cell lines were trypsinized as 
mentioned above and resuspended in their respective culture medium 
containing 5-10% Dimethyl sulfoxide (DMSO) (Freshney, 1994). 
Approximately 2X10
6
 cells were transferred into a cryovial in 1 ml, sealed it 
tightly and placed in Mr. Frosty (Thermo Scientific, USA) that provides the 
critical -1ºC/min cooling rate required for successful cell cryopreservation and 
recovery and placed in -80ºC freezer (Sanyo, Japan) for 24 h before 
transferring it into liquid nitrogen tank (Thermo Scientific, USA).  Cell 
thawing and recovery was performed with rapid thawing by submerging in a 
37ºC water bath (Memmert, Germany). The cells were centrifuged at 1000 
rpm for 5 min to remove DMSO and seeded onto a T-25 flask for further 
culture in appropriate medium. 
2.2 DNA subcloning 
2.2.1 Polymerase chain reaction (PCR) 
To amplify the desired gene product, PCR was performed in DNA thermal 
cycler model 480 and 9600 (Biometra, Germany) using high fidelity Taq DNA 
polymerase - Advantage®-HF 2 cDNA PCR polymerase (Clontech, USA) 
with specific primer pairs (Table 2.1). A 50 µl reaction was set in a 0.5 ml 
PCR tube (Axygen, USA) with the following components: 5X Reaction buffer 
- 5 µl, 50 X dNTP mix – 5 µl, DNA template – 25 ng, sense and anti-sense 
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primer (10 µM) – 1 µl and HF- taq polymerase - 1 µl and made up to 50 µl 
with RNase free water. A typical cycling parameter used for the PCR was – 
Initial denaturation at 94ºC for 1min, 35-40 cycles of denaturation at 94ºC for 
30 sec, annealing and extension at 68ºC for 1-3 min (1min/1kbp) and final 
extension of 72ºC for 10 min.  
2.2.2 Agarose gel electrophoresis  
1% (w/v) agarose gel was cast by dissolving agarose in 1X Tris-acetate 
Ethylene di-amine tetra acetic acid (EDTA) (TAE) buffer. Agarose was 
melted in a microwave (National, Singapore) by micro-cooking it at high 
heating for 3 min. Agarose was allowed to cool under running tap water till it 
reaches 50ºC followed by addition of SYBR
®
 safe DNA gel stain (Life 
technologies, USA) at 1:10,000 dilution and poured into the gel cast tray after 
insertion of comb. The gel (5-7 mm thick) was allowed to cool and solidify at 
room temperature. When the gel hardened, agarose gel was transferred to the 
electrophoresis reservoir tray (Bio-rad, USA) and topped with 1X TAE buffer 
so that the gel is covered to a depth of about 2 mm. The comb was carefully 
removed and PCR product was loaded after mixing with 10X DNA loading 
dye (3.9 ml glycerol, 500 μl 10% (w/v) SDS, 200 μl 0.5 M EDTA, 0.025 g 
bromophenol blue, 0.025 g xylene cyanol in 10 ml total volume with H2O).  
Appropriate 100 bp (Generuler, USA) or 1 kbp (Generuler, USA) marker was 
loaded in the adjacent well. The gel was connected to a power source (Bio-rad, 
Italy) run for 20 – 30 min at 5 V/cm of the gel. At the end of the run, the gel 
was visualized using DNA visualization apparatus (Bio-rad, Italy). 
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2.2.3 Gel extraction 
Gel extraction kit from Qiagen (USA) was used to isolate the desired 
amplified PCR product. The agarose gel was run as above with slight 
modifications. Crystal violet (0.001%) was used to visualize DNA (Yang et al, 
2001). After the gel run, the desired band was excised using a clean sharp 
scalpel. Briefly, 3 volumes of buffer QG was added to 1 volume of the gel and 
incubated at 50ºC on a heat block (Techne, UK) for 10 min with intermittent 
mixing to dissolve the gel product. After dissolving, 1 volume of isopropanol 
was added, mixed and transferred into a QIAquick column and spun at 13,000 
rpm for 1 min. The column was washed with 0.75 ml of buffer PE and spun as 
before. In order to remove any residual ethanol bound to column, it was 
centrifuged for 1 min and elution of the PCR product was done by adding 30 
µl of RNase free water (pre-heated to 50ºC) and the DNA was collected into a 
clean 1.7 ml microcentrifuge tube (Axygen, USA).  
2.2.4 Quantification of DNA using NanoDrop 
NanoDrop software (NanoDrop technologies, USA) was opened in the 
computer and the NanoDrop pedestal was cleaned with MilliQ water. The 
NanoDrop software was initialized and blanked with appropriate solution 
(water or buffer used to dissolve DNA). 1 µl of the sample was loaded and the 
concentration of the DNA was measured by clicking on the measure button.  
2.2.5 Ligation 
The desired gene product and vector (where necessary) was gel purified as 
mentioned above and the ligation reaction was set up as per the manufacturer‘s 
instruction (Promega, USA): In a 20 µl reaction, 2 µl of 10 X DNA ligase 
buffer (300 mM Tris-HCl (pH 7.8), 100 mM MgCl2, 100 mM DTT and 10 
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mM ATP), 1 µl of T4 DNA ligase (1 Weiss units) was added into a clean 0.6 
ml microcentrifuge tube (Axygen, USA) and made up with RNase free water. 
DNA: Vector ratio of 3:1 was used. Ligation reaction was incubated at 4ºC 
overnight.  
2.2.6 Transformation  
Calcium chloride based chemically competent E.Coli DH5α cells (50 µl) 
were used for the standard transformations (Seidman et al, 2001). The 
bacterial cells were incubated on ice for 30 min after pipetting the desired 
plasmid (1 ng) into the microcentrifuge tube after gently swirling to ensure 
mixing of plasmid and bacteria. Heat shock was performed by rapidly dipping 
the tube into 42ºC water bath (Bio Laboratories, Singapore) for 30 sec. The 
tube was kept on ice for 2 min and then 900 µl of Luria-Bertani (LB) media 
was added (5 g yeast extract, 10 g tryptone and 10 g of NaCl in 1 L of H2O) 
(Life technologies, USA) and incubated for 1 h at 37ºC in a bacterial shaker 
rotating at 250 rpm (Thermo Scientific, USA). The cells were spun down and 
plated on a LB/ampicillin plate or other appropriate antibiotic containing plate 
and incubated at 37ºC for 12-16 h. When a vector containing LacZ cassette 
was used, blue-white screening was performed based on the principle of α-
complimentation. So the LB plates were supplemented with X-gal (20 µl of 50 
mg/ml) (Promega, USA) and Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
(10 µl of 1 mM) (Promega, USA). 
2.2.7 Colony PCR screening 
Colony PCR is used to confirm the presence of the desired gene product 
and the orientation in the vector. The positive colonies obtained on the LB 
antibiotic plate is picked using a 0.1-10 µl pipette tip and resuspended in 5 µl 
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of sterile H2O. 1 µl from this is used as the DNA template source. The PCR 
reaction (KAPA Biosystems, South Africa) volume is 20 µl containing 2 µl of 
10X Buffer A, 1 µl of 10 mM dNTP, 10 µM of forward primer (preferably 
present on the vector before the 5‘ end of gene), 10 µM of reverse primer 
(within 500 bp of 5‘ end of the gene product) and made upto 20 µl with sterile 
H2O. The PCR conditions were – initial denaturation at 95ºC for 3 min, 35 
cycles of 95ºC for 30 sec, annealing at 55ºC, extension at 72ºC for 30 sec and 
final extension of 72ºC for 10 min. The PCR product was subsequently 
analyzed by agarose gel electrophoresis for the desired size product as 
explained earlier.  
2.2.8 Plasmid isolation  
The bacterial colony containing the plasmid with the gene of interest was 
inoculated from a freshly streaked plate into 5 ml of LB medium containing 
ampicillin (50 µg/ml) in round bottom bacterial culture tubes (BD 
Biosciences, USA). The tubes were incubated at 37ºC for 12-16 hr with 
vigorous shaking at 250 rpm in a bacterial shaker (Thermo Scientific, USA). 
The plasmid mini prep was carried out according to manufacturer‘s 
instructions (Omega bio-tek, USA). Briefly, the bacterial culture was pelleted 
at 13,000 rpm for 1 min in a 1.7 ml microcentrifuge tube and 250 µl of 
Solution I containing RNase was added and resuspended, followed by addition 
of equal volume of Solution II (lysis buffer) and mixed by inverting 5 times. 
This mixture was incubated for 2-3 min at room temperature and 350 µl of 
Solution III was added and mixed by inverting the tube to precipitate the 
protein and genomic DNA. The solution was centrifuged at 13,000 rpm for 10 
min at room temperature and supernatant was carefully transferred to a HiBind 
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DNA mini column with a 2 ml collection tube that was pre-equilibrated with 
100 µl of Equilibration buffer. The column was centrifuged, followed by 
addition and centrifugation steps for 500 µl of HB buffer and 700 µl of DNA 
wash buffer. Empty column was centrifuged again to remove any residual 
ethanol. Elution was done by addition of 30 µl of RNase free H2O and plasmid 
was quantified using NanoDrop (NanoDrop technologies, USA).  
2.2.9 Restriction digestion 
Digestion of DNA with restriction endonucleases was performed to sub-
clone the gene of interest, in situ probe synthesis etc. All the restriction 
endonucleases used for this study were purchased from New England Biolabs 
(UK) or Promega (USA). 3 µg of the plasmid containing the insert was 
restriction digested in a 20 µl reaction containing 2 µl of 10X reaction buffer, 
0.5 µl of enzyme (5 Units), 0.2 µl of 100X BSA, made upto 20 µl with sterile 
H2O. The reaction mixture was incubated at 37ºC for 3 hr 30 min. The 
restriction digested products were separated by agarose gel electrophoresis and 
gel purified as explained above.    
2.2.10 DNA sequencing 
DNA sequencing was performed using BigDye
®
 terminator (Applied 
Biosystems Inc., USA). DNA template (300 – 500 ng) was used for the DNA 
sequencing PCR with a primer concentration of 1.6 pmol and a BigDye 
premix containing buffer, dNTP, ddNTPs and DNA Taq polymerase in a 10 µl 
reaction. The PCR conditions involve 96ºC for 30 sec, 25 cycles of 50ºC for 
15 sec and 60ºC for 1 min. The microcentrifuge contents were spun down and 
the amplified product was purified by ethanol precipitation. Briefly, the PCR 
product was transferred into a fresh microcentrifuge containing three volumes 
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of ethanol one tenth volume of sodium acetate (3M). The reaction was mixed 
and incubated at room temperature for 10 min before centrifuging at 13,000 
rpm for 10min to pellet the PCR products. The supernatant was carefully 
discarded and pellet washed twice with 70% ethanol and centrifuged at 13,000 
rpm for 10min. The pellet was dried at 50ºC for 5 min and resuspended in 4 µl 
of automatic sequencing loading buffer. The solution was transferred to a 96 
well reaction plate and sequencing was performed using the 377 ABI PRISM 
automated DNA sequencer (Applied Biosystems Inc., USA).  
2.2.11 Constructs and vectors  
Human ADAMTS5 cDNA in pCMV6-XL4 vector was obtained from 
Origene (SC115752) and was used as a template to generate all the expression 
constructs of ADAMTS5 – full-length, domain deletion mutants and 
catalytically inactive (E411A) point mutant (Fig. 2.1) with the Advantage
®
-HF 
2 cDNA PCR polymerase (Clontech, USA) and set of primers (1
st
 Base, 
Singapore) to amplify the mutants as well as the full length ADAMTS5 (TS5-
FL) (Table 2.1). Full-length ADAMTS5 (TS5-FL) and the auto-catalytic 
fragments (TS5-p45 and TS5-60) were PCR amplified, gel purified and cloned 
using pEF6/V5-His TOPO
®
 TA kit (Life technologies, USA). Briefly, the 
amplified product was gel purified and ligated into pEF6/V5-His TOPO
 
vector 
(Fig. 2.2). Ligation reaction involved addition of 4 µl of gel purified PCR 
product, 1 µl of salt solution (1.2 M NaCl, 0.06 mM MgCl2), 1 µl of pEF6/V5-
His TOPO vector (0.5 µg/µl) and incubated at room temperature for 5 min. 
The reaction was placed on ice and the reaction mixture was transferred to one 
vial containing One Shot
® 
TOP10 chemically competent E.coli and mixed 
gently. The cells were incubated on ice for 30 min and heat shock for 30 sec at 
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42ºC followed by incubation at 37ºC for 45 min at 250 rpm after adding 250 
µl of Super Optimal Broth with SOC medium. The cells were spun down and 
resuspended in a small volume of 50 µl and plated onto LB ampicillin plate 
and incubated for 12-16 hr at 37ºC incubator (Jouan, Germany). The positive 
clones were confirmed by colony PCR screening. 
 
Fig. 2.1 Schematic representation of ADAMTS5 and its domain 
deletion mutants used in this study: The tag at the C-terminal end of 
all of the constructs comprises a V5-epitope and a C-terminal histidine 
tag (blue star) or a c-myc epitope and a C-terminal histidine tag 
(brown star). For those constructs that lack endogenous signal peptide 
(TS5-ΔMP, TS5-TSR1 and TS5-CT), secretary Ig-κ signal peptide 




For the deletion constructs that do not have an endogenous signal peptide 
(TS5-ΔMP, TS5-TSR1 and TS5-CT), secretary Ig-κ signal peptide from the p-
Sec Tag 2C mammalian expression vector was incorporated in frame with the 
sequence. Briefly, the desired constructs were amplified using specific primers 
(Sigma-Proligo, Singapore) and designed to include restriction sites HindIII 
for forward primers and XhoI for the reverse primers (Table 2.1). The 
amplified product was cloned into pGEM
®
-T vector (Promega, USA) (Fig. 
2.3), sequence confirmed and sub-cloned into pSec Tag2C vector (Invitrogen, 
USA) (Fig. 2.4) using restriction based cloning as explained above. The Ig-κ 
signal peptide incorporated TS5-TSR1 and TS5-CT were further sub-cloned 
into pEF6/V5-His TOPO mammalian expression vector.   
 







Fig. 2.3 Vector map of pGEM
®
-T vector (Adapted from 
www.promega.com). 
 
Fig. 2.4 Vector map of pSecTag 2C (Adapted from 
www.invitrogen.com). 
2.2.12 Site-directed mutagenesis 
For generating the catalytically inactive ADAMTS5 (TS5-E411A), 
QuikChange™ Site-Directed Mutagenesis Kit (Stratagene, USA) was used. 
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Briefly, mutagenic primer pair containing the point mutation was designed 
according to manufacturer‘s instructions (Table 2.1). The TS5-FL in 
pEF6/V5-His TOPO
® 
vector was used as the template and amplified by PCR 
to incorporate the desired point mutation. The sample reaction comprised of 5 
µl of 10X reaction buffer (100 mM KCl, 100 mM (NH4)2SO4, 200 mM Tris-
HCl (pH 8.8), 20 mM MgSO4, 1% Triton
®
 X-100, 1 mg/ml nuclease-free 
bovine serum albumin (BSA)), 25 ng of TS5-FL in pEF6/V5-His TOPO
® -
plasmid, 125 ng of forward and reverse primers, 1 µl of dNTP mix, made upto 
50 µl with RNase free H2O and 1 µl of PfuTurbo DNA polymerase (2.5 U/µl). 
Cycling parameter for the site directed mutagenesis involved initial 
denaturation at 95ºC for 30 sec, 18 cycles of 95 ºC for 30 sec, 55ºC for 1 min, 
68ºC for 18 min (2 min/kbp of plasmid length) and cooled at 4 ºC for 2 min. 
Following PCR, the non-methylated parental DNA template was digested with 
1 µl of Dpn I restriction enzyme (10 U/µl) and incubated at 37ºC for 1 hr. The 
circular, nicked dsDNA was transformed into Epicurian coli XL1-Blue 
supercompetent cells by transferring 1 µl of the Dpn I-treated DNA. The 
positive clones were confirmed by colony PCR, plasmid isolated and sequence 
confirmed.  
2.2.13 List of primers 
All the primer pair used in the study has been tabulated below with a brief 
description of the purpose it was used in and the corresponding annealing 
temperature for the PCR (Table 2.1).  
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2.3 Transient Transfection 
2.3.1 Branched polyethylenimine (bPEI) mediated transfection 
Branched polyethylenimine (bPEI) (Sigma-Aldrich, USA) is one of the 
very efficient, cost effective and commonly used method to introduce plasmid 
DNA into mammalian cells (Schlaeger & Christensen, 1999). Transient 
transfection of mammalian cells was performed to confirm the expression of 
the ADAMTS5 protein and other domain deletion mutants. HEK293T or 
B16F10 mouse melanoma cell lines were used to transfect the desired 
plasmids. The cells were seeded in a 6 well plate or a 10 cm dish (Greiner bio-
one, Germany).  Once 70-80% confluence is attained, the cells were washed 
with 1X PBS once and transfection mix was added drop wise. Transfection 
mix comprised of DNA: bPEI in a ratio of 1.5:2 in 1X PBS (10% of the 
volume of media used for culture, i.e., 200 µl for 6 well plate and 1 ml for 10 
cm dish). 2.5 or 15 µg of endotoxin free plasmid DNA was used for 
transfection for 6 well plate or 10 cm dish respectively. bPEI working solution 
was 1 mg/ml in sterile MilliQ H2O. This mix of DNA and bPEI was vortexed 
thrice and incubated at room temperature for 20 min before adding onto the 
cells. The cells were incubated overnight with complete medium and replaced 
with serum free medium containing heparin (100 µg/ml) for 48 hr before 
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Cloning of TS5-CT from 
pSecTag2C vector into pEF6/V5-
His TOPO
®
 Vector. TS5-FL_RP CGCGCTCGAGCACATTTCTTCAACAAGC 
11 TS5-FL1 AGAAACAACGGACGCTACTG 50ºC 
Primers used for sequencing 
12 TS5-FL2 GACAGTTCAAAGCCAAAGAC 50ºC 
13 TS5-FL3 TGGTTCCACAGAAGATAAGC 50ºC 
14 TS5-FL4 TCTGTCCTGGGAGTTCTTCG 50ºC 
15 TS5-FL5 CAATGGGTGGACTATTTACG 50ºC 
17 TS5-FL6 GCTCACTTCCAGGCTCTTGT 50ºC 
18 TS5-FL7 CGAAGAAGCCGTCGAGACCC 50ºC 
19 TS5-FL8 GACAGTTCAAAGCCAAAGACC 50ºC 
20 TS5-FL10 ATTAGAATTTCCTTCGTGGC 50ºC 
21 
zfats5_insitu_FP TCCTGTTATCCGAGCGAAAG 




55ºC Morpholino knockdown 
zfats5_MO_RP GGAGTCGTCGTGGGACAGAC 
23 T7 Primer TAATACGACTCACTATAGGG 
55ºC Colony PCR 
24 SP6 Primer ATTTAGGTGACACTATAG 
Table 2.1 Primer pairs used in this study.
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2.3.2 Concentration of conditioned medium 
Post transfection and incubation with serum free medium, the conditioned 
medium (CM) was harvested after 48 hrs. Two different methods were 
employed for the concentration of CM based on the downstream application of 
the protein. For functional assays, the CM was concentrated using Amicon 
Ultra-15 Centrifugal Filter Units (Millipore, USA). CM was transferred into 
the filter unit with appropriate molecular weight cut off membrane and 
centrifuged at 4,500 rpm for 15 min (Beckman Coulter, USA) to obtain a 20X 
concentrated CM (200 µl). The protein was quantified, aliquoted and stored in 
-80ºC till further use.  
For assays that do not need the native structure of the protein intact such as 
western blotting, acetone precipitation of the protein was performed. Four 
times the volume of the sample, ice cold acetone (-80ºC cooled acetone) was 
added, mixed and kept at -80ºC for 4 min. The precipitated total protein was 
centrifuged at 4,500 rpm for 15 min. Supernatant was decanted carefully and 
acetone was allowed to evaporate from the uncapped tube at room temperature 
for 30 min. The pellet was dissolved in 100 µl of 2X SDS-loading dye (100 
mM Tris-Cl (pH 6.8), 4% (w/v) SDS (sodium dodecyl sulfate; electrophoresis 
grade), 0.2% (w/v) bromophenol blue, 20% (v/v) glycerol, 200 mM β-
mercaptoethanol) and sample boiled for 5 min at 100ºC on a heat block 
(Techne, Germany).    
2.3.3 Quantification of protein concentration 
Bradford protein assay was used to quantify the total protein content in 
CM. BSA standard was prepared (10 mg/ml). Five dilutions of BSA standard 
were prepared from 0-500 µg/ml. Standard and test sample (20 µl) was 
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pipetted into 96 well plate in triplicate (Nunc, Denmark). Diluted (1:5 in 
distilled water and filtered) Bradford reagent (Bio-Rad, USA) was added and 
mixed well. Absorbance was measured at 595 nm using a xMark™ Microplate 
Absorbance Spectrophotometer (Bio-Rad, USA). Based on the standard curve, 
the concentration of total protein was quantified in CM.  
2.3.4 Aggrecanase assay 
Fifty μl of concentrated CM of pEF6/V5-His TOPO®  Empty vector (EV), 
TS5-FL or TS5-E411A was incubated with 500 nM aggrecan from bovine 
articular cartilage (Sigma-Aldrich, USA) in a buffer containing 50 nM Tris-
HCl, pH 7.4, 100 nM NaCl and 10 nM CaCl2 at 37 ºC for 16 h. Next, 
fragments were enzymatically deglycosylated using aggrecan chondroitinase 
ABC (0.1 U per 10 μg of aggrecan; Sigma-Aldrich, USA) at 37ºC for 1 h, 
followed by 2 h incubation at 37 ºC with 0.002 U per 10 μg aggrecan of endo-
β-galactosidase (Sigma-Aldrich, USA). The sample was subjected to western 
blot analysis using neo-epitope specific AGEG antibody (kindly provided by 
Dr. Hideaki Nagase).  
2.4 Western Blotting 




 3 Cell (Bio-Rad, USA) SDS-PAGE apparatus was used 
to hand cast gels. 8 to 15% polyacrylamide gels were used depending on the 
molecular weight of the band to be resolved. Briefly, the clean glass plates 
with a spacer having a 1.5 mm gap were fit into a cast. First, resolving gel was 
poured till two third of the vertical length. Resolving gel consists of 30% 
acrylamide/bisacrylamide solution (37.5:1, acrylamide/bis; Bio-Rad, USA) 
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and 1.5 M Tris-Cl (pH 8.8) in varying proportions to obtain different 
percentage of gel, 150 µl of 10% SDS and 10% fresh ammonium per sulfate 
(APS) and made upto 15 ml with MilliQ H2O. 8 µl of TEMED was added and 
poured into the glass plates. MilliQ H2O (1 ml) was added to produce a 
smooth, level surface on top. Once the gel is solidified, the water was decanted 
and 4% stacking gel was poured. Stacking gel is composed of 1.2 ml of 40% 
acrylamide/bisacrylamide solution with 1 ml 0.5 M Tris.Cl (pH 6.8), 80 μl of 
10% SDS, 80 μl of 10% fresh APS  made upto 10 ml with H2O and 8 μl 
TEMED was added. The combs were placed after pouring the gel and allowed 
to solidify. Once set, the glass cassette was carefully removed from the cast set 
up and placed in a Mini-PROTEAN 3 electrophoresis module assembly. Both 
inner and outer chamber of the tank was filled with the SDS-running buffer 
(15 g/L Tris base, 72 g/L Glycine, pH 8.3, SDS 5 g). The samples and protein 
marker (Bio-Rad, USA) were loaded into the wells and the electrical leads 
were connected to a suitable power supply and run at 120 V for 1 to 1.5 hr 
depending on the percentage of the resolving gel. For staining of protein gel 
for total protein where necessary, the resolving gel was carefully placed in a 
20 cm culture dish and stained with Coomassie blue (0.1% Coomassie R250, 
10% acetic acid, 40% methanol in 1L of H2O) for 60 min on a shaker (GFL, 
Germany). The gel was destained by immersing in destaining solution (20% 
methanol, 10% acetic acid) for 1 h with few Kimwipes
®
 (Kimberly Clark 
Professional, USA) and replaced with fresh destaining solution overnight till 
the protein bands are distinctly visible and background is removed. The 
polyacrylamide gel was placed on a gel illuminator (Hoefer, USA) and image 
was taken using a digital camera Canon Powershot A2300 (Singapore). 
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2.4.2 Gel transfer 
Wet electroblotting transfer system (Bio-rad, USA) was used to transfer 
the resolved protein on the polyacrylamide gel into the nitrocellulose 
membrane (Bio-rad, USA). Briefly, the nitrocellulose membrane, thick blot 
papers (4) and foam pads were soaked in transfer buffer (48 mM Tris, 39 mM 
glycine, 0.04% SDS, 20% methanol). The membrane was placed over the gel, 
sandwiched between two blot papers on each side followed by a foam pad in a 
mini gel holder cassette. Care was taken to remove any bubble formed and the 
cassette was placed into the mini trans-blot central core and the set up was 
placed inside the electrophoresis system along with the bio-ice cooling unit. It 
was made sure that the membrane was towards the positive electrode. The 
membrane transfer was done at 100 V for 1 h.  
2.4.3 Blocking and immunoprobing 
The nitrocellulose membrane post transfer was placed in a plastic box and 
blocked with 10 ml of 5% non-skimmed milk in 1X Tris buffered saline (50 
mM Tris-Cl, 150 mM NaCl, pH to 7.6) and 1% Tween-20 (TBST). The 
membrane was agitated on a shaker for 1-2 hr. The milk was replaced by the 
antibody with appropriate dilution prepared in 3% BSA in 1X TBST and 
incubated overnight at 4ºC with shaking. This was followed by three washes 
with 1X TBST for 10 min each on a shaker. The appropriate secondary 
antibody conjugated with horse radish peroxidase (HRP) in 3% BSA in 1X 
TBST was added to the membrane at room temperature with agitation for 1 hr. 
Post incubation, membrane was washed three times with 1X TBST for 10 min.  
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2.4.4 Chemiluminescent detection 
Enhanced chemiluminescent substrate was used for the detection of the 
HRP activity (Thermo Scientific, USA).  Briefly, the membrane was placed in 
the developing cassette, incubated with equal volumes of the luminol/enhancer 
and the peroxide buffer, covered with a plastic sheet. An unexposed X-ray 
film (Kodak, USA) was placed on top on the plastic sheet and incubated in 
dark for 5 min. The film was developed in a dark room using an automated X-
ray film processor (Kodak, USA).  
2.4.5 Stripping and re-probe  
Stripping of the nitrocellulose membrane was done by incubating the 
membrane in the stripping buffer (1.5% glycine, 0.1% SDS, Adjust pH to 2.2) 
with agitation for 15 min. The membrane was washed for 5 min thrice with 1X 
TBST before blocking with 5% non-fat milk. The antibody incubation and re-
probing was done as explained earlier.  
2.5 In vitro cell-based assays 
2.5.1 Endothelial cell (EC) tube formation assay 
Tube-like structure formation from ECs was performed using ECMatrix
®
 
Matrigel (Chemicon, USA) according to the manufacturers‘ protocol.  
ECMatrix
®
 and diluent buffer was thawed and kept on ice. Diluent Buffer 
(100 µl of 10X) was mixed with 900 µl of ECMatrix
®
 solution in a sterile 
microfuge tube and mixed well.  The work was carried out in a cold room.  A 
volume of 50 µl was plated into a 96 well plate or 10 µl into a µ-Slide 
Angiogenesis chamber (Ibidi GmbH, Germany) and kept at 37ºC for 1 hr to 
solidify. ECs (2.0 X 10
4
 cells) per sample were pre-incubated with 100, 250 
89 
 
and 500 nM of mammalian expressed N-terminal ADAMTS5 (ATS5-p45) 
(R&D systems, USA) for 30 min at 37°C in CSC complete medium with or 
without TS5-inhibitor (1 µM). In another set of experiment, equal amount of 
total protein (10 µg) from concentrated CM from two 10 cm dishes of B16F1 
transfected with vector or TS5-FL was pre-incubated with ECs. After pre-
incubation, the cells were plated onto a pre-formed Matrigel and incubated at 
37°C with 5% CO2 for 6–8 h before documenting the tube-like structure 
formation using Zeiss Axiovert 200 inverted light microscope (Germany). 
Capillary length was quantified from representative fields using NIH ImageJ 
1.45 software. 
2.5.2 Cell proliferation assay 
ECs (1x10
4
 per well) were cultured overnight in a gelatin (0.2%) pre-
coated 96-well plate in CSC complete medium (Cell system, USA) at 37°C. 
Cells were starved the following day for 3 h in CSC basal medium containing 
2% FBS and incubated with varying concentrations of TS5-p45 (100 – 500 
nM) with 20 ng/ml VEGF (R&D systems, USA). 1X BrdU was also added to 
the medium. After 24 h of incubation, EC proliferation was determined using 
BrdU cell proliferation kit (Chemicon International Inc., USA) according to 
manufacturer‘s instruction. Briefly, the ECs were fixed following treatment by 
adding 100 µl of fixing solution and rotated on a horizontal shaker for 20 min. 
The cells were washed for 3 times with 1X wash buffer and incubated with 
100 µl anti-BrdU antibody for 1 h with agitation at room temperature. 
Following 3 washes with wash buffer, 100 µl of secondary antibody 
conjugated to HRP was added and incubated for 30 min at room temperature. 
Cells were washed again three times with the wash buffer and a final wash 
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with milliQ H2O. 100 µl of 3,3',5,5'-Tetramethylbenzidine (TMB) substrate 
was added and incubated for 10 min with agitation or till the color develops. 
Stop solution of 100 µl was added to stop the reaction and the absorbance was 
read in a micro-plate reader (Bio-Rad, USA) at 450 nm.  
For non-ECs such as B16F1 and Swiss3T3, the cells were starved 
overnight with serum free DMEM media and then treated with the TS5-p45 as 
above in serum free media for 24 h. BrdU incubation was for just 2 h before 
proceeding with cell fixing and cell proliferation assay. For stable cell lines 
overexpressing ADAMTS5 or other domain deletion mutants, the cells were 
seeded onto a 6 well plate (10
4
 cells/well) for overnight in complete media. 
The next day, cells were starved overnight in serum free DMEM to attain 
synchronization. Following starvation, the medium was replaced with DMEM 
+ FBS (5%) + PS (1%) medium and cell counting was done every alternate 
day till day 5. Cell counting was performed using Nucleocounter 
(Chemometec, Denmark) as explained earlier.  
2.5.3 Cell apoptosis assay  
1 X 10
4
 ECs were seeded per well in a gelatin coated 96-well plate in CSC 
complete medium and incubated overnight at 37°C. ECs were starved on the 
following day for 3 h before treatment with TS5-p45 (100, 250 and 500 nM) 
in the presence of 20 ng/ml VEGF. They were incubated at 37°C for a period 
of 24 h prior to cell death detection. Cell apoptosis was determined using a 
Cell Death ELISA kit (Roche Diagnostics, Germany). Briefly, the cells were 
centrifuged at 200 g for 10 min and the media discarded carefully. The cells 
were lysed by adding 100 µl of lysis buffer and again centrifuged. Lysate (20 
µl) was transferred into the streptavidin coated micro-plate and 80 µl of 
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immunoreagent containing anti-histone and anti-DNA antibody for 2 hr at 
room temperature with agitation on a shaker. The microplate was washed three 
times with the incubation buffer and 100 µl of substrate solution added. The 
microplate was incubated for 20 min under agitation or till the color develops. 
The reaction was stopped by pipetting 100 µl of stop solution. The absorbance 
was measured at 405 nm in a microplate reader (Bio Rad, USA).   
In another experiment, ECs were pre-treated for 1 h at 37 °C with Z-VAD-
FMK (carbobenzoxy-valyl-alanylaspartyl-[O-methyl]- fluoromethylketone) 
(Calbiochem Inc., UK), a cell-permeable pan caspase inhibitor that 
irreversibly binds to the catalytic site of caspase proteases and apoptosis assay 
was performed as explained above. For non-ECs, the treatment was done 
under serum free DMEM media and apoptosis assay performed as above. For 
non-ECs such as B16F1 mouse melanoma, the apoptosis assay was performed 
as explained above with 5X10
3
 cells.   
2.6 Stable cell-line generation 
2.6.1 Determination of antibiotic sensitivity of tumor cells 
5X10
4 
of B16F1 or A549 cells were seeded into the 6 well culture dish in 
DMEM + FBS (10%) + PS (1%) medium. After overnight incubation at 37 ºC 
at 5% CO2, the media was replaced with complete media containing 
blasticidin antibiotic (Life technologies, USA) at various concentrations – 0, 2, 
4, 6, 8, 10 µg/ml. Media with antibiotic was replenished every alternate day 
and the assay was performed for a week. The cells were observed under phase 
contrast microscope (Zeiss Primovert, Germany) to visualize the cell 
morphology. Concentration of more than 4 µg/ml lead to cell death, cells 
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rounded off, became non-adherent and was washed away in case of both cell 
lines. To give a more stringent selection system, 8 µg/ml blasticidin was used 
for the stable cell line generation and maintenance. Similarly, for zeocin (Life 
technologies, USA), 400 µg/ml concentration was used.  
2.6.2 Lipid mediated transfection 
For generation of stable cell lines, lipid mediated plasmid transfection was 
performed in B16 mouse melanoma and A549 human lung adenocarcinoma 
using TransIT
®
-LT1 transfection reagent (Mirus, USA). Approximately 18 hr 
before transfection, the cells were plated on a 10 mm dish to attain 60-70 % 
confluence in complete growth medium after one day of seeding. In a sterile 
microcentrifuge tube containing 250 µl of DMEM, 2.5 µg of plasmid and 7.5 
µl of transfection reagent were added and mixed by pipetting. The mix was 
incubated at room temperature for 15-30 min and added drop wise onto the 
cells. The cells were incubated overnight at 37ºC at 5% CO2, trypsinized and 
the cells were seeded into five 10 cm dishes with complete media at a very 
low dilution. After 24 hr, the medium was replaced with complete media 
containing antibiotic (blasticidin or zeocin). Media was replaced every two to 
three days for 2-3 weeks till single distinct colonies appear that are antibiotic 
resistant.  
2.6.3 Selection of stable clones 
Once the large and distinct colonies (75-100 mm in diameter) have 
appeared, they were isolated using bottom of sterile blue tips that were cut to 
0.5 cm height. Edge of the cut tip was dipped in sterile Vaseline (Vaseline, 
USA) to coat with a layer of Vaseline and carefully placed around a single 
colony to seal it. Trypsin (50 µl) was added into the well and incubated for 4-5 
93 
 
min. The trypsinized colony was transferred into a 96 well plate. After 
overnight incubation, the cells were replenished with fresh media. Once the 
well reaches 90% confluency, the colony was expanded into 24 well plate 
followed by 6 well plate and finally into a T-25 flask. The cells were 
cryofrozen as explained earlier once the T-25 flask reaches 90% confluence. 
For one stable cell line generation, 30-40 single isolated clones were picked 
and validated. 
2.6.4 Validation of stable clones  
The stable clones were cultured in T-25 flasks and once they attain 80% 
confluency, the medium was replaced with serum free medium containing 
heparin (100 µg/ml). After 48 h, the total protein in the CM was acetone 
precipitated. Western blotting was performed and immunoprobing was done 
using primary antibody mouse anti-V5 (1:5000) or mouse anti-c-myc (1:2000) 
(Life technologies, USA) depending on the protein tag present in the 
overexpressing clones. The positive clones were expanded and cryofrozen till 
further use. 
In order to check for the homogeneity of the clones, immunocytochemistry 
was performed on the clones that have high expression. Briefly, 3X10
4 
cells 
were seeded into a 96 well plate and post 24 h, the cells were fixed using 4% 
paraformaldehyde (PFA) (Sigma-Aldrich, USA). Cells were washed three 
times with 1X PBS and were permeabilized by 0.25% Triton-X-100 detergent 
for 20 min followed by three washes of 1X PBS. The cells were washed again 
and blocked in 3% BSA in 1X PBS for 3 h at room temperature with agitation 
on a shaker. The cells were then incubated with 100 µl of primary antibody 
(anti-V5 or anti-c-myc) (1:500 dilution in 3% BSA) for overnight at 4 ºC. 
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Following day, the antibody was washed three times with 1X PBS and 
incubated with anti-mouse IgG conjugated to Alexa Flour
®
 568 (Life 
technologies, USA) for 1 h at room temperature in dark. The unbound 
secondary antibody was washed with 1X PBS thrice and 50 µl of DAPI (1 
µg/ml) was added to stain the nuclei. This was followed by three 1X PBS 
washes and the cells were visualized under the Zeiss Axiovert 200 inverted 
light microscope (Germany).  
2.7 Syngeneic mouse tumor implant assay 
2.7.1 Animals 
Adult (7- to 8-week-old) female C57BL/6J mice were used in this study. 
Animal care and experimentation was carried out following institutional 
guidelines approved by the local institutional animal care and use committee 
(IACUC; protocol 078/08).  Housing included ideal cage size, autoclaved 
bedding, proper ventilation, controlled temperature (24ºC), relative humidity 
(40 -70%) and 12-14 h of light and 10-12 h of dark photoperiod. Maximum of 
5 mice per cage was kept in one cage, provided with automated water system 
and rodent diet ad libitum. At the end of the study, the mice were euthanized 
by placing them into a CO2 chamber until they stop breathing and dead.  
2.7.2 Subcutaneous syngeneic/xenograft mouse tumor model 
Briefly, 1X10
6
 of B16 mouse melanoma cells in 0.1 ml of PBS 
overexpressing ADAMTS5 or its various truncated forms were injected into 
the dorsal right flank of the mouse along with the corresponding empty vector 
control on the left flank of the same mouse. In case of A549, 5X10
6
 of A549 
cells overexpressing ADAMTS5 or the empty vector was injected into the 
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dorsal flanks of the nude mice. Health status of the mice was monitored 
routinely and visible tumor dimensions were measured after 10 days using a 
digital caliper every day until day 16 after injection in the case of B16 
melanoma and for 35 days in A549 cell line. Tumor volume was determined 




, where the length is the 
largest dimension of the tumor and the width is the perpendicular dimension 
(Tomayko & Reynolds, 1989). Mice were sacrificed and tumors excised and 
processed for sectioning or snapfrozen in liquid nitrogen and stored at -80°C 
for further analysis. 
2.8 Immunohistochemistry (IHC) 
2.8.1 Fixation 
Half of the total tumors excised were rinsed in 1X PBS to wash away the 
blood and fat tissue before transferring into freshly prepared 4% PFA in 1X 
PBS. The tumors were rotated on a nutator (Labnet International, USA) for 3-
4 h before replacing the solution with fresh 4% PFA followed by overnight 
incubation with agitation at 4°C. 
2.8.2 Paraffin embedding 
The tumors were dehydrated through a series of graded ethanol to displace 
the biological fluid and then infiltrated with the paraffin wax (Sigma-Aldrich, 
USA). Briefly, the PFA containing tumors were replaced with 50% ethanol 
and agitated for 6 h at room temperature. Later, it was replaced with 70% 
ethanol and incubated overnight at 4°C. Next day, the dehydration was 
continued with 90% ethanol for 2-4 h and 100% ethanol for 1 h. The tumors 
were submerged in 100% histoclear (Sigma-Aldrich, USA) and incubated for 
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1hr at room temperature with fresh histoclear replaced three times every hour 
and a final overnight incubation at 4°C with agitation.  Next day, the tumors 
were placed on weighing boats and submerged in melted paraffin (65°C) for 1 
hr. The paraffin was replaced with fresh paraffin and kept overnight in the 
oven at 65°C. The following day, fresh paraffin was added and the tumor 
containing boats were kept at room temperature and allowed to solidify. Care 
was taken to avoid bubbles and not to disturb till complete solidification.  
2.8.3 Sectioning 
The solidified tumors embedded in paraffin were cut into cubes with the 
tumors in the center. It was made sure that there was 2-3 mm margin around 
the tumors. The embedded solid tumor was placed on a wooden block and 
sealed with liquefied wax using a cigarette lighter. The tumor tissue was 
sectioned (5 µM) using a microtome (Riechert-Jung Inc., Germany). The 
sections were transferred carefully with a paint brush into a waterbath (42°C) 
and allowed to spread. The section was later carefully transferred onto a 
polysilane coated glass slide (Thermo-Scientific, USA). The sections were 
labeled and dried on a glass slide drier (Riechert, Germany) at 40°C overnight. 
The slides were stored in a slide box till further use at room temperature.  
2.8.4 Dewaxing and rehydration 
The slides containing tissue sections were dewaxed by heating at 65°C for 
8 min followed by dewaxing in histoclear for 10 min. The slides were 
submerged into fresh histoclear for 10 min for two more times. This was 
followed by the rehydrating in a series of alcohol grades starting from absolute 
ethanol (3 times, 10 min each), 90% ethanol (2 times, 5 min each), 70% 
ethanol once for 5 min and rehydrated in 1X PBS for 5 min.  
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2.8.5 Antigen retrieval 
Antigen retrieval was carried out in an antigen retriever (Electron 
Microscopy Sciences, USA). Briefly, the rehydrated slides were placed in the 
processing chambers and filled with R-Buffer A (pH 6). The chamber 
containing slides were transferred into the rack and retriever was filled with 
750 ml of deionized water and the lid closed tightly. The retriever was 
switched on to generate high pressure and temperature optimal for antigen 
retrieval. The slides were washed in 1X PBS and proceed with IHC staining.  
2.8.6 Immunohistochemistry (IHC) 
The slides were dried with Kimwipe and a continuous hydrophobic circle 
was drawn using a DAKO pen (Dako, Denmark) around the tumor sections. 
The slides were then blocked with 3% BSA in 1X PBST for 1 h before 
incubating with the specific primary antibody (1:500 dilutions) overnight at 
4°C. The slides were washed three times with 1X PBST for 5 min each and 
incubated with corresponding secondary antibody (1:1000 dilutions) for 2 h at 
room temperature. The slides were washed as earlier and stained with DAPI (1 
µg/ml in 1X PBS) (Chemicon, USA) for 10 min. The slides were washed with 
1X PBS three times and coverslip (Cell Path Ltd., UK) was mounted with 
suitable mounting medium (1X PBS: Glycerol – 1:1 ratio). The section was 
imaged in Zeiss Axiovert 200 inverted light microscope with appropriate 
filters. 
2.8.7 Microvessel density (MVD) determination 
The sections were stained with anti-PECAM1 antibody (Santa Cruz, USA) 
overnight at 4°C and corresponding anti-rabbit secondary antibody conjugated 
with Alexa flour 568 (Life technologies, USA). The microvessel in the tumor 
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sections were visualized under 10X or 20X magnification and quantified 
(Weidner et al, 1991). Three random fields were chosen per section, three 
sections per tumor and two such tumors per construct.     
2.8.8 Proliferation index  
Proliferating cell nuclear antigen (PCNA) was used as a marker to 
investigate the proliferation rate in the tumor tissue sections (Kubben et al, 
1994). Anti-PCNA antibody (Santa Cruz, USA) (1:500) was used to stain 
nuclei that are in S phase of replication. Corresponding anti-mouse Ig-G 
conjugated with rhodamine – Alexa fluor 568 (Life technologies, USA) 
(1:1000 dilutions) was used. Three random fields were chosen per section, 
three sections per tumor and two such tumors per construct. In a given field, 
total number of DAPI stained nuclei were counted and corresponding number 
of PCNA stained nuclei were counted and the fraction was represented as a 
percentage of proliferating cells.  
2.8.9 Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assay 
The sections were stained with TUNEL assay (Roche Diagnostics GmbH, 
Germany) according to the manufacturer‘s protocol. Briefly, after blocking in 
3% BSA, the slides were incubated with 50 µl of TUNEL reaction mixture 
containing 45 µl of label solution (nucleotide mixture) and 5 µl of enzyme 
solution (Terminal deoxynucleotidyl transferase). The enzyme catalyzes 
polymerization of fluorescein labeled nucleotides to free 3‘ –OH DNA ends in 
a template independent manner (Whiteside & Munglani, 1998). The slides 
were incubated at room temperature in a humidified chamber for 1 hr in dark. 
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The sections were counterstained with DAPI for 10 min and visualized under 
fluorescent microscope as explained earlier.  
2.9 Tumor Protein Extraction  
The snap frozen tumor tissues were grinded in a mortar with a pestle in 
liquid nitrogen and a part of the tumor was crushed till they become powder. 
The tissue was transferred into a 1.7 ml microcentrifuge tube and 1ml of urea 
lysis buffer (TRIS base 40 mM, Urea 7 M, Thiourea 2 M, NP-40 or CHAPS 
4%, DTT 10 mM) was poured (Chen et al, 2005). The tissue lysate was 
vortexed and subjected to further sonication (Daihan Scientific, Korea) at 10% 
output for 20 pulses. The lysate was centrifuged at 13,000 rpm for 1 hr at 4°C 
and the supernatant was aliquoted, quantified and stored at -80°C until further 
use.  
2.10 Angiogenesis antibody array 
Proteome Profiler
TM
 mouse angiogenesis antibody array (R&D systems, 
USA) was used to detect the relative levels of 53 mouse angiogenesis related 
protein. The array was hybridized with an equal amount of total protein (200 
µg, quantified using Bradford method as described earlier) from ADAMTS5 
overexpressing and empty vector tumor tissue protein lysate. The assay was 
performed according to the manufacturer‘s protocol. The membrane 
containing 53 mouse angiogenesis related proteins were placed in a 4 well 
multi-well plate and incubated with 2 ml of blocking buffer on a rocking 
platform shaker for one hour (GFL, Germany). While blocking, the samples 
were prepared in 1 ml of array buffer 4 containing 200 µg of equal amount of 
total protein from tumors of B16 overexpressing ADAMTS5 or corresponding 
empty vector. A volume of 15 µl of reconstituted detection antibody cocktail 
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was added to each sample and mixed at room temperature for an hour. Array 
buffer 6 was aspirated from the multi-well plate and the antibody-protein 
mixture was added and incubated at 4°C with rocking. The nitrocellulose 
membranes were washed three times in 15 ml of wash buffer for 10 min each. 
The membranes were transferred to the 4-well multi-dish and 2 ml of 
Streptavidin-HRP in array buffer 6 and incubated for 30 min at room 
temperature. This was followed by 10 min of three washes and then developed 
using chemiluminescence substrate as described earlier.     
Validation of the antibody array was done by performing western blotting 
using mouse specific antibodies against the pro-angiogenic growth factors that 
were shown to be downregulated.  Tumor tissue total protein lysate or the cell 
lysate (50 µg) was used and immunoblotting performed as explained earlier.   
2.11 Co-immunoprecipitation of VEGF and ADAMTS5 
ADAMTS5 full-length (TS5-FL) and empty vector control (Vec) were 
transfected into HEK293T and the CM was concentrated using 50 kDa 
molecular weight cut off centrifugal filters (Millipore, USA). Anti-V5 (1 µg) 
antibody was immobilized into 10 µl of Protein A/G agarose beads (Promega, 
USA) in a wash buffer (0.025 M Tris, 0.15 M NaCl, 0.001 M EDTA, 1% NP-
40, 5% glycerol, pH 7.4) with 1 h at room temperature rocking. The unbound 
antibodies were washed off by rinsing it in wash buffer thrice followed by a 
quick spin each time. Total protein of 1 mg from the CM and 200 µg of 
VEGF165 were mixed in wash buffer and were incubated at 4ºC overnight 
rocking. This mixture was added into the microcentrifuge containing anti-V5 
conjugated agarose beads and immunoprecipitation was performed for 
overnight at 4ºC with mild agitation. The bound beads were centrifuged at 
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13,000 rpm for 30 sec and the unbound mixture of supernatant containing 
VEGF and other impurities were discarded. The resin was washed twice with 
the wash buffer before eluting the bound beads with 50 µl of 2X SDS loading 
dye.  Immunoblotting was performed with anti-VEGF antibody (Santa-Cruz, 
USA) and anti-V5 antibody (Life technologies, USA). 
2.12 Experimental mouse lung metastasis assay 
2.12.1 Tail vein injection 
2.5X10
5
 B16F10 mouse melanoma cells overexpressing ADAMTS5 
(B16/TS5-FL), overexpressing catalytically inactive ADAMTS5 (B16/TS5-
E411A) or corresponding empty vector (B16/Vec) and 1X PBS as control 
were injected into the dilated lateral vein of the mouse (Elkin & Vlodavsky, 
2001). Seven to eight weeks old C57Bl/6J black mice was placed in a 
restrainer (Harvard Apparatus, USA) with its tail protruding out of the cage 
through the restrainer opening. Dilation was done using a hand held infra-red 
lamp (Philips, Singapore). The tail was wiped with gauze sprayed with 70% 
ethanol. The cells in 100 µl of were injected using a 27 gauge needle (Nipro 
Corporation, Thailand) and a 1 ml syringe (Terumo, Philippines). It was taken 
care that the cells were not clumped or did not force itself back into the 
syringe after injection. After 17 days (death of first mice), the mice were 
euthanized with CO2 fixation. The lungs were dissected, washed in 1X PBS 
and weighed. The lungs were stored in PFA till further fixation and 
embedding as described earlier.  
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2.12.2 Immunohistochemistry  
The lung tissues were fixed, embedded and sectioned as mentioned earlier. 
Haematoxylin and eosin (H&E) staining and CD-31 staining was performed 
on the lung sections. For H&E staining, the sections were deparaffinized by 
heating at 65ºC for 8 min followed by 3 washes of histoclear for 10 min each. 
The sections were submerged in 100% ethanol (2 washes, 10 min each), 90% 
ethanol (2 washes, 10 min each) and 70% ethanol (2 washes, 5 min each), 
washed in 1X PBS and deionized water followed by 5 min of Haematoxylin 
stain (Vector Laboratories Inc., USA). The sections were washed with 
deionized water and stained with eosin stain (Sigma-Aldrich, USA) for 30 sec 
and dehydration in 95% ethanol followed by 100% ethanol (2 washes, 10 min 
each). The coverslip was mounted on the sections using mounting medium and 
imaged using Zeiss upright Axiovision 200 microscope.  
2.13 Zebrafish development biology studies  
2.13.1 Zebrafish (Danio rerio) maintenance 
Wild type zebrafish and a transgenic line Tg(fli1:EGFP) fish line of 
approx. 1 year old adults were used for the experiments. Tg(fli1:EGFP) fish 
line have the promoter fli1 (the earliest endothelial cell marker in zebrafish) 
which expresses EGFP in endothelial cells and hence all the blood vessels 
(Lawson & Weinstein, 2002). Fish were maintained in our biological sciences 
departmental fresh water aquarium facility according to standard procedures. 
Zebrafish embryos were collected after natural spawning, maintained at 28 ºC 
in E3 Medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4 
and 0.1% Methylene Blue) and staged as described in The Zebrafish book 
(Westerfield, 1995). Fish maintenance and experimental protocols were 
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approved by Institutional Animal Care and Use Committee (IACUC) of 
National University of Singapore (Protocol 007/06). Embryonic and larval 
stages are expressed in hours post fertilization (hpf). Embryos were treated 
with 0.003% 1-phenyl-2-thiourea (PTU; Sigma-Aldrich, USA) prior to day1 
of development for reduced pigmentation. 
2.13.2 Total RNA isolation  
Embryos (groups of 50) at the correct developmental stages were collected 
in a 1.5 ml eppendorf tube. Trizol reagent (1 ml) (Life technologies, USA) was 
added after decanting most of the fish water. In the case of adult organs, the 
tissues were collected from 5 wild type adult fishes (6 months old) comprising 
both male and females to minimize the sex and individual mice variations. The 
samples were vortexed and homogenized using a hand held motor pellet pestle 
(Sigma-Aldrich, USA) to disaggregate the embryos. After centrifugation, the 
homogenized supernatant was subjected to phase separation by adding 0.2 ml 
of chloroform, vortexed and centrifuged for 15 min at 13,500 rpm at 4ºC to 
separate phases. Aqueous phase containing RNA was precipitated by adding 
0.5 ml of 100% isopropanol and centrifuged at 12,000 g for 10 min at 4ºC. 
Precipitated RNA was washed once with 75% ethanol and the RNA pellet 
dried. The RNA pellet was redissolved in RNAase-free water and stored at -
80ºC until further use. Quantity and purity of RNA samples were determined 
by UV spectrophotometry (absorbance at 260 and 280 nm) and its integrity 
using agarose gel electrophoresis. 
2.13.3 Two-step Reverse Transcription (RT) – PCR 
First-strand cDNAs from different stages of zebrafish embryos were 
synthesized using 1 µg of DNAse I treated total RNA using SuperScript III 
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Reverse transcriptase (RT) (Life technologies, USA) according to 
manufacturer‘s recommendation. cDNA of 1 µl was used as a template for the 
PCR reaction using Kapa Taq DNA polymerase (Kapa Biosystems, South 
Africa) in the presence of 5% DMSO. 937 bp product of zebrafish adamts5 
primer pair (Table 2.1) and following PCR conditions: Initial denaturation of 1 
min at 95ºC, followed by 30 cycles of 1 min at 94ºC, 30 s at 55ºC and 1 min at 
68ºC with a final extension of 10 min at 68ºC. Zebrafish beta actin served as 
the control (Table 2.1). Same PCR conditions as above were used for beta 
actin with the exception of extension time - 30 s and 25 cycles. The PCR 
products were resolved by electrophoresis in 1% agarose gel stained with 
Sybersafe DNA gel stain (Life technologies, USA). 
2.13.4 Whole mount in situ hybridization (WISH) 
2.13.4.1 In vitro transcription & riboprobe synthesis 
Same primer pair and PCR conditions used for the RT-PCR was used to 
amplify the 937 bp product of adamts5. The PCR product was gel extracted 
(Qiagen, USA) and cloned into pGEMT vector (Promega, USA). The DNA 
sequence of the amplified product was sequenced and confirmed to be 
identical to a part spanning from Exon 4 to Exon 7 which consists complete 
metalloproteinase region, part of prodomain and disintegrin domain of 
zebrafish adamts5  (AEO79845.1). This sequence was used to generate probe 
for in situ hybridization. Sense probe of the same mRNA sequence served as 
the negative control. Briefly, 10 µg of zebrafish adamts5-pGEMT vector was 
digested with SacII (for anti-sense probe) and NdeI (for sense probe) for 4 h at 
37 ºC and purified following agarose gel electrophoresis. Linearized plasmid 
(1 µg) was used for the in vitro transcription system for SP6 (anti-sense) or T7 
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(sense) promoters. The RNA probes labeled with digoxigenin-UTP were 
synthesized according to manufacturer‘s instructions (Roche Diagnostics, 
Germany). Purification of RNA was performed using Qiagen RNA easy mini 
kit and eluted with RNase free water, quantified using Nanodrop (Biofrontier 
Technology, USA) and verified by gel electrophoresis. 
2.13.4.2 Embryo collection, fixation and permeabilization 
Pairs of male and female fishes were set up in breeding tanks separated 
with plastic divider night before eggs are collected. The next morning, divider 
is removed and the fish pair is allowed to mate for 10-20 min. The eggs are 
collected in a lower tank separated from the fishes with a mesh in order to 
prevent cannibalism. The eggs are collected in a petri dish after cleaning and 
incubated at 28ºC incubator till fixing in E3 medium with PTU. If the embryos 
are less than 24 hpf, then they are directly fixed in 4% PFA and incubated 
overnight at 4ºC on a rocking platform shaker. The next day, PFA was washed 
away with 1X PBST (3 times) before manually dissecting the chorion or 
enzymatically using pronase solution. For embryos more than 24 hpf, the 
embryos were first dechorionated before fixing in PFA. The embryos were 
dehydrated with methanol gradation of 25%, 50%, 75% and finally 100% in 
1X PBST for 5 min each. This was followed by rehydration with downgraded 
methanol concentration of 75%, 50%, 25% and finally in 1X PBST.  
2.13.4.3 Permeabilization and hybridization 
The embryos (> 24hpf) were permeabilized by treating with proteinase K 
(Roche Diagnostics, Germany) (10 µg/ml in 1X PBST) for 1-10 min 
depending on the zebrafish embryo stage. The embryos were refixed in 4% 
PFA for 20 min at room temperature and then washed with 1X PBST three 
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times (Thisse & Thisse, 2008). Permeabilized embryos were prehybridized 
with the hybridization buffer (HB) (50% deionized formamide, 5XSSC, 0.1% 
Tween 20, 50 μg/ml of heparin, 500 μg/ml of RNase-free tRNA adjusted to 
pH 6.0 by adding citric acid) by incubating the embryos for 4-6 h in HB at 
70ºC. The HB was discarded and hybridization was performed with the anti-
sense or corresponding sense probe (3 ng/ml) in HB and incubated at -68ºC 
overnight.   
2.13.4.4 Post-hybridization 
The probes were aspirated and the embryos were gradually washed in a 
series of HB and SSC containing reagent mix with different proportions. It 
was made sure that all the reagent mix was prewarmed to 70ºC. Gradually HB 
was changed to 2XSSC through a series of 10 min, 70°C washes in HB diluted 
with 2X SSC. Embryos were washed in each of the following: 75% HB, 50% 
HB, 25% HB and 100% 2X SSC. Washes were performed in a 70°C water 
bath. This was followed by two washes of 30 min with 0.2X SSC at 70°C. The 
embryos were progressively replaced of 0.2X SSC with 1XPBST through a 
series of 10 min washes in 75%, 50%, 25% of 0.2X SSC in 1X PBST and 
finally washed with 1X PBST (Thisse & Thisse, 2008). 
2.13.4.5 Anti-digioxigenin conjugated alkaline phosphatase binding 
Post hybridization step was followed by blocking of the dechorionated 
embryos in 1X blocking buffer (Roche Diagnostics, Germany) for 3 hrs at 
room temperature with mild agitation. The blocking buffer was replaced with 
anti-DIG antibody (1:5000 dilution in 1X blocking buffer) (Roche 
Diagnostics, Germany) and incubated overnight at 4ºC.  
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2.13.4.6 Colorization and mounting 
The excess antibody bound to embryos was washed away using 15 min of 
6 washes of 1X PBST after removal of the antibody solution. The embryos 
were then incubated in staining buffer (100 mM Tris pH 9.5, 50 mM MgCl2, 
100 mM NaCl, 0.1% Tween-20) replaced every 5 min for 3 times. This was 
followed by incubation of the embryos in staining solution (nitroblue 
tetrazolium chloride (NBT; Promega, USA) (50 mg/ml) and 5-bromo-4-
chloro-3-indolyl phosphate (BCIP; Promega, USA) (50 mg/ml) in 2:1 ratio in 
1ml of staining buffer). The embryos were kept in dark covered with 
aluminum foil with routine inspection of the coloration using spot plates under 
a dissection microscope (Olympus, Japan). When the desired staining was 
achieved, the excess NBT/BCIP was washed away in 1X PBST with three 
washes of 5 min each. The excess staining was removed by treating the 
embryos in grades of methanol. The embryos were dehydrated with 50%, 75% 
and 100% methanol in 1X PBST for 5 min each and rehydrated in the reverse 
order with the same concentration and incubation time. The embryos were 
then mounted on glass slides in 100% glycerol (Thisse & Thisse, 2008). 
2.13.4.7 Cryo-sectioning 
Briefly, after overnight staining of the different stages of zebrafish 
embryos, they were embedded in 5% sucrose and 1.5% Agarose solution. 
Following solidification, the embryos blocks were trimmed and incubated 
overnight in 30% sucrose. Next day, the embryos were embedded on a 
cryostat chunk with the help of Optimal Cutting Temperature Compound 
(Sakura, Japan) and frozen in liquid nitrogen and stored at -30ºC freezer until 
further use. These cryostat chunks were placed in a cryosectioning machine 
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(Leica, Germany). Sections of 5 to 10 µm were obtained and transferred onto a 
superfrost polysilane coated glass slide. Image analysis was performed as 
using Zeiss Axio microscope (Germany).   
2.13.5 Morpholino based knockdown 
Embryos were injected with morpholino (MO) or the corresponding 
mismatch morpholino (MisMO) (Gene Tools, USA) to knockdown adamts5. 
Briefly, the samples for injection were prepared to different concentrations in 
sterile water. The needles for the injection were prepared from fine thin glass 
capillary tubes (World Precision Instruments Inc., USA). The needle was fixed 
in a Sutter Micropipette puller P-97 (Sutter Instruments Co, USA). The 
optimized conditions of heat and pull time was set at pressure-500, heat-
500/550, pull-150/150, velocity-100/100 and time-150/150 to generate sharp 
needles. The tip was cut with a surgical blade on a parafilm to have a hole in 
the sharp tip to introduce MO into the embryo. 1-2 cell stage of zebrafish 
embryos were placed under a dissection microscope (Olympus SZX12, Japan) 
and 10 ng of MOs and corresponding MisMOs were injected (2.3 nl/embryo) 
into the cytoplasm of embryos using Nanoliter 2000 (World Precision 
Instruments, USA) by placing them on a 1.2% agarose plate with scaffolds to 
prevent embryo movement during injection (Bill et al, 2009). The injected 
embryos were reared in E3 medium and subsequently with E3+PTU. 
2.14 Statistical Analysis 
The data were presented in the form of mean ± standard deviation (STD) 
or standard error (SE). Two-tailed, unpaired student‘s t-test was used for 
comparing experimental data from different groups. A p-value of less than 
0.05 was considered significant in all cases (* p<0.05; **p<0.01).  
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CHAPTER 3. RESULTS 
3.1 Characterization of ADAMTS5 in angiogenesis in vitro 
3.1.1 Full-length ADAMTS5 (TS5-FL) and the 45-kDa auto-catalytic 
fragment (TS5-p45) inhibit EC tube formation in vitro 
Based on the previous result that the recombinant TSR1 of ADAMTS5 
(TS5-TSR1) is anti-angiogenic in vitro (Sharghi-Namini et al, 2008), the 
effect of full-length ADAMTS5 on angiogenesis was investigated. EC tube 
formation assay was employed for the same purpose. ECs when seeded at 
subconfluent densities on appropriate ECM support such as Matrigel undergo 
morphological differentiation forming capillary or tube-like structures after 6-
8 hrs. The differentiation process mimics the formation of blood vessels in 
many ways such as cell adhesion, migration, alignment and tubule formation. 
This assay helps to determine the impacts of various angiogenic regulators‘ on 
angiogenesis (Arnaoutova et al, 2009). Tube formation is typically quantified 
by measuring the number, length or the area of these capillary structures.  
Equal amount of total protein of concentrated conditioned media (10 µg) 
from TS5-FL (containing 23 nM of TS5-FL) and empty vector transfected 
B16 melanoma cells (B16/Vec) were pre-incubated with HUVECs before 
plating the cells onto pre-formed Matrigel. As shown in Fig. 3.1 A, TS5-FL 
conditioned media inhibited EC tube formation in vitro. The capillary length 





Fig. 3.1 TS5-FL inhibits tube formation in vitro: A. Conditioned 
Media (CM) from TS5-FL transfected B16 cells inhibit EC tube 
formation on Matrigel. Control is media + 2% FBS; B16/Vec is CM 
from empty vector transfected B16 cells. Equal amount of total protein 
from the CM of B16/Vec and B16/TS5-FL cells were used. (Scale bar 
– 100 μm) B. Quantification of the anti-angiogenic activity of TS5-FL 
conditioned media. The average length of the tube-like structure from 
5 random fields in 10X (n=3 repeat experiments). * P < 0.05, 
compared to untreated HUVEC. 
TS5-p45 is a catalytically-active autocatalytic cleavage product of 
ADAMTS5 that contains the N-terminal portion of the protein up to the 
beginning of the cysteine-rich domain (Fig. 2.1) (Zeng et al, 2006). The effect 
of recombinant TS5-p45 on EC tube formation on Matrigel was studied. 
Mouse myeloma derived recombinant TS5-p45 was pre-incubated with 
HUVECs before plating the cells onto pre-formed Matrigel. As shown in Fig. 
3.2, TS5-p45 inhibited EC tube formation in a dose-dependent manner. In the 
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presence of TS5-p45, the individual cells failed to form tubes or formed tubes 
of very short length. 
 
 
Fig. 3.2 Auto-catalytic fragment of ADAMTS (TS5-p45) inhibits 
tube-formation in vitro: A. TS5-p45 dose-dependently inhibits EC 
tube-formation on Matrigel. Representative pictures are shown. Scale 
bar: 100 μm. B. Quantification of the capillary length at various 
concentrations of TS5-p45. The average length of the tube-like 
structure from 5 random fields in 10X (n=3 repeat experiments). * P < 
0.05, ** P < 0.01 compared to untreated HUVEC. 
3.1.2 TS5-p45 inhibits EC proliferation in vitro  
EC proliferation is a key component of angiogenesis and VEGF is a potent 
EC mitogen (Ferrara & Davis-Smyth, 1997). To determine whether TS5-p45 
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inhibits VEGF stimulated EC proliferation, proliferation assay was performed 
by testing BrdU incorporation into newly synthesized DNA of the ECs. TS5-
p45 significantly and dose-dependently inhibited VEGF-induced EC 
proliferation after 24 h treatment. In addition, it inhibited EC proliferation to 
below the basal level of EC proliferation under basal medium, indicating that 
TS5-p45 can also inhibit basal level of EC proliferation (Fig. 3.3).  
 
Fig. 3.3 TS5-p45 inhibits EC proliferation in vitro: TS5-p45 inhibits 
VEGF mediated HUVEC cell proliferation in a dose-dependent 
manner. Results are represented as mean of 3 independent experiments 
(+ SEM). * P < 0.05, ** P < 0.01 compared to HUVEC treated with 
VEGF alone. 
3.1.3 TS5-p45 induces EC apoptosis in vitro 
Potent anti-angiogenesis inhibitors interfere with the EC survival 
mechanisms and induce EC apoptosis (Cook & Figg, 2010). VEGF is a well-
known EC survival factor, protecting ECs from apoptosis (Ferrara et al, 2003). 
In order to further understand the action of TS5-p45 on ECs, we investigated 
its effect on EC apoptosis. Apoptosis was measured by quantifying the 
cytosolic oligo-nucleosomal bound DNA fragments. TS5-p45 induces EC 
113 
 
apoptosis in the presence of VEGF (20 ng/ml) in a dose-dependent manner 
(Fig. 3.4).  At 500 nM, TS5-p45 induced EC apoptosis almost as potent as 
serum withdrawal (Fig. 3.4). Significantly, this apoptosis induction is caspase-
dependent as pretreatment of HUVECs with the pan-caspase inhibitor Z-
VAD-FMK abolished the ability of TS5-p45 to induce apoptosis.  
 
Fig. 3.4 TS5-p45 induces HUVEC apoptosis dose-dependently in 
the presence of VEGF: Cell death was measured after 24 h of TS5-
p45 treatment. Pre-incubation with PAN-Caspase inhibitor – Z-VAD-
FMK abolished the apoptotic effect of TS5-p45 on HUVEC. Results 
are represented as means + SEM (n=3). * P < 0.05, ** P < 0.01 
compared to HUVEC treated with VEGF alone unless specified. 
3.1.4 Anti-angiogenic function of TS5-p45 is independent of its 
proteoglycanase activity 
Since both TS5-FL and TS5-p45 are catalytically active, it is important to 
determine whether the anti-angiogenic effect is dependent on its catalytic 
function. In order to investigate this, mammalian expressed catalytically active 
TS5-p45 was used in the presence or absence of chemical ADAMTS5 enzyme 
inhibitor. ADAMTS5 inhibitor (5-((4-Chlorobenzylthio-3-trifluoromethyl-N-
methyl-1H-pyrazol-4-yl) methylene)-2-thioxothiazolidin-4-one) is a zinc-
114 
 
chelating thioxothiazolidinone derivative. It has an IC50 of 1.1 µM towards 
ADAMTS5 aggrecanase activity (Bursavich et al, 2007). In addition, this 
inhibitor is 40 times more specific to ADAMTS5 than its close homolog 
ADAMTS4 (IC50 of 44 µM for aggrecan) (Gilbert et al, 2007).  
Firstly, the effective concentration at which the inhibitor is not toxic to 
cells (HUVECs) was evaluated. It was found to be 1µM (data not shown). 
TS5-p45 was pre-incubated with the inhibitor followed by the incubation of 
TS5-p45 with its substrate aggrecan in the assay buffer. After the incubation 
and deglycosylation, the reaction mixture was boiled with 2X SDS Dye and 
western blotting was performed. The blot was probed with anti-AGEG neo-
epitope antibody that detects specific cleavage in aggrecan core protein by 
TS5-p45. As shown in Fig. 3.5A, upon incubation with the inhibitor, TS-p45 
lost its catalytic function and did not cleave the aggrecan core protein, 






Fig. 3.5 Catalytic activity of TS5-p45 is dispensable for its anti-
angiogenic function: A. TS5-p45 inhibitor inhibits the catalytic 
activity of TS5-p45 on aggrecan. TS5-p45 has a C-terminal His tag, 
thus anti-His antibody was used to show equal amount of TS5-p45 
used in the assay B. TS5-p45 inhibits tube formation independent of its 
catalytic function C. Quantification of the capillary length at various 
concentrations of TS5-p45 in the presence or absence of inhibitor. The 
average length of the tube-like structure from 5 random fields in 10X 
(n=3 repeat experiments) (+SEM). * P < 0.05 compared to untreated 
HUVEC.   
To analyze the effect of the catalytic activity of TS5-p45 in its anti-
angiogenesis function, TS5-p45‘s impact on EC tube formation was tested in 
the presence of TS5-inhibitor. As shown in Fig. 3.5B, TS5-p45 inhibits tube-
formation in the presence of inhibitor thus suggesting that the catalytic activity 
is dispensable for its anti-angiogenic function. Meanwhile, the inhibitor alone 
did not interfere with the tube-formation of ECs at 1 µM concentration (Fig. 
3.5B, Panel 2). The capillary tubes were quantified (Fig. 3.5C). TS5-p45 was 
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also shown to inhibit EC proliferation and induce EC apoptosis in the presence 
of TS5-inhibitor. This further confirms that TS5-p45 angiogenesis inhibition is 
independent of its catalytic function (Fig. 3.6A and 3.6B).     
 
Fig. 3.6 TS5-p45 inhibits angiogenesis independent of its catalytic 
function: A. TS5-p45 (500 nM) inhibits VEGF (20 ng/ml) mediated 
EC in the presence and absence of TS5-inhibitor (1 µM). Results are 
presented as mean of 3 independent experiments (+ SEM). * P < 0.05 
compared to HUVEC treated with VEGF alone. B. TS5-p45 (500 nM) 
induces EC apoptosis in the presence and absence of TS5-inhibitor (1 
µM). Results are presented as mean of 3 independent experiments (+ 
SEM). * P < 0.05 compared to HUVEC treated with VEGF alone. 
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Together, these in vitro experiments indicate that both TS5-FL and the 
autocatalytic fragment TS5-p45 function similarly to recombinant TS5-TSR1 
in inhibiting angiogenesis in vitro. In addition, the anti-angiogenic function of 
ADAMTS5 is independent of its catalytic activity.  
3.2 Investigating the role of ADAMTS5 in cancer using mouse 
melanoma model in vivo 
3.2.1 Expression of ADAMTS5 in mouse cell lines 
The anti-angiogenic function of ADAMTS5 in vitro suggests that this 
multi-domain metalloproteinase may influence tumor angiogenesis and 
growth. To evaluate whether ADAMTS5 influences tumor growth and 
angiogenesis in vivo, syngeneic mouse tumor model was used. Expression of 
endogenous level of ADAMTS5 in various mouse cell lines was analyzed 
(Fig. 3.7). Among the various cell lines analyzed, NIH3T3 (mouse fibroblast) 
showed the lowest expression of ADAMTS5 (Fig. 3.7). This was followed by 
LLC1 (Lewis lung carcinoma). NIH3T3 is a transformed cell line but not 
oncogenic and hence cannot be used to generate tumor in a syngeneic mouse 
model (Xuan et al, 1995). LLC1 on the other hand, is a non-adherent cell line 
which leads to practical difficulty in generation of stable clones. Thus, B16 
mouse melanoma that had the relatively least endogenous expression was 
chosen as the cell line of choice to overexpress ADAMTS5. On the other 
hand, relatively highest expression of ADAMTS5 was observed in 4T1 (breast 
cancer) cell line (Fig. 3.7). 
B16F1 had relatively low level of endogenous expression and also has the 
added advantage of availability of C57Bl/6 mice strain that is syngeneic with 
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this cell line. C57Bl/6 as a mouse model has several advantages in itself. 
Firstly, C57Bl/6 is known for its strain stability and easy breeding. Also, this 
is the first mouse strain whose genome is completely sequenced.   
 
Fig. 3.7 Endogenous expression of ADAMTS5 in mouse cancer cell 
lines: Cell lysate was probed with anti-ADAMTS5 antibody 
recognizing the N-terminal catalytic domain of ADAMTS5. β-actin 
served as the loading control.  
3.2.2 Establishment of stable clones overexpressing ADAMTS5 in B16 
mouse melanoma (B16/TS5-FL) 
In order to overexpress ADAMTS5 in B16F1 mouse melanoma, full-
length ADAMTS5 was cloned into pEF6/V5-His TOPO
®
 vector in frame 
without the stop codon to incorporate the His and V5 tags at the C-terminal of 
the TS5-FL. This plasmid also has a blasticidin resistance gene that can be 
used for stable cell line selection. Expression in mammalian system was 
confirmed by transfection of 15 µg TS5-FL plasmid using bPEI (transfection 
reagent) into HEK293T and western blotting of the protein secreted into CM 
containing 100 µg/ml of heparin.  
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Meanwhile, optimal concentration of blasticidin required to select the 
stable antibiotic resistant clones of B16F1 was evaluated. A blasticidin of 6 
µg/ml was observed to be the optimal concentration resulting in cell 
cytotoxicity where all the cells rounded off and were found floating after 4-5 
days (data not shown). For a much stringent condition, 8 µg/ml of blasticidin 
was used for the stable clone selection.  
 
 
Fig. 3.8 Relative expression and homogeneity of ADAMTS5 in 
B16/TS5-FL stable lines: A. Western blotting was performed with 
equal amount of CM loaded from four B16/TS5-FL clones and 
negative control (B16/Vec). B. Immunocytochemistry showing 
homogenous expression of TS5-FL in B16/TS5-FL (Clone 12) when 
stained with anti-V5 antibody and corresponding Alexa-fluor 568 
conjugated secondary antibody. Blue – DAPI (nuclear stain), Red – 




Once the expression of TS5-FL and the optimal concentration of 
blasticidin were identified, B16F1 was transfected with TS5-FL plasmid and 
the cells were split in 1:10 ratio into five 10 cm dishes. The dishes were 
maintained under blasticidin (8 µg/ml) selection medium for 2-3 weeks. Once 
the individual colonies grew bigger and became distinct, around 40 clones 
were isolated and expanded. The CM from the clones was acetone precipitated 
and western blotting was performed, probed with anti-V5 antibody. High 
expressing clones were chosen and the clone having highest relative 
expression was identified by loading equal amount of total protein in CM. 
Clone 12 was shown to have the highest expression (Fig. 3.8A). For negative 
control, B16 F1 line was transfected with empty pEF6/V5-His TOPO
®
 vector 
and the colonies were obtained under blasticidin selection. All the clones were 
pooled to obtain a single B16/Vec control line.  
In order to check for the homogeneity of TS5-FL expression of clone 12, 
immunocytochemistry was performed. B16/TS5-FL (Clone 12) and the empty 
vector control (B16/Vec) were fixed when they attained 90% confluency in a 
96 well plate or a chamber slide and probed with anti-V5 and corresponding 
mouse secondary antibody conjugated to Alexa fluor 568. The cells were 
imaged using an inverted fluorescent microscope (Fig. 3.8B). B16/TS5-FL 
(Clone 12) showed around 98% homogeneity (cells expressing TS5-FL) and 
thus chosen for further studies.  
3.2.3 Cell proliferation was not affected in B16/TS5-FL upon 
overexpression of ADAMTS5 in vitro 
Overexpression of ADAMTS5 in vitro was shown to inhibit EC tube 
formation (Fig. 3.1). In addition, transfection of the plasmid containing gene 
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of interest or the empty vector might result in random integration and resulting 
in alteration of the cell line characteristics. So, before proceeding with mouse 
tumorigenesis assay, the effect of ADAMTS5 overexpression on the cell 
proliferation and apoptosis was analyzed. Equal number of B16/Vec or 
B16/TS5-FL were seeded onto a 6 well multi-well plate and once next day the 
cells were serum starved overnight before replacing with complete medium 
containing 2% FBS. The total cell number was counted using Nucleocounter 
on day1, day3 and day5. Overexpression of TS5-FL did not interfere with 
proliferation rate compared to the empty vector control (Fig. 3.9A).  
Cell proliferation assay was also performed with varying concentration of 
serum in the media to negate any possible interference from the serum on 
ADAMTS5s effect on tumor cell proliferation. However, there was no 
significant difference in the proliferation rate of B16/TS5-FL compared to 
B16/Vec (Fig. 3.9B). Similarly, apoptosis was evaluated by quantifying the 
oligo-nucleosomal fragmented DNA. There was no significant difference in 
the apoptosis of cells overexpressing TS5-FL compared to the Vec control 
(Fig. 3.9C).  
3.2.4 Overexpression of TS5-FL inhibits B16 melanoma growth in mice 
To evaluate whether ADAMTS5 influences tumor growth, syngeneic 
mouse tumorigenesis assay was performed. Briefly, 1X10
6 
B16/TS5-FL cells 
overexpressing TS5-FL (Fig. 3.10A) were inoculated subcutaneously into the 
right side of the dorsal flank of 8 week old C57Bl/6 female mice. Equal 
numbers of B16/Vec control cells were inoculated into the corresponding left 
dorsal flank. Tumor growth was monitored daily from day 10 post cell 








Fig. 3.9 Effect of overexpression of TS5-FL in B16F1 on 
proliferation and apoptosis in vitro: A. TS5-FL does not affect 
B16F1 cell proliferation rate in vitro in complete medium containing 
10% FBS. B. TS5-FL does not interfere with B16F1 cell proliferation 
rate under reduced serum or absence of serum. C. Overexpression of 
TS5-FL does not induce cell-death in B16F1 cell line under reduced 
serum or absence of serum compared to the vector control cell line. 
Results are presented as mean of 3 independent experiments. 
 
Quantification of tumor volume showed a significant reduction in the 
tumor growth rate of B16/TS5-FL compared to B16/Vec (Fig. 3.10B). After 
16th day (when mice started to die), mice were sacrificed, tumors were 
excised and the tumor weight was measured. Marked reduction in the tumor 
weight of the B16/TS5-FL compared to the control B16/Vec was observed 
(Fig. 3.10C). In addition, an obvious reduction in peri-tumoral blood vessels 
surrounding the B16/TS5-FL tumor was observed compared to the B16/Vec 
tumors (Fig. 3.10D). There was limited vascular network linked to B16/TS5-
FL tumor in contrast to the abundant vascular supply of B16/Vec. In order to 
re-confirm the expression of TS5-FL in the tumor milieu, total protein was 
isolated from the frozen tumors, western blotting was performed and probed 
with anti-V5 antibody. Fig. 3.10E confirms the expression of TS5-FL in vivo. 
3.2.5 ADAMTS5 suppresses B16 tumor growth by inhibiting tumor 
angiogenesis, tumor cell proliferation and inducing tumor cell apoptosis 
To investigate the possible cellular mechanism responsible for the 
reduction in tumor growth, tumor angiogenesis, proliferation and apoptosis 
was investigated through immunofluorescent staining of the paraffin 
embedded tumor sections. A clear reduction of tumor vasculature was 
observed in B16/TS5-FL by PECAM-1 staining of ECs (Fig. 3.11A, top 
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panels). Quantification of the microvessel density showed a more than 50% 










Fig. 3.10 Full-length ADAMTS5 is anti-tumorigenic in mice: A. 
Generation of the stable B16 cell line overexpressing ADAMTS5. CM 
of B16/TS5-FL and B16/Vec was acetone precipitated and equal 
amount of total protein was loaded onto SDS-PAGE and 
immunoblotted with anti-V5 antibody. Note that anti-V5 antibody 
would not detect any proteolytically cleaved fragments due to the C-
terminus localized V5 tag. B. ADAMTS5 suppresses B16 tumor 
growth. B16/TS5-FL tumor growth curve is compared with that of 
B16/Vec. Tumor volume was measured in C57BL/6 mice from day 10 
post tumor cell inoculation into the dorsal flank on day 0 (n=6). Plot 
represents the mean tumor volume (+ SEM).* P < 0.05. C. Tumor 
weight of B16/Vec and B16/TS5 post sacrifice (n=6). Graph 
represents the mean tumor weight (+ SEM). ** P < 0.01. D. Pictures 
showing the relative tumor size and peri-tumor vascular network of 
two representative mice. E. Immunoblot confirming the expression of 









Fig. 3.11 Full-length ADAMTS5 suppresses tumor angiogenesis, 
tumor cell proliferation and induces tumor cell apoptosis: A. 
Paraffin sections of B16/Vec and corresponding B16/TS5-FL were 
probed for microvessel density, tumor cell proliferation and apoptosis 
through immunofluoresence staining using anti-PECAM-1, anti-PCNA 
and TUNEL staining respectively. Representative photos are shown. 
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B. Quantification of microvessel density in B16/TS5-FL tumor. 
Microvessel density is the number of microvessels per microscopic 
field. C. Quantification of apoptosis in tumor. Apoptosis is quantified 
as the number of TUNEL positive cells per microscopic field. D. 
Quantification of cell proliferation in tumor sample. Cell proliferation 
is presented as the percentage of PCNA positive cells out of the total 
number of cells (DAPI positive cells) in the microscopic field. Plots 
represent the mean of 3 fields per section, 3 sections per tumor and 2 
tumors per construct (+SEM). ** P < 0.01. 
TUNEL staining was performed on the tissues to analyze if there was any 
cell death in vivo. Staining indicated a dramatic increase in tumor cell 
apoptosis (Fig. 3.11A, middle panels and Fig. 3.11C). The reduction in tumor 
growth can also be a result of reduced tumor cell proliferation. So to 
investigate the proliferation in tumor sections, nuclear PCNA staining was 
performed. It revealed a marked decrease in cell proliferation rate in B16/TS5-
FL tumor sections compared to the control B16/Vec tumors (Fig. 3.11A, 
bottom panels and Fig. 3.11D). Taken together, the reduced tumor growth in 
ADAMTS5 overexpressing B16 melanoma is the result of combined effects of 
suppressed tumor angiogenesis, reduced tumor cell proliferation and an 
increased tumor cell death.  
3.3 Autocatalytic fragments of ADAMTS5 also suppress tumor growth 
and angiogenesis in vivo 
3.3.1 Establishment of stable clones overexpressing two autocatalytic 
fragments of ADAMTS5 (TS5-p45 and TS5-p60) in B16 mouse melanoma  
ADAMTS5 is known to undergo autocatalytic cleavage at their C-terminal 
ancillary domains resulting in two shorter truncates of 45 kDa (TS5-p45) and 
60 kDa (TS5-p60) (Zeng et al, 2006) (Fig. 2.1). Ancillary domains play an 
important role in localizing the metalloproteinase to ECM and in binding to 
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substrates (Gendron et al, 2007). To investigate whether autocatalytic 
cleavage alters the ability of ADAMTS5 to suppress tumor growth and tumor 
vascularization, B16F1 stable cell line overexpressing TS5-p45 (B16/TS5-
p45) and TS5-p60 (B16/TS5-p60) were established as explained earlier.  
Briefly, around 40 clones of TS5-p45 and TS5-p60 were expanded from 
single colonies that were blasticidin resistant. The total proteins from the CM 
were acetone precipitated and western blotting was performed. The blot was 
probed against anti-V5 antibody to identify high expressing clones. Relative 
quantification was performed to identify highest expressing clones of TS5-p45 
and TS5-p60 (Fig. 3.12A and B). Note that the sizes of the TS5-p45 and TS5-
p60 are slightly higher than expected. This is a result of additional C-terminal 
tag and possible post-translational modifications of these proteins in B16F1 
cell line. Clone 15 for B16/TS5-p45 and Clone 11 for B16/TS5-p60 were 





Fig. 3. 12 Validation of auto-catalytic fragments of ADAMTS5 
stable clones: A. Equal amount of total proteins from the conditioned 
medium were loaded onto SDS-PAGE and probed with anti-V5 
antibody. Both zymogen and processed forms were detected. Clone15 
of B16/TS5-p45 showed the highest expression. B. Relative expression 
of B16/TS5-p60 clones, Clone 11 showing highest expression. C. 
Immunocytochemistry showing homogenous expression of V5 tagged 
TS5-p45 and TS5-p60 when stained with anti-V5 antibody and 
corresponding Alexa-fluor 568 conjugated secondary antibody. Blue – 
DAPI (nuclear stain), Red – TS5-p45 or TS5-p60, Scale – 50 µm. 
Representative pictures are shown.   
They were further analyzed by immunocytochemistry for homogeneity. 
Both clones showed homogenous and abundant expression of the V5-tagged 
ADAMTS5 N-terminal auto-catalytic fragments (Fig. 3.12 C).  
3.3.2 Cell proliferation rate was similar between B16/TS5-p45, B16/TS5-
p60 cells and B16/Vec cells in vitro 
Transfection process may modify the characteristics of the stable cell line. 
So, before proceeding with mouse tumorigenesis assay, the effect of 
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overexpression of TS5-p45 and TS5-p60 on the cell proliferation was analyzed 
in culture. Equal number of B16/Vec and the auto-catalytic fragments 
overexpressing B16/TS5-p45 and B16/TS5-p60 were seeded in 6 well plates 
and after overnight cell attachment, next day the cells were serum starved 
overnight before replacing with medium containing 2% FBS. The total cell 
number was counted using Nucleocounter on day1, day3 and day5. 
Overexpression of TS5-FL did not interfere with proliferation rate compared 
to the empty vector control (Fig. 3.13).  
 
Fig. 3.13 In vitro cell proliferation assay of B16 mouse melanoma 
overexpressing TS5-p45 and TS5-p60: Overexpression of the auto-
catalytic fragments of ADAMTS5 does not interfere with the tumor 
cell proliferation in B16F1. Results are presented as mean of 3 
independent experiments (+SEM). 
3.3.3 Overexpression of TS5-p45 and TS5-p60 mitigates B16 melanoma 
growth in mice 
Highest expressing clone that had no significant difference in morphology 
or proliferation rate was chosen for the study and its expression was confirmed 
by western blotting before proceeding with mouse tumorigenesis studies (Fig. 
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3.14A). Xenograft tumorigenesis assays were carried out as described above 
for the B16/TS5-FL cells. Both TS5-p45 and TS5-p60 potently suppressed 
B16 tumor growth as demonstrated in Fig. 3.14B-F. Tumor suppression 
correlated with the expression of the corresponding auto-catalytically cleaved 
protein isoforms in B16/TS5-p45 and B16/TS5-p60 tumors as shown by 














Fig. 3.14 Autocatalytically cleaved fragments of ADAMTS5 
suppress tumor growth in mice: A. Generation of stable B16 
melanoma cell lines overexpressing TS5-p45 and TS5-p60, 
respectively. Equal amount of total proteins from the conditioned 
medium were loaded onto SDS-PAGE and probed with anti-V5 
antibody. Both zymogen (top bands, indicated by *) and processed 
forms (lower bands) were detected. B. Tumor growth rates of 
B16/TS5-p45 and B16/TS5-p60 compared to its respective B16/Vec 
control. Tumor growth was measured starting from day 10 post cell 
inoculation, quantified and mean tumor size was plotted (+SEM). * P 
< 0.05. n=8 for TS5-p45; n=7 for TS5-p60. Note that cross comparison 
of tumor suppression between TS5-p45 and TS5-p60 cannot be 
accurately done due to variations of exogenous gene expression level. 
C. Tumor weights at the end of the experiments. Tumors were 
dissected, weighed and mean tumor weights were plotted (+SEM). ** 
P < 0.01. D. Dissected tumors from B16/TS5-p45 and B16/TS5-p60 
were isolated, rinsed with 1X PBS and kept below its respective vector 
control and photographed using a digital camera (n=8 for TS5-p45; 




expression in tumors by Western blot with anti-V5 antibody. ―*‖ 
indicates the zymogen form. 
 
3.3.4 ADAMTS5 auto-catalytic fragments suppress B16 melanoma 
growth by inhibiting tumor angiogenesis, tumor cell proliferation and 
inducing tumor cell apoptosis 
Similar to TS5-FL protein, suppression of B16 tumor growth by TS5-p45 
and TS5-p60 fragments correlated with a reduction in tumor vascularization, 
tumor cell proliferation coupled with an increase in tumor cell apoptosis (Fig.. 
3.15A-E). These results demonstrated that the proteolytic fragments generated 
by autocatalytic cleavage of ADAMTS5 are also anti-angiogenic and anti-










Fig. 3. 15 Autocatalytically cleaved fragments of ADAMTS5 
mitigate tumor growth by inhibiting tumor angiogenesis, tumor 
cell proliferation and induce tumor cell apoptosis: Tumor 
angiogenesis, proliferation and apoptosis by immunofluorescent 
staining. Paraffin tissue sections of (A) B16/TS5-p45 and (B) 
B16/TS5-p60 with their respective B16/Vec control tumors were 
stained with anti-PECAM-1 for tumor microvessels, anti-PCNA for 
tumor cell proliferation and TUNEL staining for the detection of 
apoptotic cells. Representative pictures are shown. C. Quantification 
of tumor microvessel density. D. Quantification of tumor apoptosis. E. 
Quantification of tumor cell proliferation. Bar graphs represent the 
mean number from 3 microscopic fields per tissue section, 3 sections 
per tumor and 2 tumors per construct (+SEM). ** P < 0.01. 
 
3.4 Anti-tumorigenic and anti-angiogenic function of ADAMTS5 is 
independent of its proteoglycanase function 
3.4.1 Point mutation E411A renders ADAMTS5 catalytically inactive  
Traditionally, matrix proteinases function as promoters of angiogenesis 
and tumor progression by digesting ECM molecules and facilitate cell 
migration and morphogenesis. To determine the relationship between the 
proteoglycanase activities of ADAMTS5 with its anti-angiogenic/anti-
tumorigenic function, catalytically inactive mutant of ADAMTS5 was 
generated by mutating glutamate at position 411 to alanine (TS5-E411A) since 
this point-mutation has been reported to destroy its catalytic activity. TS5-FL 
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or TS5-E411A plasmid was transfected into HEK293T and the CM containing 
the protein was concentrated (20 times) using centrifugal filters. The 
concentrated CM containing TS5-FL or TS5-E411A was used for the 
aggrecanase assay. HEK293T transfected with empty vector served as the 
control. Briefly, concentrated CM was incubated with aggrecan (substrate of 
ADAMTS5). After 24 h, the reaction was stopped by adding EDTA which 
serves as the chelating agent and the aggrecan was deglycosylated before 
probing with anti-AGEG antibody. This antibody recognizes the neo-epitope 
generated by specific cleavage in the G2 domain of aggrecan core protein by 
ADAMTS5 (Fig. 1.16). As shown in Fig. 3.16, TS5-FL cleaves aggrecan 
generating the neo-epitope of the 135 kDa cleaved fragment that is recognized 
by anti-AGEG antibody. Point mutation of ADAMTS5 leads to the loss of 
catalytic function in this mutant as confirmed by its inability to cleave 
aggrecan (Fig. 3.16). 
 
Fig. 3.16 Point mutation E411A renders ADAMTS5 catalytically 
inactive: CM from HEK 293T transfected with Vec, TS5-FL or TS5-
E411A were incubated with aggrecan and cleavage of aggrecan was 
detected by AGEG neo-epitope antibody. The blot was then stripped 
and probed with anti-V5 antibody to confirm equal amount of TS5-FL 




3.4.2 Establishment of stable clones overexpressing catalytically inactive 
ADAMTS5 (TS5-E411A) in B16 mouse melanoma  
To investigate whether catalytic function of ADAMTS5 is important for its 
tumor suppression, B16F1 stable cell line overexpressing TS5-E411A 
(B16/TS5-E411A) were established as explained earlier. Briefly, around 40 
clones of TS5-E411A were expanded from single colonies that were resistant 
to blasticidin selection. The total proteins from the CM were acetone 
precipitated and western blotting was performed. The blot was probed against 
anti-V5 antibody to identify high expressing clones. Relative quantification 
was performed to identify highest expressing clone of TS5-E411A (Fig. 
3.17A). Clone 12 followed by clone 10 of B16/TS5-E411A were shown to 
have high expression. The homogeneity and expression of TS5-E411A in the 
B16F1 stable line was assessed using immunocytochemistry. Clone 12 was 
shown to express TS5-E411A homogenously (Fig. 3.17B). Furthermore, cell 
proliferation rate of TS5-E411A and Vec of B16F1 mouse melanoma were 
compared over a period of 5 days as explained earlier. Overexpression of 
catalytically inactive ADAMTS5 did not alter the B16 melanoma cell 







Fig. 3.17 Relative expressions of B16/TS5-E411A clones: A. Equal 
amount of total proteins from the CM were loaded onto SDS-PAGE 
and probed with anti-V5 antibody. Clone 12 of B16/TS5-E411A 
showed the highest expression. B. Immunocytochemistry showing 
homogenous expression of V5 tagged TS5-E411A when stained with 
anti-V5 antibody and corresponding Alexa-fluor 568 conjugated 
secondary antibody. Blue – DAPI (nuclear stain), Red – TS5-FL, Scale 
– 50 µm. Representative pictures are shown. C. In vitro cell 
proliferation assay of TS5-E411A Clone 12. There was no significant 
difference in the proliferation rate upon stable overexpression of 
catalytically inactive ADAMTS5. 
 
3.4.3 Overexpression of TS5-E411A suppressed B16 melanoma growth 
in mice 
Overexpression of TS5-E411A in stable clone was confirmed by Western blot 
using antibody against the C-terminal V5 tag from the CM before proceeding 
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with mouse tumorigenesis assay (Fig. 3.18A). To evaluate whether TS5-
E411A influences tumor growth, syngeneic mouse tumorigenesis assay was 
performed as described earlier. Briefly, 1X10
6 
B16F1 cells overexpressing 
TS5-E411A were inoculated subcutaneously into the right side of the dorsal 
flank of 8 week old C57Bl/6 female mice. Equal number of B16/Vec control 
cells was inoculated into the corresponding left dorsal flank. Tumor growth 
was monitored daily from day 10 post cell inoculation when tumor nodule 
became visible. Quantification of tumor volume showed a significant 
reduction in the tumor growth rate of B16/TS5- E411A compared to B16/Vec 
(Fig. 3.18A and B). After 16th day, mice were sacrificed, tumors excised and 
the tumor weight was measured and photographed. Marked reduction in the 
tumor weight of the B16/TS5-E411A compared to the control B16/Vec was 
observed (Fig. 3.18B and C). The total protein from the tumor tissue was 
isolated and probed for the presence of TS5-E411A. The TS5-E411A 
overexpressing cell line induced tumors were shown to overexpress this 







Fig. 3.18 TS5-E411A inhibits B16 tumor growth in mice: A. 
Suppression of tumor growth upon overexpression of TS5-E411A in 
B16F1 mouse melanoma. The mean tumor volume (n=7) (+SEM) 
from B16/TS5-E411A was plotted and compared with its B16/Vec 
control tumor. * P < 0.05. B. Dissected tumors from B16/TS5-E411A 
were isolated, rinsed with 1X PBS and kept below its respective vector 
control and photographed using a digital camera (n=7). C. Tumor 
weight at the end of experiment. Plot represents the mean tumor 
weight (n=7) (+SEM). ** P < 0.01. D. Expression of TS5-E411A in 
tumor tissue lysate (the band marked by the left arrow indicates the 




3.4.4 Tumors overexpressing TS5-E411A have reduced tumor 
microvessel density, tumor cell proliferation and increased tumor cell 
apoptosis 
The reduction in tumor volume and weight of the TS5-E411A overexpressing 
melanoma suggested a possible anti-angiogenic action of this catalytically 
inactive proteinase. Using histology and immunofluorescent staining, possible 
mechanism for the anti-tumorigenic effect was investigated. A significant 
reduction in the microvessel density was observed in B16/TS5-E411A tumors 
compared to the control B16/Vec tumors (Fig. 3.19A and 3.19B). 
Consistently, increased tumor cell apoptosis and decreased tumor cell 
proliferation were evident in the tumors overexpressing TS5-E411A (Fig. 






Fig. 3.19 TS5-E411A inhibits tumor growth by inhibiting 
angiogenesis, proliferation and inducing apoptosis: A. Tumor 
angiogenesis, proliferation and apoptosis were investigated by 
immunofluorescent staining. Representative pictures are shown. B. 
Quantification of tumor microvessel density. C. Quantification of 
tumor apoptosis. D. Quantification of tumor cell proliferation. Bar 
graphs represent the mean number from 3 microscopic fields per tissue 




3.5 TSR1 mediates the anti-angiogenic and anti-tumorigenic function 
of ADAMTS5 
3.5.1 Establishment of stable clones overexpressing ADAMTS5 domain 
deletion mutants (TS5-ΔMP, TS5-TSR1 and TS5-CT) in B16 mouse 
melanoma  
To determine the domain(s) responsible for the anti-angiogenic/anti-
tumorigenic function of ADAMTS5, domain deletion analyses was 
undertaken. The deletion constructs used for the study are: TS5-∆MP which 
contains all the ancillary domains but is devoid of metalloproteinase domain; 
TS5-TSR1 which contains the central TSR1 only and TS5-CT which contains 
the C-terminal region from the cysteine-rich domain to TSR2 (without TSR1) 
(Fig. 2.1). ADAMTS5 truncates were cloned into the expression vectors and 
stable B16 cell lines were established overexpressing these truncates as 
explained earlier. Their expression was confirmed by western blotting by 
probing with the anti V5-antibody (Fig. 3.20A). Immunocytochemistry was 
performed to estimate the homogeneity of the highest expressing clone in each 
of the TS5-ΔMP, TS5-TSR1 and TS5-CT constructs. All the clones showed 
homogenous expression of the V5-tagged protein (Fig. 3.20B). These high 





Fig. 3.20 Stable cell lines validation of B16 mouse melanoma 
overexpressing TS5-ΔMP, TS5-TSR1 and TS5-CT: A. Western blot 
confirming the expression of B16/TS5-∆MP, B16/TS5-TSR1 and 
B16/TS5-CT in conditioned medium of the respective stable cell line. 
B. Immunocytochemistry showing homogenous expression of V5- 
tagged constructs. Blue – DAPI (nuclear stain), Red – V5-tagged 
constructs, Scale – 50 µm. Representative pictures are shown. 
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3.5.2 Cell proliferation was not affected in B16/TS5-ΔMP, B16/TS5-
TSR1 and B16/TS5-CT in vitro 
The generation of stable cell line includes the integration of gene of 
interest into the genome of the B16 mouse melanoma. Since this gene 
integration takes place at random places, it is necessary to choose a cell line 
that has comparable morphology and cellular proliferation rate. So, before 
proceeding with mouse tumorigenesis assay, the effect of overexpression of all 
the three constructs on the cell proliferation was analyzed. Equal number of 
B16/Vec and the domain deletion mutants overexpressing TS5-ΔMP, TS5-
TSR1 and TS5-CT in B16 mouse melanoma were seeded onto 6 well plates 
and after overnight cell attachment, the cells were serum starved for 24 hrs 
before replacing with complete medium containing 2% FBS. The total cell 
number was counted using Nucleocounter on day1, day3 and day5. 
Overexpression of all the three constructs did not interfere with proliferation 





Fig. 3.21 In vitro cell proliferation assays of stable cell lines 
overexpressing TS5-ΔMP, TS5-TSR1 and TS5-CT compared to 
the B16/Vec control. 
3.5.3 Overexpression of TS5-ΔMP and TS5-TSR1 but not TS5-CT 
inhibited melanoma growth in mice 
Xenograft mouse tumorigenesis assays were carried out by injecting 
B16/TS5-ΔMP, B16/TS5-TSR1 or B16/TS5-CT cells subcutaneously into the 
dorsal right flank while control B16/Vec cells were injected into the 
corresponding left flank of each mouse. Tumor growth was monitored daily 
from day 10 post cell inoculation when tumor nodule became visible. 
Quantification of tumor volume showed a significant reduction in the tumor 
growth rate of B16/TS5- ΔMP and B16/TS5-TSR1 however there was no 
significant change in B16/TS5-CT tumor volume compared to their respective 
control B16/Vec tumors (Fig. 3.22 A). After 16
th
 day, mice were sacrificed, 
tumors excised and the tumor weight was measured. Similar to the tumor 
volume, tumor weight also correlated with the tumor volume result. There was 
a marked reduction in tumor weights of B16/TS5- ΔMP and B16/TS5-
TSR1compared to the control B16/Vec. On the other hand, there was no 
significant difference in the tumor weight of B16/TS5-CT compared to its 








Fig. 3.22 ADAMTS5 inhibits tumorigenesis and angiogenesis 
through its TSR1 domain: A. Tumor growth rates of B16 tumors 
expressing ADAMTS5 various ancillary domains. Tumor growth rates 
of B16/TS5-∆MP (n=7), B16/TS5-TSR1 (n=6) and B16/TS5-CT (n=8) 
is compared with its corresponding B16/Vec tumor. Plot represents the 
mean tumor volume (+SEM). * P < 0.05. Note that cross comparison 
between the three different tumor groups cannot be done due to 
variations in exogenous protein expression level and different B16/Vec 
involved. B. Tumor weights at the end of the experiments. Tumors 
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were dissected, weighed and mean tumor weights of B16/TS5-∆MP 
(n=7), B16/TS5-TSR1 (n=6) and B16/TS5-CT were plotted (+SEM). 
*P < 0.05 ** P < 0.01. 
3.5.4 TSR1 mediates inhibition of tumor growth by suppressing tumor 
angiogenesis, tumor cell proliferation and inducing tumor cell apoptosis 
To investigate the possible cellular mechanism responsible for the 
reduction in B16 tumor growth, tumor angiogenesis, proliferation and 
apoptosis was investigated through immunofluorescent staining of the paraffin 
embedded tumor sections as explained earlier. A clear reduction of the tumor 
vasculature was observed in B16/TS5-ΔMP, B16/TS5-TSR1 but not B16/TS5-
CT by PECAM-1 staining of ECs. Quantification of the microvessel density 
showed a reduction of more than 40% in tumors overexpressing B16/TS5-
ΔMP, B16/TS5-TSR1 but there was no significant difference in B16/TS5-CT 
(Fig. 3.23 A, B and C left panels). 
TUNEL staining indicated a dramatic increase in the tumor cell apoptosis 
in tumors overexpressing B16/TS5-ΔMP, B16/TS5-TSR1. However, there 
was no significant change in B16/TS5-CT compared to its vector control (Fig. 
3.23 A, B and C, center panels). Meanwhile, PCNA staining revealed a 
marked decrease in the cell proliferation rate in B16/TS5-ΔMP, B16/TS5-
TSR1 but not B16/TS5-CT tumors compared to the control B16/Vec tumors 
(Fig. 3.23 A, B and C  right panels). Taken together, the loss of TSR1 domain 






Fig. 3.23 TS5-TSR1 inhibits tumorigenesis by inhibiting 
angiogenesis, proliferation and induction of tumor cell apoptosis: 
A. Microvessel densities in B16 tumors overexpressing TS5-∆MP. B. 
Apoptosis in tumors overexpressing TS5-TSR. C. Cell proliferation in 
tumors overexpressing TS5-CT. Graph represents the mean of the 
respective number in 3 microscopic fields per section, 3 sections per 




3.6 Mechanism of ADAMTS5 mediated angiogenesis inhibition 
3.6.1 Overexpression of ADAMTS5 downregulates pro-angiogenic 
factors in B16 melanoma in vivo 
To further understand how ADAMTS5 suppresses tumor growth and 
angiogenesis, an antibody array containing 53 mouse angiogenesis-related 
proteins were used to probe for possible protein expression alterations in the 
ADAMTS5 overexpressing tumor (B16/TS5-FL) compared to the vector 
control (B16/Vec). Notably, no protein from this antibody array was 
significantly up-regulated when ADAMTS5 was overexpressed in B16 
melanoma (Fig. 3.24). In contrast, significant down-regulation of several pro-
angiogenic proteins in the ADAMTS5 overexpressing tumors was observed. 
The pro-tumorigenic/pro-angiogenic protein insulin-like growth factor binding 
protein-3 (IGFBP-3) and placental growth factor (PlGF) were both down-
regulated more than 3-fold. In addition, angiogenic stimulators such as VEGF, 
platelet derived-endothelial cell growth factor (PD-ECGF) and serpin E1, also 
called as plasminogen activator inhibitor-1 (PAI-1) were down-regulated 2-
fold (Fig. 3.24). Hence, ADAMTS5 seems to inhibit angiogenesis and 
tumorigenesis at least partially through down-regulation of these potent pro-
angiogenic molecules. Surprisingly, we also observed the down-regulation of 
a well-known anti-angiogenic protein Serpin F1, also called pigment 




Fig. 3.24 Down-regulation of the pro-angiogenic factors in ADAMTS5 
overexpressing B16 mouse melanoma. Using a mouse angiogenesis antibody 
array, 53 angiogenesis related proteins were investigated by probing with 
equal amount of total protein from tumor lysate of B16/Vec and B16/TS5-FL. 
The six significantly suppressed angiogenesis related proteins that are above 
the threshold (dotted lines) are highlighted. The fold change represents the 
mean of two independent experiments. 
3.6.2 Down-regulation of pro-angiogenic factors in B16 melanoma in 
vivo is mainly mediated by the TSR1 domain of ADAMTS5 
To further validate the results obtained from the angiogenesis antibody 
array, western blotting was performed on tumor protein lysate from tumor 
overexpressing ADAMTS5 compared to its corresponding empty vector 
control. The tumor protein lysate was probed with antibodies that recognized 
epitopes in mouse IGFBP-3, PlGF, PD-ECGF and VEGF. There was a marked 
reduction in all the four angiogenesis regulating factors in tumors 
overexpressing ADAMTS5 (Fig. 3.24, left panels). Since TSR1 was mainly 
mediating the anti-angiogenic function of ADAMTS5, we also investigated 
the possibility of down-regulation of these factors in tumor overexpressing 
TSR1 compared to its vector control. B16/TSR1 showed a marked reduction 
in IGFBP-3 and PD-ECGF (Fig. 3.24, Right panels). However, there were no 
significant changes in the expression of PlGF and VEGF in B16/TS5-TSR1 
154 
 
tumors compared to the B16/Vec control.  β-actin served as the loading 
control.  
3.6.3 Stable cell lines overexpressing TS5-FL or TSR1 do not alter the 
expression of pro-angiogenic factors in vitro 
B16 melanomas overexpressing TS5-FL and TSR1 showed a significant 
downregulation in pro-angiogenic growth factors in vivo. Thus, it was 
important to investigate whether these angiogenic regulators are 
downregulated in cultured B16 cells. B16/Vec, B16/TS5-FL and B16/TS5-
TSR1 were cultured in vitro in 2% FBS medium.  
 
Fig. 3.24 Downregulation of pro-angiogenic factors is mainly 
mediated by TSR1 of ADAMTS5: Tumor tissue lysates containing 
50 µg of total protein from B16/TS5-FL and B16/Vec or B16/TS5-
TSR1 and B16/Vec were probed for the four angiogenesis regulating 
proteins using IGFBP-3, PlGF, VEGF and PD-ECGF specific 
antibodies. Representative immunoblots are shown. 
 
The cell lysate was analyzed for all the four pro-angiogenic growth factors 
that were downregulated in vivo by immunoblotting as explained earlier. 
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There was no significant change in the expression of IGFBP-3, PlGF, VEGF 
and PD-ECGF in either TS5-FL overexpressing of TS5-TSR1 overexpressing 
cell lines compared to B16/Vec (Fig. 3.25). This shows that the 
downregulation of the pro-angiogenic factors requires the B16 melanoma 
tumor microenvironment.   
 
Fig. 3.25 Pro-angiogenic factors are not downregulated in cell lines 
overexpressing TS5-FL or TS5-TSR1 in vitro. 
3.6.4 ADAMTS5 does not bind and sequester VEGF 
ADAMTS5 overexpressing tumors were shown to downregulate VEGF 
compared to their empty vector control (Fig. 3.24). Previous reports have 
shown that other members of ADAMTS family such as ADAMTS1 being able 
to bind and sequester VEGF, thus inhibiting angiogenesis (Luque et al, 2003). 
To determine if ADAMTS5 also binds to VEGF, HEK293T cells were 
transfected with Vec or TS5-FL containing plasmids and the CMs were 
concentrated as explained in the material and methods (Section 2.3 and 2.11). 
Co-immunoprecipitation was performed by using anti-V5 antibody tagged 
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Protein A/G agarose beads. TS5-FL was incubated with VEGF165 in the 
presence of heparin. Anti-V5 antibody was used as the bait to pull down TS5-
FL. The sample was then immunoblotted with anti-VEGF antibody to analyze 
if there was any interaction between TS5-FL and VEGF. TS5-FL failed to co-
immunoprecipitate with TS5-FL, suggesting that this proteoglycanase does not 
interact with VEGF165 (Fig. 3.26).  
 
Fig. 3.26 ADAMTS5 does not sequester VEGF165: VEGF165 pure 
protein was loaded as a positive control to check the specificity of 
antibody in the third lane of top panel. The panels at the bottom 
demonstrate that TS5-FL is present in the concentrated CM.  
3.7 Role of ADAMTS5 in human cancers  
3.7.1 ADAMTS5 expression in human cancers and cell lines 
Once it was established that ADAMTS5 does play a role in murine cancer 
using mouse melanoma model, ADAMTS5s role in regulating human cancers 
was investigated. Firstly, we analyzed its expression in various cancer cell 
lines using an N-terminal specific antibody that recognizes a unique epitope in 
the catalytic domain of ADAMTS5 (Fig. 3.27A). The cancer cell lines 
analyzed were A549 (lung adenocarcinoma), HT1080 (fibrosarcoma), G401 
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(Kidney derived tumor), JAR (choriocarcinoma), PC3 (prostate cancer), U87 
(glioblastoma) and HeLa (cervical cancer). Out of the following cancers, 
HT1080 cell line had the lowest expression followed by A549 cell line. The 
highest expression was observed in HeLa cell line (Fig. 3.27A).  
The expression of this anti-angiogenic proteinase was also investigated in 
human tumor tissue samples and their corresponding normal tissues. Eight 
different tissue types were analyzed – Lung, skin, stomach, ovary, breast, 
colon, kidney and liver. Western blotting was performed with equal amount of 
total protein. Coomassie stained gel was used as the loading control since 
there was variation in the expression level of the house keeping genes such as 
β-actin or α-tubulin (Fig. 3.27B).  Downregulation of the anti-tumorigenic 
proteinase was observed in lung, skin, breast and stomach tumor samples 
compared to their normal tissue. In the rest of the tumor tissues such as colon, 






Fig. 3.27 ADAMTS5 expression in human cancer tissues and cell 
lines: A. Expression of ADAMTS5 in human cancer cell lines from 
various tissue sources. B. Expression of ADAMTS5 in human tumor 
tissue samples compared to their corresponding normal tissues.   
3.7.2 Establishment of stable clones overexpressing ADAMTS5 in A549 
human lung adenocarcinoma  
Since A549 had a relatively low expression of ADAMTS5 and was shown 
to be downregulated in lung cancer tissues compared to the normal (Fig. 3.27), 
A549 was chosen to overexpress ADAMTS5 and for further tumor xenograft 
studies.   
Optimal concentration of blasticidin required to select the stable antibiotic 
resistant clones of A549 was evaluated. Blasticidin at 6 µg/ml was observed to 
be the optimal concentration of cytotoxicity where all the cells rounded off 
and cell death occurred after 4-5 days. For a much stringent condition, 8 µg/ml 
of blasticidin was used for the stable clone selection.  
A549 was transfected with TS5-FL plasmid and around 40 clones that 
were resistant to blasticidin were isolated and expanded as explained earlier in 
the case of B16F1 mouse cell line. The CM from the clones was subjected to 
western blotting and probed with anti-V5 antibody. High expressing clones 
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were chosen and the clone having highest relative expression was identified by 
loading equal amount of total protein in CM. Clone 20 was shown to have the 
highest expression (Fig. 3.28A). For negative control, A549 line was 
transfected with empty pEF6/V5-His TOPO
®
 vector and the colonies were 
obtained under blasticidin selection after 2-3 weeks. All the clones were 
pooled to obtain a single A549/Vec control line. 
In order to check for the homogeneity of TS5-FL expression in Clone 20, 
immunocytochemistry was performed. A549/TS5-FL (Clone 20) showed 
around 96% homogeneity in cells expressing TS5-FL and was chosen for 
tumorigenesis studies (Fig. 3.28 B). 
 
 
Fig. 3.28 Validation of the stable cell lines overexpressing TS5-FL 
in A549: A. Equal amount of total proteins from the conditioned 
medium were loaded onto SDS-PAGE and probed with anti-V5 
antibody. Clone20 of A549/TS5-FL showed the highest expression. B. 
Immunocytochemistry showing homogenous expression of V5 tagged 
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TS5-FL when stained with anti-V5 antibody and corresponding Alexa-
fluor 568 conjugated secondary antibody. Blue – DAPI (nuclear stain), 
Red – TS5-FL. Representative Pictures are shown. 
3.7.3 A549 cell proliferation in culture was not affected upon TS5-FL 
overexpression 
Before inoculating the A549 modified cells into the nude mice, their 
proliferation rate was assayed in vitro so as to ensure that integration of the 
plasmid and overexpression of ADAMTS5 did not alter the characteristics of 
the A549 cell line. Equal number of A549/Vec and A549/TS5-FL were seeded 
in 6 well plates and after overnight cell attachment, next day the cells were 
serum starved overnight before replacing with medium containing 2% FBS. 
The total cell number was counted using Nucleocounter on day1, day3 and 
day5. Overexpression of TS5-FL did not interfere with proliferation rate 
compared to the empty vector control (Fig. 3.29). 
 
Fig. 3.29 Growth kinetics of A549 stable cell lines in vitro: 
A549/TS5-FL has a proliferation rate that is similar to A549/Vec in 
vitro over a period of 5 days.  
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3.7.4 Overexpression of TS5-FL reduced A549 tumor growth in nude 
mice (Performed by our collaborator - Dr. Hongrui Liu and Prof. Yizhun 
Zhu) 
Xenograft mouse tumorigenesis assays were performed in nude mice. 
Briefly, A549/TS5-FL cells were injected subcutaneously into the dorsal right 
flank while control A549/Vec cells were injected into the corresponding left 
flank of each mouse. Tumor growth was monitored weekly from day 7 post 
cell inoculation when tumor nodule became visible. The experiment was 
continued for 5 weeks. The mice were sacrificed on 35
th
 day. Quantification of 
tumor volume showed a significant reduction in the tumor growth rate of 
A549/TS5- FL compared to control A549/Vec tumors (Fig. 3.30 A). On 35
th
 
day mice were sacrificed, tumors were excised and the tumor weight was 
measured. Similar to the tumor volume, tumor weight also correlated with the 
tumor volume result. There was a marked reduction in tumor weights of 





Fig. 3.30 Overexpression of TS5-FL in A549 lung adenocarcinoma 
suppresses tumor growth in nude mice: A. Suppression of tumor 
growth upon overexpression of TS5-FL in A549 adenocarcinoma. The 
mean tumor volume (n=7) (+SEM) from A549/TS5-FL was plotted 
and compared with its A549/Vec control tumor. * P < 0.05. B. Tumor 
weight at the end of the experiment. Plot represents the mean tumor 
weight (n=7) (+SEM). ** P < 0.01. 
3.7.5 A549/TS5-FL reduces tumor growth by inhibiting tumor 
angiogenesis, tumor cell proliferation and inducing tumor cell apoptosis 
To investigate the possible cellular mechanism responsible for the tumor 
growth suppression, tumor angiogenesis, proliferation and apoptosis was 
investigated through immunofluorescent staining of the paraffin embedded 
tumor sections. A clear reduction of tumor vasculature was observed in 
A549/TS5-FL by PECAM-1 staining of ECs (Fig. 3.31A, top panels). 
Quantification of the microvessel density showed a more than 50% reduction 
in tumors overexpressing ADAMTS5 (Fig. 3.31B, left panel). TUNEL 
staining was performed on the tissues to analyze if there was any cell death in 
vivo. Staining indicated a dramatic increase in tumor cell apoptosis (Fig. 
3.31A, lower panels and Fig. 3.31B, center panel). The reduction in tumor 
growth can also be a result of reduced tumor cell proliferation. So to 
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investigate the proliferation in tumor sections, nuclear PCNA staining was 
performed. It revealed a marked decrease in cell proliferation rate in 
A549/TS5-FL tumor sections compared to the control A549/Vec tumors (Fig. 
3.31A, bottom panels and Fig. 3.31B, right panel). Taken together, the reduced 
tumor growth in ADAMTS5 overexpressing B16 melanoma is the result of 
combined effects of suppressed tumor angiogenesis, reduced tumor cell 
proliferation and an increased tumor cell death. 
 
 
Fig. 3.31 Full-length ADAMTS5 suppresses tumor angiogenesis, 
tumor cell proliferation and induces tumor cell apoptosis in A549 
lung adenocarcinoma: A. Paraffin sections of A549/Vec and 
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corresponding A549/TS5-FL were probed for micro-vessel density, 
tumor cell proliferation and apoptosis through immunofluoresence 
staining using anti-PECAM-1, anti-PCNA and TUNEL staining 
respectively. B. Quantification of micro-vessel density, cell 
proliferation and apoptosis in A549/TS5-FL tumor. Micro-vessel 
density is the number of micro-vessels per microscopic field. Cell 
proliferation is presented as the percentage of PCNA positive cells per 
total number of tumor cells (DAPI positive cells) in the microscopic 
field. Apoptosis is quantified as the number of TUNEL positive cells 
per microscopic field.  Plots represent the mean of 3 fields per section, 
3 sections per tumor (+SEM). ** P < 0.01. 
3.8 ADAMTS5 inhibits experimental lung metastasis in mice 
Tumor metastasis is a multi-stage process during which malignant cells 
spread from the primary tumor to distant organs such as lung, bone etc. 
(Talmadge & Fidler, 2010). Many anti-angiogenic proteins have been shown 
to inhibit tumor metastasis in mice (Chakraborty et al, 2012; O'Reilly et al, 
1994). On the other hand, there are other reports indicating that anti-
angiogenic drugs may help the primary tumor to metastasize by creating a 
hypoxic environment (Ebos et al, 2009). In the case of ADAMTS5, we 
demonstrated that it is as an anti-angiogenic and anti-tumorigenic proteinase in 
mice. In contrast, a previous report has indicated that ADAMTS5 is 
overexpressed in glioma and promotes the glioma cell invasion in vitro by 
cleaving brevican (Nakada et al, 2005). Thus, how ADAMTS5 influences 
tumor metastasis warrant careful investigation. 
3.8.1 TS5-FL inhibits experimental B16 melanoma lung metastasis in 
mice 
To determine if ADAMTS5 influences tumor metastasis, experimental 
pulmonary metastasis assay using B16 mouse melanoma model was chosen. 
Stable derivatives of B16 melanoma cells overexpressing the full-length 
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ADAMTS5 (B16/TS5-FL) was used in this study. Pooled empty vector 
modified cells (B16F10/Vec) served as the control. Stable B16 clones 
overexpressing TS5-FL was injected intravenously into C57Bl/6 mice through 
the lateral tail vein. At the end of 17 days (when mice became sluggish), mice 
were euthanized and lungs harvested, photographed and weighed. As shown in 
Fig. 3.32A, the B16 cells overexpressing ADAMTS5 showed a reduced 
number of metastatic foci on the lungs compared to the empty vector control. 
The tumor lung weight also showed a significant reduction in the B16/TS5-FL 
compared to B16/Vec lungs (Fig. 3.32B).  
 
 
Fig. 3.32 ADAMTS5 inhibits experimental pulmonary metastasis 
in vivo: A. Overexpression of TS5-FL in B16 mouse melanoma have 
reduced number of metastatic foci on the lungs of mice post 17 days of 
tail vein injection of B16/TS5-FL compared to the B16/Vec control. A 
representative metastasized lung of B16/Vec and B16/TS5-FL injected 
mice are shown. B. Quantification of lung weight of the mice dissected 
after 17
th
 day of B16 mouse melanoma injection overexpressing TS5-
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FL or empty Vec cells. Mean lung weights were plotted (n=6) (+ 
SEM). * P < 0.05. 
3.8.2 Inhibition of metastasis is independent of its proteoglycanase 
function  
Metalloproteinases are well known for its role in cell invasion and 
metastasis (Deryugina & Quigley, 2006). Even ADAMTS5 has been 
implicated in tumor invasion in brain cancer (Nakada et al, 2005). 
Surprisingly, overexpression of ADAMTS5 resulted in suppression of 
metastasis in vivo. So, in order to investigate whether the catalytic domain is 
important for the same, pulmonary metastasis assay was performed with B16 
mouse melanoma overexpressing catalytically inactive ADAMTS5 (TS5-
E411A). Similar to TS5-FL, TS5-E411A overexpressing cells showed reduced 
number of metastatic foci on lungs compared to the B16/Vec control (Fig. 
3.33A). This confirmed that the catalytic activity was not involved in 
ADAMTS5s anti-metastatic function. Quantification of the metastasized lung 
weight corroborated with the result that there was reduced invasion of the B16 





Fig. 3.33 Anti-metastatic function of ADAMTS5 is independent of 
its catalytic function: A. Overexpression of TS5-E411A in B16 
mouse melanoma have reduced number of metastatic foci on the lungs 
of mice compared to the empty vector control. A representative picture 
of the lung of B16/Vec and B16/TS5-E411A injected mice are shown. 
B. Quantification of lung weight of the mice dissected after 17
th
 day of 
B16 mouse melanoma injection overexpressing TS5-E411A or empty 
Vec cells. Mean lung weights were plotted (n=6) (+ SEM). * P < 0.05. 
3.8.3 Histopathological analyses of the lungs also revealed a reduction of 
metastatic foci and suppression of angiogenesis in the metastasized 
tumors  
Lungs of the mice having metastatic nodules from all the three groups 
(B16/Vec, B16/TS5-FL and B16/TS5-E411A) were fixed in formaldehyde and 
paraffin embedded for histopathological analysis. H&E staining was 
performed to analyze the metastatic foci in the lungs. B16/Vec had relatively 
large metastatic foci in size and number compared to the B16/TS5-FL or 
B16/TS5-E411A infected lungs (Fig. 3.34, Upper panels). The lung section 
was also stained with PECAM-1 for the vascularization. In the metastatic foci, 
there was marked reduction in the angiogenesis in case of B16/TS5-FL and 
B16/TS5-E411A compared to the B16/Vec overexpressing metastasized tumor 




Fig. 3.34 Histopathological analyses of lungs after experimental 
metastasis assay: Immunohistochemistry of the lungs showed reduced 
size of metastatic foci (upper panel) and angiogenesis (lower panel) in 
B16/TS5-FL and B16/TS5-E411A compared to the B16/Vec control. 
Scale bar in upper panel – 50 µM. The dark circles in the upper panel 
indicate the region of metastasis in the lung. The red staining in lower 
panels indicates angiogenesis in metastatic foci.  
3.9 Characterization of adamts5 in zebrafish embryonic angiogenesis  
Zebrafish (Danio rerio) serves as an excellent model organism to study 
both developmental and physiological functions due to the numerous 
advantages. To name a few - short life cycle, transparent embryos, sequenced 
genome, range of genomic tools etc. (Grunwald & Eisen, 2002). A total of 
fourteen ADAMTS members have been identified in zebrafish. Interestingly, 
zebrafish lacks adamts4 (aggrecanase-1) which is closely related to adamts5 in 
terms of its proteolytic function and sequence similarity. Most of the 
ADAMTS clades have only one zebrafish orthologue with the exception of 
ADAMTS8 (4 orthologues) and ADAMTS15 (3 orthologues) (Huxley-Jones 
et al, 2007). The physiological role of many ADAMTSs including ADAMTS5 
is not yet clearly understood partly because of the redundancy and functional 
complementarity of other metalloproteinases. Thus, a careful and detailed 
examination of embryonic and adult expression of ADAMTSs with the 
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context of substrate availability and also co-expression of other adamts that 
have a functional complementation may shed light into their functions. Also, 
the availability of the transgenic zebrafish line Tg(fli1:EGFP) that expresses 
EGFP in the vascular endothelium helps to understand the role of a gene in 
physiological and embryological angiogenesis. Availability of technical tools 
to knockdown any genes of interest in zebrafish embryo allow the quick 
revelation of the gene function during embryogenesis. Taken together, 
zebrafish serves as an excellent model to study the role of adamts5 in 
physiological and embryological angiogenesis.   
3.9.1 Bioinformatics analysis of zebrafish adamts5 gene 
Full-length protein sequence of zebrafish Adamts5 was retrieved from 
GenBank (Gen Bank Accession No. JF778846.1) 
(http://www.ncbi.nlm.nih.gov/genbank/). Multiple sequence alignment of 
ADAMTS5 from various mammalian and avian origins was performed. 
Multiple sequence alignment shows that this multi-domain proteinase is highly 
conserved among all the members (Fig. 3.35A). The metalloproteinase domain 
and the ancillary domains share a very high amino acid sequence identity of 
69%. High similarity is only lacking in the case of prodomain (33% amino 
acid identity). This is understandable as prodomain only helps to maintain 
enzyme latency till it is secreted to ECM and gets cleaved leading to the 
activation of this metalloproteinase (Longpre et al, 2009). Phylogenetic 
analysis shows that zebrafish adamts5 is more closely related to chicken 
adamts5 than that of mammals (Fig. 3.35 B). With respect to mammalian 
ADAMTS5, zebrafish adamts5 is more closely related to mouse and rat 




Human           MLLGWAS-----LLLCAFRLPLAAVGPAATPAQDKAGQPPTAAAAAQPRRRQGEEVQERA 55 
Monkey          MLLGWAS-----LLLCAFRLPLAAAGPAAAPAQDKAGQPATAAAAAQPRRRQGEEVQERT 55 
Rat             MLLEWASLLLLLLLLCASCLALAADNPAAAPAQDKTRQPRAAAAAAQPDQRQWEETQER- 59 
Mouse           MRLEWAPLLLLLLLLSASCLSLAADSPAAAPAQDKTRQPQAAAAAAEPDQPQGEETRER- 59 
Chicken         ------------------------------------------------------------ 
Frog            ------------------------------------------------------------ 
Zebrafish       ------------MWLVVLLCCVLDASVARPPAN--------------------------- 21 
                                                                             
 
Human           EPPGHPHPLAQRRRSKGLVQNIDQLYSGGGKVGYLVYAGGRRFLLDLERDGSVGIAG-FV 114 
Monkey          EPPGHPHPLAQRRSSKGLVQNIDQLYSGGGKVGYLVYAGGRRFLLDLERDGSVGTAG-FV 114 
Rat             ---GHPQPLARQRRSSGLVQNIDQLYSGGGKVGYLVYAGGRRFLLDLERDDTVGAAGGIV 116 
Mouse           ---GHLQPLAGQRRSGGLVQNIDQLYSGGGKVGYLVYAGGRRFLLDLERDDTVGAAGSIV 116 
Chicken         ------------------------------------------------------------ 
Frog            -----------------------QIYAGGGKVGYILYADGKKFLLDLERDELLLSPHFST 37 
Zebrafish       ---------ASLLAPDGTVRAVDRIYHGGGKAGYLLYLDEQRFQLDMERDETIPDHQFSA 72 
                                                                             
 
Human           PAGGGTSAPWRHRSHCFYRGTVDGSPRSLAVFDLCGG-LDGFFAVKHARYTLKPLLRGPW 173 
Monkey          PTGGGTSAPWRHRSHCFYRGTVDGSPRSLAVFDLCGG-LDGFFAVRHARYTLKPLLRGPW 173 
Rat             TAGGGLSASSGHRGHCFYRGTVDGSPRSLAVFDLCGG-LDGFFAVKHARYTLKPLLRGSW 175 
Mouse           TAGGGLSASSGHRGHCFYRGTVDGSPRSLAVFDLCGG-LDGFFAVKHARYTLKPLLRGSW 175 
Chicken         ------------------------------------------------RYTVRPARRGGE 12 
Frog            KYLGRLHPQHRFQRHCFYRGTVDSSPQSLAVFNLCGG-LDGYFAVKHAHYTIKPLIKGTA 96 
Zebrafish       DAP--------PRRECVYRGTVNSNAQSLAVFNLCGGGLEGFFALDHSRYTITPVIRAKG 124 
                                                                :**: *  :.   
 
Human           AEEEKG-RVYGDGSARILHVYTREGFSFEALPPRASCETPASTPEAHEHAPAHSNPSGRA 232 
Monkey          AEEETG-RVYGDGSARILHVYTREGFSFEALQPRASCETPASTPEPHERPPAHSNPGGRA 232 
Rat             AESE---RVYGDGSSRILHVYTREGFSFEALPPRTSCETPASPSGPQESPSVHSSSRRRT 232 
Mouse           AEYE---RIYGDGSSRILHVYNREGFSFEALPPRASCETPASPSGPQESPSVHSRSRRRS 232 
Chicken         EEDEGGPRIYGEGPARAPHFFRRERFSFETLPARPSCETRG----PAGAATAPESGRRR- 67 
Frog            ETVPTRASCETHGLRKRLHKHGKG----ATRHPHQHQQTQENPQKANQTSAPSDPNLKET 152 
Zebrafish       HENDVH-IVEDADATRALHLYTRERFSFEAMPERHSCGTRDRKTRKHKKEMHGRRWWTKF 183 
                            .  :  * . :      :   :    *                   .  
 
Human           ALASQLLDQSALSPAGGSGPQTWWRRRRRSISRARQVELLLVADASMARLYGRGLQHYLL 292 
Monkey          ALASQLLDQSAVSPAGGPGPQTWWRRRRRSISRARQVELLLVADASMARLYGRGLQHYLL 292 
Rat             ELAPQLLDHSAFSPAGNAGPQTWWRRRRRSISRARQVELLLVADSSMAKMYGRGLQHYLL 292 
Mouse           ALAPQLLDHSAFSPSGNAGPQTWWRRRRRSISRARQVELLLVADSSMARMYGRGLQHYLL 292 
Chicken         ------------------------RRRRRSVSRARQVELLLVADASMARKYGKGLQHYLL 103 
Frog            LFQSTALK----------------KRQRRSVSKSRQVELLLVADESMAKKYGKDLHHYLL 196 
Zebrafish       IRPDASP-----------------TRRKRSVSRARHVELLLVADASMTKKYGKDLQHYLL 226 
                                         *::**:*::*:******** **:: **:.*:**** 
 
Human           TLASIANRLYSHASIENHIRLAVVKVVVLGDKDKSLEVSKNAATTLKNFCKWQHQHNQLG 352 
Monkey          TLASIANRLYSHASIENHIRLAVVKVVVLGDKDKSLEVSKNAATTLKNFCKWQHQHNQLG 352 
Rat             TLASIANRLYSHASIENHIRLAVVKVVVLTDK--SLEVSKNAATTLKNFCKWQHQHNQLG 350 
Mouse           TLASIANRLYSHASIENHIRLAVVKVVVLTDKDTSLEVSKNAATTLKNFCKWQHQHNQLG 352 
Chicken         TLASIASRLYAHASLENHVRLAVVKVVVLGEKEKGLEVNRNAATTLKNFCKWQHQHNRLD 163 
Frog            TLASIASRLYSHPSIENHIRLAVVKVVMLTDKDKGPEVSKNAATTLKNFCKWQHQHNQLD 256 
Zebrafish       TLASIASKLYGHASIENPIRLSVVKVALLSEHEKGIEISKNAAATLKSFCKWQNQQNPLD 286 
                ******.:**.*.*:** :**:****.:* ::  . *:.:***:***.*****:*:* *. 
 
Human           DDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTVAHEI 412 
Monkey          DDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTVAHEI 412 
Rat             DDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTVAHEI 410 
Mouse           DDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTVAHEI 412 
Chicken         DDHDEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTVAHEI 223 
Frog            DEHDQHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTVAHEI 316 
Zebrafish       DDHQHHHDAAILFTRQDLCGHHSCDTLGMADVGTVCSPERSCAIIEDDGLHAAFTVAHEI 346 
                *:*:.*:********:******************:********:**************** 
 
Human           GHLLGLSHDDSKFCEETFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCL 472 
Monkey          GHLLGLSHDDSKFCEETFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCL 472 
Rat             GHLLGLSHDDSKFCEENFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCL 470 
Mouse           GHLLGLSHDDSKFCEENFGTTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCL 472 
Chicken         GHLLGLSHDDSKFCEENFGSMEDKRLMSSILTSIDASKPWSKCTSATITEFFDDGHGNCL 283 
Frog            GHLLGLSHDDSKFCEENFGSLEDKRLMSSVLTSIDASKPWSKCTSATITDFLDDGHGNCL 376 
Zebrafish       GHLLGLSHDDSKFCEERFGSSEDKRLMSSILTSIDASKPWSRCTSNTITDFFDDGNAECL 406 
                **************** **: ********:***********:*** ***:*:***:.:** 
 
Human           LDLPRKQILGPEELPGQTYDATQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTK 532 
Monkey          LDQPRKQILGPEELPGQTYDATQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTK 532 
Rat             LDVPRKQILGPEELPGQTYDATQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTK 530 
Mouse           LDLPRKQILGPEELPGQTYDATQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTK 532 




Frog            LDQPRNQILGPEELPGQSYDAIRQCKLAFGPTYTVCPGMDVCSRLWCAVVRQGQMVCLTK 436 
Zebrafish       LDAPRVPLLGPEELPGQSYDAVQQCRLAFGSEYSVCPGMDICARLWCSVIRKGQMVCLTK 466 
                ** **  :*********:*** :**.*:**. *:******:*:****:*:*:******** 
 
Human           KLPAVEGTPCGKGRICLQGKCVDKTKKKYYSTSSHGNWGSWGSWGQCSRSCGGGVQFAYR 592 
Monkey          KLPAVEGTPCGKGRICLQGKCVDKTKKKYYSTSSHGNWGSWGSWGQCSRSCGGGVQFAYR 592 
Rat             KLPAVEGTPCGKGRICLQGKCVDKTKKKYYSTSSHGNWGSWGPWGQCSRSCGGGVQFAYR 590 
Mouse           KLPAVEGTPCGKGRVCLQGKCVDKTKKKYYSTSSHGNWGSWGPWGQCSRSCGGGVQFAYR 592 
Chicken         KLPAVEGTPCGKGRICLQGKCVDKTKKKYYSASSHGNWGSWGPWGQCSRTCGGGVQFAYR 403 
Frog            KLPAVEGTPCGKGRICLHGKCVDKNKKKYYSVSSHGNWGSWGPWGQCSRTCGGGVQFAYR 496 
Zebrafish       KLPAVEGTPCGKGRICLQGKCVDKTKKRHYSTSKDGSWSSWGAWGSCSRSCGGGVQFAQR 526 
                **************:**:******.**::**.*..*.*.***.**.***:******** * 
 
Human           HCNNPAPRNNGRYCTGKRAIYRSCSLMPCPPNG-KSFRHEQCEAKNGYQSDAKGVKTFVE 651 
Monkey          HCNNPAPRNNGRYCTGKRAIYRSCGLMPCPPNG-KSFRHEQCEAKNGYQSDAKGVKTFVE 651 
Rat             HCNNPAPRNSGRYCTGKRAIYRSCSVIPCPPNG-KSFRHEQCEAKNGYQSDAKGVKTFVE 649 
Mouse           HCNNPAPRNSGRYCTGKRAIYRSCSVTPCPPNG-KSFRHEQCEAKNGYQSDAKGVKTFVE 651 
Chicken         HCNNPAPRNNGRYCTGKRAIYRSCNVTPCPANA-KSFRQEQCEARNGYQSDAKGVKTFVE 462 
Frog            HCNNPAPKNSGKYCIGKRAIYRSCNVTPCPSNVSKSFRQQQCEARNGYQTDAKGVKTFVE 556 
Zebrafish       LCNNPAPRNNGRYCTGKRAVYRSCSVTPCPTTG-KSFRQEQCEVRNGPQTDPKGVKTLVE 585 
                 ******:*.*:** ****:****.: ***..  ****::***.:** *:*.*****:** 
 
Human           WVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRLYSNSVCVRGKCVRTGCDGI 711 
Monkey          WVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRPYSNSVCVRGKCVRTGCDSI 711 
Rat             WVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRPYSNSVCVRGRCVRTGCDGI 709 
Mouse           WVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRPYSNSVCVRGRCVRTGCDGI 711 
Chicken         WVPKYAGVLPGDVCKLTCRAKGTGYYVVFSQKVTDGTECRPYSNSVCVRGKCIRTGCDGI 522 
Frog            WVPKYAGVQPGDVCKLICQAKGTGYYVVFSQKVTDGTECRPYSNSVCVRGKCVRTGCDGI 616 
Zebrafish       WVPKFAGVLPKDVCKLTCRAKGTGYYVVFSQRVVDGTECRPYSSSVCVKGKCVRTGCDGI 645 
                ****:*** * ***** *:*********** :*.****** **.****:*:*:*****.* 
 
Human           IGSKLQYDKCGVCGGDNSSCTKIVGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRF 771 
Monkey          IGSKLQYDKCGVCGGDNSSCTKIVGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRF 771 
Rat             IGSKLQYDKCGVCGGDNSSCTKIIGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRF 769 
Mouse           IGSKLQYDKCGVCGGDNSSCTKIIGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRF 771 
Chicken         IGSKLQYDKCGVCGGDNSSCTKVMGTFTKKSKGYTDIVKIPEGATHIKVRQFKTKDQSRF 582 
Frog            IGSKLQFDKCGICGGDNSSCTKVMGTFTTKSKGYTDIVKIPEGATHIKVRQYKAKDQTRF 676 
Zebrafish       IGSKLQYDKCGICGGDGNSCIKVAGNFTKKSKGYTDVVKIPEGSTHLKVRQYKAKGQSRY 705 
                ******:****:****..** *: *.*..*******:*:****:**:****:*:*.*:*: 
 
Human           TAYLALKKKNGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILI 831 
Monkey          TAYLALKKKNGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILI 831 
Rat             TAYLALKKKTGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILI 829 
Mouse           TAYLALKKKTGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILI 831 
Chicken         TAYLALKKKNGEYLVNGKYMISTSETIIDINGTVMNYSGWSHKDDFLHAMGHSATKEVLI 642 
Frog            TAYLALKKKSGEYITNGKYMISTSETIIEMNGFVMNYSGWSHAEDMLHSMGHSSTQEVLI 736 
Zebrafish       TAYLALRRPGGDYLLNGKLMISTSETIIPLNGSVLNYTGWSQRDEAFHSMGPAALQESLL 765 
                ******::  *:*: *** ********* :** *:**:***: :: :*.** :: :* *: 
 
Human           VQILATDPTKPLDVRYSFFVPKKS------------------------------------ 855 
Monkey          VQILATDPTKPLDVRYSFFVPKKS------------------------------------ 855 
Rat             VQILATDPTKALDVRYSFFVPKKT------------------------------------ 853 
Mouse           VQILATDPTKALDVRYSFFVPKKT------------------------------------ 855 
Chicken         VQILATDPTQPVDVRYSFFVPKKQ------------------------------------ 666 
Frog            VQILATDQSKPLDVRYSFYVPSKQ------------------------------------ 760 
Zebrafish       VQILSTDAKKPLDIRYSFFMPRKTPLPARTSPEAPPRMSLEAPPRMSLEAPPRMSLEAPP 825 
                ****:** .:.:*:****::* *                                      
 
Human           --TPKVNSVTSHGSN-KVGSHTSQ----------------------------------PQ 878 
Monkey          --TPKVNSVTSHGSN-KVGSHTSQ----------------------------------LQ 878 
Rat             --TQKVNSVISHSSN-KVGLHSPQ----------------------------------LQ 876 
Mouse           --TQKVNSVISHGSN-KVGPHSTQ----------------------------------LQ 878 
Chicken         --GQMTNSVTGSGSSSKVTPQLTQ----------------------------------PR 690 
Frog            --VPNTNSIN--NIN-NVVPKISQ----------------------------------PQ 781 
Zebrafish       RMAPEALPRTSPEAPPRIPPEAPPRTPPEAPPTVASLSSAELVTFTSDVPPTTESPKFPR 885 
                     . .        .:  . .                                    : 
 
Human           WVTGPWLACSRTCDTGWHTRTVQCQDGNRKLAKGCPLSQRPSAFKQCLLKKC 930 
Monkey          WVTGPWLACSRTCDTGWHTRTVQCQDGNRKLAKGCPLSQRPSAFKQCLLKKC 930 
Rat             WVTGPWLACSRTCDTGWHTRTVQCQDGNRKLAKGCILSQRPSAFKQCLLKKC 928 
Mouse           WVTGPWLACSRTCDTGWHTRTVQCQDGNRKLAKGCLLSQRPSAFKQCLLKKC 930 
Chicken         WVTGPWLSCSRTCDTGWHTRTVQCKDGHGKLAKGCLLSQRPSAFKQCLLKKC 742 
Frog            WVTGPWLSCSRTCDTGWHTRTVQCQDGHGKLAKGCLLSQRPSAFKQC----- 828 
Zebrafish       WLTGPWMSCSRTCDTGWQSRTVQCKDANGKLSKNCPLSARPSAFKHCLIKKC 937 





Fig. 3.35 Multiple sequence alignment and phylogenetic tree of 
ADAMTS5: A. Multiple protein sequence alignment of ADAMTS5 
from various species performed using ClustalW. Identical amino acids 
are indicated by a (*) symbol below the sequence. Conserved and 
semi-conserved substitutions are indicated by (:) and (.) respectively. 
B. Phylogenetic tree of ADAMTS5 amino acids were constructed 
using the neighbor-joining method. (0.1 is the standard genetic 
distance). 
3.9.2 Expression pattern of adamts5 
3.9.2.1 Expression analysis of adamts5 mRNA during embryogenesis using 
semi-quantitative RT-PCR 
Temporal expression of zebrafish adamts5 was analyzed using semi-
quantitative RT-PCR. Primers span exon/intron boundary region to overcome 
problems associated with the amplification of genomic DNA. Using BLAST, 
it was ensured that the primers designed were unique to zebrafish adamts5 to 
avoid false priming. The adamts5 transcripts were detected in 2 cell stage (< 
0.75 hpf) suggesting maternal expression (Fig. 3.36). Adamts5 expression was 
observed during the early embryonic development stages until 24 hpf. From 
24 hpf, there was an elevated expression of this proteoglycanase till 120 hpf 




Fig. 3.36 Temporal expression of zebrafish adamts5: Semi-
quantitative RT-PCR was performed with cDNA obtained from wild 
type embryos at various stages and beta actin served as a housekeeping 
gene. 
3.9.2.2 Whole mount in situ hybridization (WISH) of adamts5 during 
early embryogenesis (<24 hpf) in zebrafish 
WISH was performed to study the expression pattern of adamts5 in early 
development of zebrafish up to 120 hpf. WISH data further confirmed the RT-
PCR results that adamts5 was expressed maternally as mRNA signal was 
detected at 2 cell-stage (Fig. 3.37 A). Ubiquitous expression of this 
proteoglycanase was observed during blastula period (Fig. 3.37 C), 
gastrulation (Fig. 3.37 E, G, I and K) and early segmentation stages (Fig. 3.37 
M and O). This staining was quite specific as there was no signal when stained 
with the sense probe for all the corresponding stages (Fig. 3.37 B, D, F, H, L, 




Fig. 3.37 Whole mount in situ hybridization of early stage 
zebrafish embryos (0.75 hpf – 11.66 hpf) using anti-sense (Panel A, 
C, E, G, I, K and M) or sense Danio rerio adamts5 probe (Panel B, 
D, F, H, J, L and N):  Adamts5 is expressed ubiquitously form very 
early stage (0.75 hpf) suggesting maternal expression till the 5 somite 
stage. The expression of adamts5 was absent in yolk during all the 
stages. Scale bar 25 µm. 
3.9.2.3 WISH of adamts5 during late embryogenesis (>24 hpf) in zebrafish 
During the 2
nd
 day of embryogenesis upto 120 hpf, adamts5 mRNA 
becomes more localized and is observed at the anterior parts of the embryos 
(Fig. 3.38 and 3.39). From 24 hpf onwards, adamts5 expression is persistently 
observed in neural tissues, specifically eye and brain but not in mesodermal 
tissues such as notochord. Expression was observed in forebrain, midbrain and 
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hindbrain including the otic vesicle and extended to the posterior border of 
rhombencephalon (Fig. 3.38A and B). Cross section of the 24 hpf embryo 
further presented the high level expression of adamts5 in the midbrain, with 
lower level of expression in the eye, forebrain and hindbrain (Fig. 3.38C).  In 
the posterior region of 24 hpf embryo, expression is limited to the ventral 
region of the trunk just above the yolk that comprises of lateral plate 
mesoderm and paraxial mesoderm surrounding the dorsal aorta (Fig. 3.38D 
and E). Zebrafish adamts5 shows expression in the region surrounding dorsal 
aorta and axial vein.  
 
Fig. 3.38 Whole mount in situ hybridization of zebrafish embryos 
(24 hpf): A. 24 hpf, lateral view. B. 24 hpf, dorsal view. C. 24 hpf, 
Lateral posterior view. D and E. Cross-sections of 24 hpf. Fb – 
forebrain, Mb – midbrain, hb-hindbrain, ey – eye, ov – otic vesicle, av- 
axial vein, le – lens, rt – retina, tc – telencephalon, di- diencephalon, rt 
– retina, me- mesoderm, da – dorsal aorta, lpm – lateral plate 
mesoderm, nc – notochord. Scale bar 100 µm in all except Panel C, D 
and E having scale bar of 10 µm. 
 
At 48 hpf and 72 hpf, adamts5 continues to express in the brain, eye and 
otic vesicle (Fig. 3.39A, B and D). A more dispersed expression of this gene 
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was observed in the craniofacial region from 48-72 hpf, a region rich in 
cartilage, suggesting its role in aggrecan degradation during normal embryonic 
cartilage development (Fig. 3.39A, B and D). At 120 hpf, the expression of 
adamts5 was observed in the craniofacial region, (Fig. 3.39F, H, I and J). 
Adamts5 was observed in cranial tissues that are rich in cartilage such as 
quadrate, basibranchial cartilage and trabecular bar (Fig. 3.39I). Thus it can be 
speculated that adamts5 plays an important role in ECM aggrecan turnover 
required for the cartilage morphogenesis during craniofacial development in 
zebrafish. In addition, swim bladder and the intestinal region of the zebrafish 
showed strong expression of adamts5 (Fig. 3.39F, 3.39H and 3.39J). It is 
difficult to speculate its role in the intestinal region at this stage and further 
studies are required to clarify its role in the gut and intestinal bulb during 72 
and 120 hpf respectively. Taken together, the expression pattern of adamts5 
demonstrates that this proteoglycanase was expressed ubiquitously during the 
earlier stages of the development, becomes restricted to the anterior parts of 
the embryo from 24 hpf and gets restricted to brain and intestinal region at 120 
hpf. 
3.9.2.4 Expression of adamts5 mRNA in adult tissues 
Total RNA from various tissues of the 6 month old adult zebrafish and 
performed semi-quantitative RT-PCR to evaluate the spatial expression of 
adamts5. Adamts5 was predominantly expressed in tissues such as stomach, 
muscle and gills (Fig. 3.40). This proteoglycanase was also detected in organs 




Fig. 3.39 Whole mount in situ hybridization for adamts5 in 
zebrafish embryos (48 hpf – 120 hpf): A and B. 48 hpf lateral view 
and dorsal view respectively, stained with antisense probe. C. 48 hpf 
lateral view, sense probe. D. 72 hpf lateral view, anti-sense probe. E. 
72 hpf lateral view, sense probe. F. 120 hpf lateral view, anti-sense 
probe. G. 120 hpf lateral view, sense probe. H. 120 hpf dorsal view, 
anti-sense probe. I and J. Cross-section of 120 hpf zebrafish larva 
stained with anti-sense probe. Mb – midbrain, ey – eye, ov – otic 
vesicle, pa – pharyngeal arch, inb – intestinal bulb, sb – swim bladder 
te – telencephalon, de – diencephalon, tb – trabecular bar, qu – 





Under our experimental conditions, no adamts5 was observed in pancreas 
and very low expression was observed in intestine and ovary. Expression of 
adamts5 in muscles suggests its role in myogenesis and versican turnover. The 
maximum expression of adamts5 was observed in spleen and warrants further 
study to clarify the role of this proteoglycanase. 
 
Fig. 3.40 Spatial expression of adamts5 gene: Semi-quantitative 
RT-PCR was performed with cDNA obtained from various organs of 
wild type adult zebrafish (6 month old). 
3.9.2.5 Morpholino based knockdown analysis of adamts5  
3.9.2.5.1 Knockdown of adamts5 leads to severe morphological 
defects in wild type zebrafish embryos 
In order to investigate the functional role of adamts5 in zebrafish 
embryogenesis, loss of function studies was carried using morpholino 
antisense oligonucleotide (MO) based knockdown of adamts5. Splice blocking 
MO was used in this study. Adamts5 MO was designed so as to specifically 
target the exon3-intron3 boundary (Fig. 3.41A). Exon3 codes for the catalytic 
domain. Targeting exon3-intron3 boundary will result in the intron inclusion. 
At the protein level, this leads to the frame shift and abrupt termination in the 
catalytic domain itself because of inclusion of a stop codon in the intron3. MO 
was injected into the 1 cell stage of the zebrafish wild type embryos and 
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incubated at 28ºC in E3 medium for 24 hrs. Total RNA was extracted and RT-
PCR was performed to confirm the efficient knockdown of adamts5. 
Mismatch MO served as the control. Injection of MO results in the intron5 
inclusion into the adamts5 transcript and thus disrupting the open reading 
frame of the adamts5. As shown in Fig. 3.41B, adamts5 MO could 
knockdown the gene in the zebrafish embryos by 80% upon injection with 2.3 
pmol of the MO per embryo. The splicing interfered product was observed 
only in the MO injected embryos and the product matched the size of intron 5 
inclusion. This product was cloned and sequenced. Sequence analysis revealed 
that intron 5 of adamts5 is indeed included in the splicing-blocked product.  
The phenotype of the embryos injected with mismatch MO and adamts5 
MO were carefully observed throughout their development for any possible 
phenotypic defects. Injection of MO at a 2.3 pmol concentration per embryo 
resulted in severe morphological defects (Fig. 3.41C and D) (Table 3.1). These 
include deformed development, distorted body axis, curved tail, notochord 
with irregular shape, irregular somites indicating growth retardation etc. 
Injection of mis MO showed no such phenotypic differences.  
3.9.2.5.2 Knockdown of adamts5 does not affect embryological 
angiogenesis in zebrafish 
In order to investigate the role of adamts5 in embryological and physiological 
angiogenesis, MO based knockdown was undertaken in transgenic zebrafish 








Fig. 3.41 Knockdown analysis of adamts5 by morpholino: A. 
Genomic structure and morpholino targeting region of adamts5 
(not to scale). B. Confirmation of the knockdown of adamts5 by 
semi-quantitative RT-PCR. β-actin served as the control. C. 
Morphological defects of zebrafish embryos upon adamts5 
knockdown are shown after 30 hpf and 48 hpf. Scale bar 100 µm. 
D. Quantification of the morphological defects in embryos injected 
with adamts5 MO (N indicates the number of zebrafish embryos 
with morphological defects). ** P<0.01.  
Morphology Phenotype defect Percentage 
Body axis Reduction in length and 
distorted 
72 
Notochord Irregular shape and 
shortened 
61 
Somite Patterning affected, 
reduced number 
78 
Tail Severely curled, bent 
and shortened. 
81 




Table 3.1 Morphological defects in embryos after knockdown of adamts5.  
 
Since higher dose of MO (2.3 pmol) resulted in severe morphological 
defects that overshadows adamts5’s possible role in regulating 
vasculogenesis/angiogenesis, lower doze of MO (1.55 pmol) was used to 
knockdown adamts5. No obvious perturbed angiogenesis was observed at this 
dose of MO (Fig. 3.42).  In zebrafish vasculogenesis results in the formation 
of axial vessels giving rise to dorsal aorta and posterior cardinal vein. There 
was no marked disruption of the vasculogenesis after MO injection at 12-16 
hpf (data not shown). Subsequently, sprouting angiogenesis pre-dominates 
resulting in the formation of intersegmental vessels (ISVs) which is formed 
soon after 24 hpf and complete at about 72 hpf. Injection of adamts5 MO did 
not lead to obvious changes in the  formation of ISVs. This suggests that either 
adamts5 is not a key regulator in embryonic angiogenesis or that other adamts 
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have compensated the absence of adamts5 in the MOs. Further investigations 




Fig. 3.42 Knockdown of adamts5 does not affect embryological 
angiogenesis in zebrafish: A. Vasculogenesis and angiogenesis were 
carefully monitored upon injection of mis MO and adamts5 MO. 
There was no significant disruption or excessive ISVs in adamts5 MO 
injected embryos compared to mis MO, indicating no perturbance in 
angiogenesis. Scale bar 50 µm. B. Quantification of the embryos after 
adamts5 knockdown showed no significant difference in the ISVs (N 







CHAPTER 4. DISCUSSION 
4.1 ADAMTS5: A new anti-angiogenic member of the ADAMTS family 
In this work, we demonstrated for the first time that ADAMTS5 is a potent 
anti-angiogenic proteinase both in vitro and in vivo (Kumar et al, 2012b; 
Nissinen & Kähäri, 2012). We showed that the full-length ADAMTS5 is an 
anti-angiogenic, anti-tumorigenic and anti-metastatic protein. In addition to 
the full-length protein, its autocatalytic truncated products TS5-p45 and TS5-
p60 also function as anti-angiogenic/anti-tumorigenic polypeptides. 
Importantly, the anti-angiogenic/anti-tumorigenic function of ADAMTS5 is 
independent of its proteoglycanase activity and is mediated through its TSR1 
domain (Kumar et al, 2012b). 
In ADAMTS family, ADAMTS1 and ADAMTS8 were first reported as 
anti-angiogenic proteins more than a decade ago (Vazquez et al, 1999). After 
its discovery, more and more members of this family have been shown to 
regulate angiogenesis (Kumar et al, 2012a). Up to now, 8 of the 19 ADAMTS 
members (ADAMTS1, ADAMTS2, ADAMTS4, ADAMTS5, ADAMTS8, 
ADAMTS9, ADAMTS12 and ADAMTS13) are known to regulate 
angiogenesis  (Table 1.4). However, due to the catalytic activity of its 
metalloproteinase domain, some of the members such as ADAMTS1 and 
ADAMTS4 have also shown pro-angiogenic function in vivo (Liu et al, 2006c; 
Rao et al, 2013). ADAMTS13 is an exception. By itself, it acts as a pro-
angiogenic protein on ECs in vitro by enhancing EC proliferation and 
inhibiting EC death. But, it negatively modulate VEGF mediated EC 
proliferation (Lee et al, 2012). Notably, even though all the family members 
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have similar domain structure and many sharing the same substrate activity, 
the anti-angiogenic mechanisms are not the same among the family members.  
ADAMTS1 and ADAMTS8 were the first two angiogenic inhibitors 
discovered in ADAMTS family. Angio-static effect of these two members was 
shown to be more potent than the well-known anti-angiogenic peptides such as 
endostatin or TSP-1 (Vazquez et al, 1999). ADAMTS1 and ADAMTS8 anti-
angiogenic effects were in the nanomolar concentration range. ADAMTS5 
was also shown to be effective in inhibiting angiogenesis in the nanomolar 
range that is comparable to the ADAMTS1 and ADAMTS8 (Fig. 3.1, 3.2, 3.3 
and 3.4) (Vazquez et al, 1999). 
Metalloproteinases are well known regulators of angiogenesis but mostly 
acting as promoters by degrading various components of ECM. Angiogenesis 
requires the degradation of basement membrane so that new vessels can sprout 
through EC migration. In addition, these enzymes can release the angiogenic 
growth factors from their ECM bound state as a result of ECM degradation 
(Rundhaug, 2005; van Hinsbergh & Koolwijk, 2008). On the contrary, there 
are metalloproteinases such as MMP-9 and MMP-12 that inhibits angiogenesis 
through the cleavage and release of angio-inhibitory peptides such as 
angiostatin and endostatin (Handsley & Edwards, 2005). Since ADAMTS 
members are metalloproteinases, the catalytic activity may play a role in 
angiogenesis. Firstly, based on the requirement of catalytic activity in 
regulating angiogenesis, ADAMTSs can be classified as catalytic dependent or 
independent angiogenesis regulators. ADAMTS1 (Liu et al, 2006c), 
ADAMTS4 (Rao et al, 2012) and ADAMTS9 (Koo et al, 2010) have been 
reported to be regulating angiogenesis through their metalloproteinase activity. 
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Secondly, this regulation of angiogenesis through the catalytic activity can be 
pro-angiogenic or anti-angiogenic (Table 1.4) (Fig. 1.14). Metalloproteinase 
mediated cleavage results in release of heparin-binding growth factor and 
enhances angiogenesis as in the case of ADAMTS1 (Liu et al, 2006c). On the 
other hand, catalytic activity was also shown to inhibit angiogenesis. For 
instance, TSP1and TSP2 are found to be substrates of ADAMTS1 and 
cleavage of TSP1 and TSP2 by ADAMTS1 mediates the release of anti-
angiogenic fragments (Lee et al, 2006). ADAMTS9 has also been shown to 
lose its anti-angiogenic function upon loss of its catalytic activity, but the 
mechanism of action is unexplored so far (Koo et al, 2010). Other ADAMTS 
members regulate angiogenesis independent of its catalytic activity. These 
include ADAMTS2, wherein the catalytically inactive ADAMTS2 reduced 
tumor vascularization (Dubail et al, 2010) and ADAMTS12, in which 
overexpression of catalytic domain alone lost the ability to inhibit 
tubulogenesis of bovine aortic ECs (Llamazares et al, 2007). ADAMTS5 
belongs to this subset of ADAMTSs whose anti-angiogenesis activity is 
independent of its catalytic function. Auto-catalytically cleaved fragment TS5-
p45 was shown to inhibit angiogenesis in the presence of chemical inhibitor of 
ADAMTS5 enzyme in vitro (Fig. 3.5 and Fig. 3.6).  In addition, catalytically 
inactive ADAMTS5 (TS5-E411A) suppressed tumor angiogenesis in vivo 
(Fig. 3.19A and D). These results convincingly demonstrate that the catalytic 
activity of ADAMTS5 is dispensable for and independent from its anti-
angiogenic function.  
Proteinase-independent angiogenesis regulation in ADAMTSs is mainly 
through their ancillary domains containing TSRs. Iruela Arispe‘s lab 
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discovered the anti-angiogenic ADAMTS members (ADAMTS1 and 
ADAMTS8) when they initiated a search for novel proteins that share a high 
sequence similarity with the well-known anti-angiogenic TSP-1 and TSP-2 
TSR motifs. In addition to these two, ADAMTS2 (Dubail et al, 2010), 
ADAMTS4 (Rao et al, 2012) and ADAMTS12 (Llamazares et al, 2007) have 
also been shown to exert their anti-angiogenic function through their ancillary 
domains consisting of TSRs. Similarly, we established in this work that 
ADAMTS5 also brings about its anti-angiogenic function through its TSR1 
domain (Fig. 3.22). Thus, this work here adds ADAMTS5 as a new member to 
the anti-angiogenic subgroup of ADAMTS family that mediates its function 
through its ancillary TSR1 domain and independent of catalytic activity. 
4.2 ADAMTS5: Emerging role in cancer inhibition 
Cancer is a complex, multi-stage process that involves various steps and is 
the top most reason for lethality in humans. During the process of 
carcinogenesis, tumor cells closely interact with its ECM and surrounding 
cells such as ECs, fibroblasts, myoblasts etc. Several critical molecules have 
been reported to play key roles in modulating such cell-cell and cell-ECM 
interactions. Many metalloproteinases such as MMPs and ADAMs have been 
shown to regulate cancer (Duffy et al, 2009; Gialeli et al, 2011; Rocks et al, 
2008). Best established view is that metalloproteinases promote tumor 
progression through promoting angiogenesis, bio-availability of growth factors 
etc. (Duffy et al, 2011; Gialeli et al, 2011).  However, there are emerging 
examples of metalloproteinases that inhibit cancer growth during various 
stages of tumor progression. Metalloproteinases can cleave the ECM resulting 
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in the production of the angiogenesis inhibitors such as angiostatin, endostatin 
(Gialeli et al, 2011). 
 Recent studies have unraveled the ADAMTS family members‘ role in 
cancer progression and metastasis (Wagstaff et al, 2011). Ten out of 19 
ADAMTSs have been reported to be regulated during cancer progression or 
metastasis (Table 1.5) (Kumar et al, 2012a).  Most of the ADAMTS members 
are known to be downregulated in one or more type of human cancers. These 
include ADAMTS5, ADAMTS8, ADAMTS9, ADAMTS12, ADAMTS15 and 
ADAMTS18 (Table 1.5) (Kumar et al, 2012a). This downregulation is mostly 
due to the hypermethylation of the gene in ADAMTS members such as 
ADAMTS5, ADAMTS9, ADAMTS15 and ADAMTS18. This suggests a 
possible tumor inhibition function of these metalloproteinases. In some of the 
members this tumor suppressor function is correlated with the anti-angiogenic 
function of the metalloproteinase such as ADAMTS9 (Du et al, 2012; Koo et 
al, 2010) and ADAMTS12 (Llamazares et al, 2007). However, in case of other 
ADAMTSs such as ADAMTS15 and ADAMTS18, there are no reports 
linking their role in inhibiting angiogenesis and tumor suppression. In 
addition, not all ADAMTS family members regulate cancer through 
influencing angiogenesis. For example, ADAMTS9 acts as a tumor suppressor 
by directly inhibiting tumor cell proliferation and inducing tumor cell 
apoptosis through inhibition of Akt signaling pathway (Du et al, 2012). Thus, 
direct impact on tumor cells in addition to angio-inhibition is also an important 
mechanism for ADAMTS members to regulate cancer. 
ADAMTS5‘s potential role in inhibiting cancer progression was suggested 
for the first time in as early as 2004 by Porter and colleagues. ADAMTS5 was 
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shown to be downregulated transcriptionally in breast carcinoma compared to 
the non-neoplastic mammary tissue (Porter et al, 2004). In addition, 
ADAMTS5 was also shown to be relatively low level of mRNA in prostate 
cancer cell lines such as PC3, DUI45 and LNCaP compared to the prostate 
stromal cell line BPH (Cross et al, 2005). Further, this gene was shown to be 
epigenetically silenced in colorectal cancer and T-cell acute lymphoblastic 
leukemia through methylation of CpG sites in the ADAMTS5 promoter region 
(Kim et al, 2011; Roman-Gomez et al, 2005). Taken together, all these studies 
clearly hint at the possible tumor suppressor and tumor inhibitory properties of 
ADAMTS5.  
Here, it was unequivocally demonstrated that ADAMTS5 is an anti-
tumorigenic metalloproteinase whose inhibition of cancer progression is 
correlated with inhibition of angiogenesis. Thus, ADAMTS5 belongs to the 
sub-group of members those regulate cancer through mediating angiogenesis. 
Overexpression of ADAMTS5 in B16 melanoma cells suppressed xenograft 
B16 melanoma tumor growth in mice and this tumor-growth suppression is 
linked to suppressed tumor vasculature, reduced tumor cell proliferation as 
well as enhanced tumor cell apoptosis (Fig. 3.10 and Fig. 3.11). Based on the 
fact that overexpression of ADAMTS5 did not influence B16 proliferation in 
culture (Fig. 3.9), it seems likely that the reduction of tumor cell proliferation 
and stimulation of tumor cell apoptosis are indirect results of suppressed 
tumor angiogenesis by ADAMTS5. In support of this, recombinant TS5-p45 
not only inhibited EC tube formation on Matrigel and proliferation in vitro, it 
also induced EC apoptosis in the presence of VEGF without affecting tumor 
cells in culture (Fig. 3.5 and Fig. 3.6).   
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Overexpression of catalytically inactive E411A mutant of ADAMTS5 
(TS5-E411A) did not interfere with its anti-tumorigenic function (Fig. 3.18). 
Thus, the anti-tumorigenic function of ADAMTS5 is independent of its 
proteoglycanase activity. This feature is similar to ADAMTS2 (Dubail et al, 
2010) and ADAMTS12 (Llamazares et al, 2007) where the catalytically 
inactive proteinases inhibited tumorigenesis like their wild-type proteinases.  
The ancillary domains play important roles in the function of ADAMTS5 
(Gendron et al, 2007). They help in binding and localization of the secreted 
metalloproteinase to the cell surface and ECM (Zeng et al, 2006). TS5-p60 is 
localized to the ECM and possesses greater affinity towards the cell surface 
compared to the shorter isoform TS5-p45. Lack of both cysteine rich and 
spacer domain (TS5-p45) has been shown to decrease the aggrecanase activity 
considerably (Gendron et al, 2007). Nevertheless, overexpression of TS5-p60 
or TS5-p45 in B16 tumors both suppressed tumor growth accompanied by 
reduced tumor angiogenesis, increased tumor cell apoptosis and decreased 
tumor cell proliferation (Fig. 3.14 and Fig. 3.15). Thus, the anti-tumorigenic 
activity of ADAMTS5 is not mediated through its cysteine-rich, spacer or the 
C-terminal TSR2 domain.  
Consistent with our previous report that the central TSR (TSR1) of 
ADAMTS5, but not the C-terminal TSR (TSR2) is anti-angiogenic in vitro 
(Sharghi-Namini et al, 2008), we show here that ADAMTS5 inhibits 
angiogenesis and tumorigenesis in mice through its TSR1 domain. In fact, 
TSR1 alone is sufficient to inhibit B16 tumorigenesis in vivo (Fig. 3.22 and 
Fig. 3.23). Removal of TSR1 in TS5-CT fragment leads to the loss of angio-
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inhibitory and tumor-suppression property, while all constructs that contain 
TSR1 possess anti-angiogenic/anti-tumorigenic function.  
As mentioned earlier, the presence of TSR domain is the characteristic 
feature of ADAMTS metalloproteinase family. However, the importance of 
TSR in the anti-tumorigenic activity of ADAMTS members has not been 
completely resolved. For example, TSR domains were shown to be essential 
for the anti-angiogenic activity of ADAMTS1 (Liu et al, 2006c). Yet 
overexpression of ADAMTS1‘s three TSRs alone was shown to be unable to 
inhibit CHO cell tumorigenecity in mice (Kuno et al, 2004a). In comparison, 
the anti-tumorigenic activity of ADAMTS5 is modulated through its central 
TSR1 domain.  
In addition, in this study we have shown that this anti-angiogenic function 
of ADAMTS5 is not limited to mouse melanoma but also relevant in human 
cancer. Human tissue expression data showed that there is a downregulation of 
ADAMTS5 in various tumor tissues such as lung, skin, stomach and breast 
compared to their corresponding control normal tissue samples (Fig. 3.27). 
Overexpression of ADAMTS5 inhibited the tumor progression in A549 lung 
adenocarcinoma through inhibiting angiogenesis, inducing cell death and 
inhibiting cell proliferation (Fig. 3.30 and Fig. 3.31).  
In summary, ADAMTS5 is an anti-angiogenic, anti-tumorigenic 
metalloproteinase that mediates its action through TSR1 domain in both 
mouse melanoma and human lung adenocarcinoma. 
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4.3 ADAMTS5 is a suppressor of cancer metastasis  
Due to the size and nutrient limitations, some tumor cells try to spread 
from the primary tumor site to the surrounding normal tissues in the local area 
resulting in the local metastasis. In other cases, cancer cells penetrate from the 
primary tumor and infiltrate into the circulation through vascular or lymphatic 
system. These cells inhabit at a distant site forming secondary or metastatic 
tumors. Tumor expansion requires invasion of surrounding stroma, which is 
frequently associated with the destruction and remodeling of ECM (Deryugina 
& Quigley, 2006). This process is mainly mediated by the extracellular 
metalloproteinases. Many of the metalloproteinase family such as MMPs and 
ADAMs have been associated with the cancer cell invasion and metastasis by 
virtue of their ability to degrade ECM, alter cell morphology and enhance cell 
motility thus initiating cell invasion and distant metastasis (Bourboulia & 
Stetler-Stevenson, 2010; Duffy et al, 2009).  
ADAMTS family members have also been shown to be involved in cancer 
progression and metastasis (Rocks et al, 2008; Wagstaff et al, 2011). 
Eventhough many of the ADAMTSs have been reported to be silenced or 
downregulated in primary tumor growth, very few studies have addressed their 
role during cell invasion and metastasis. The only member whose role in 
metastasis is well studied is ADAMTS1. However, there are conflicting 
reports of both pro- and anti-metastatic function of ADAMTS1. Kuno et al. 
showed that both the full-length protein as well as the C-terminal regions 
exhibited an anti-metastatic activity (Kuno et al, 2004b). In contrast, Liu et al. 
reported that full-length ADAMTS1 increased the number of lung metastases 
while C-terminal regions of the protein exhibited anti-metastatic activity using 
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two tumor models - TA3 mammary carcinoma and Lewis lung carcinoma (Liu 
et al, 2006c). Notably, Liu et al. showed that a catalytic active-site mutant of 
ADAMTS1 inhibited metastasis instead, indicating that catalytic activity is 
important for the pro-metastatic activity of ADAMTS1. The primary 
mechanism for eliciting this function being the shedding of trans-membrane 
precursors heparin-binding epidermal growth factor (HB-EGF) and 
amphiregulin that activate the EGFR receptor, ultimately promoting invasion 
(Liu et al, 2006c). Most importantly, this work convincingly demonstrated that 
while the full-length ADAMTS1 is pro-metastatic, autocatalytic fragments of 
ADAMTS1 composed of N-terminal and C-terminal cleavage fragments 
containing TSR domains act as anti-metastatic molecules in the same tumors. 
Thus, they proposed that the proteolytic status of ADAMTS1 in the local 
environment determines its net effect on tumor metastasis. 
Earlier reports on ADAMTS5 have suggested that this may be a pro-
metastatic metalloproteinase, at least in glioblastoma. ADAMTS5 is 
upregulated in glioblastoma tissues compared to the normal brain tissues in 
humans (Held-Feindt et al, 2006a; Nakada et al, 2005). Overexpression of 
ADAMTS5 led to a marked increase in U87 glioma cell invasiveness in vitro 
through a Matrigel layer containing its substrate brevican (Nakada et al, 
2005). However, there are no other reports of ADAMTSs being upregulated in 
tumor tissues compared to their normal tissues. On the contrary, it is evident 
from this study that ADAMTS5 is an anti-metastatic metalloproteinase that 
can inhibit experimental pulmonary metastasis in a proteoglycanase 
independent fashion (Fig. 3.32 and Fig. 3.33). The metastasized tumors 
overexpressing TS5-FL or TS5-E411A had decreased vasculature and less 
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metastatic foci compared to the B16/Vec control (Fig. 3.34). ADAMTS5s 
anti-metastatic function is comparable to that of ADAMTS1s ancillary domain 
mediated anti-metastatic/anti-angiogenic function. However, further studies 
need to be done to investigate the mechanism that governs ADAMTS5s anti-
metastatic function. The discrepancy between ADAMTS5s role in promoting 
invasiveness in glioblastoma and anti-metastatic function in mouse melanoma 
can be attributed to the different type of tumors with different kinds of 
substrates. Brain is abundant in brevican which is cleaved by ADAMTS5, thus 
helping in glial cell invasiveness. However, in other tissues this proteoglycan 
substrate is limited and thus it is conceivable that different cancers would have 
different microenvironment and express different protein pools leading to 
different net behaviors and outcomes. 
In addition to ADAMTS5, a couple of other ADAMTS members have 
been shown to negatively regulate metastasis. ADAMTS9 was shown to be 
downregulated in nasopharyngeal carcinoma during lymph node metastasis 
(Bergers & Hanahan, 2008). Several reports have investigated the correlation 
between the multimeric state of vWF and ADAMTS13 metalloproteinase 
activity on vWF in a wide range of cancers (Koo et al, 2002; Oleksowicz et al, 
1999). Comparing metastatic tumors with the primary solid tumor, there was a 
strong correlation between metastatic tumors and the multimeric uncleaved 
vWF in blood plasma. In contrast to the above studies suggesting an inverse 
correlation between ADAMTS13 and metastasis, Böhm et al. reported that 
there was no correlation between ADAMTS13 activity and tumor malignancy 
in brain and prostate cancers (Table 1.3) (Böhm et al, 2003). Thus, further 
studies are required to clarify the relationship between catalytic activity of 
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ADAMTS13 and cancer stages. As vWF is an anti-angiogenic glycoprotein, 
ADAMTS13‘s role in regulating angiogenesis through vWF cleavage warrants 
further investigation.  
In summary, ADAMTS5 is a novel member of the ADAMTS family that 
impacts metastasis. However, the mechanism is unclear up to now which 
would be a fertile area to explore. 
4.4 Possible mechanisms of action of ADAMTS5 in anti-angiogenesis and 
anti-tumorigenesis 
It is believed that the amount of angiogenesis is a combined result of 
angiogenesis stimulators and inhibitors in the local tissue environment. Using 
a mouse angiogenesis antibody array, we discovered that overexpression of 
ADAMTS5 in tumors lead to down-regulation of several pro-angiogenic 
growth factors including VEGF, PlGF, PD-ECGF, PAI-1 and IGFBP3 (Fig. 
3.24). Validation of the angiogenesis array showed that all the above factors 
were indeed downregulated in TS5-FL overexpressing tumors. However, in 
the case of TS5-TSR1 overexpressing tumors, the downregulation was limited 
to IGFBP-3 and PD-ECGF (Fig. 3.24). This suggests that even though TSR1 
is the main mediator of its anti-angiogenic function, the ancillary domains 
might play a role in potentiating this effect. It was also observed that this 
downregulation of anti-angiogenic factors was limited to in vivo. Stable cell 
lines overexpressing TS5-FL or TS5-TSR1 did not alter the expression of the 
angiogenic regulators in vitro suggesting that this is an in vivo (Fig. 3.25). 
VEGF, PlGF and PD-ECGF are well established angiogenesis growth 
stimulators that play important roles in promoting tumor progression (Ferrara 
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& Kerbel, 2005; Hicklin & Ellis, 2005; Liekens et al, 2007; Luttun et al, 
2002). In the case of IGFBP3, both pro- and anti-angiogenic effects have been 
reported. Its pro-angiogenic function seems to be dependent on IGF function 
(Granata et al, 2007; Lofqvist et al, 2007). IGF-1 is a well-known anti-
apoptotic and pro-proliferative growth factor. IGFBP-3 enhances IGF-1 
function through up-regulation of IGF-1 (Granata et al, 2004). Incidentally, 
IGF-1 has also been shown to directly drive human melanoma cell 
proliferation through an autocrine mechanism (Molhoek et al, 2011). Hence, 
downregulation of IGFBP-3 is likely to have a negative effect on tumor 
growth and angiogenesis. Nevertheless, whether this is indeed the scenario in 
B16 melanoma needs experimental substantiation.  
In addition, the serine protease inhibitor plasminogen activator inhibitor 1 
(PAI-1) (also called Serpin-E1) is also significantly down-regulated in 
ADAMTS5 overexpressing B16 tumors. PAI-1 is known to have dual 
functions in angiogenesis (Devy et al, 2002). At physiological concentration 
(2 to 4 ng/ml), PAI-1 promotes tumor angiogenesis and tumor invasion; in 
contrast, it inhibits angiogenesis at pharmacological concentration (greater 
than 17 ng/ml) (Bajou et al, 2004; Devy et al, 2002). Thus, in B16 melanoma, 
the endogenous PAI-1 is likely to promote tumor angiogenesis and function as 
an angiogenesis stimulator. Thus, the combined down-regulation of pro-
angiogenic factors VEGF, PlGF, PD-ECGF, IGFBP3 and PAI-1 are one 
mechanism of how ADAMTS5 inhibits angiogenesis and tumor growth in B16 
melanoma. The significance of reduced anti-angiogenic PEDF in ADAMTS5 
overexpressed B16 melanoma is unclear at this stage. It is possible that the 
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down-regulation of pro-angiogenic proteins overpowers the effect of reduced 
PEDF in B16 melanoma and leads to a net result of tumor suppression.  
4.5 ADAMTS5 expression and function in vertebrate embryos and adult 
tissues: lessons from zebrafish studies 
Zebrafish provides an excellent platform to study the biological function of 
various genes during embryogenesis and physiology. These include short 
generation time, large number of egg production, external fertilization, 
transparent embryos, a wide range of tools for genetic manipulation and the 
presence of good database (Briggs, 2002). The availability of the transgenic 
fish Tg(fli1:EGFP) in which all the blood vessels are labeled with EGFP 
allows researchers to study vasculogenesis and angiogenesis during both 
embryogenesis and physiology (Serbedzija et al, 1999). In addition, zebrafish 
receive enough oxygen via passive diffusion to develop normally for several 
days even when the normal angiogenesis is perturbed thus making it an 
excellent choice of model organism (Ny et al, 2006).  
Expression pattern of zebrafish adamts5 and MO knockdown suggests an 
important role for this proteoglycanase in vertebrate embryogenesis. 
Expression pattern of adamts5 in the early stages of the zebrafish embryos is 
different from the expression pattern reported in mice. In mice, expression of 
Adamts5 was not detected till E9.5 and was restricted to neuromuscular 
structures (McCulloch et al, 2009a). However, in zebrafish, ubiquitous 
adamts5 expression is observed which may suggest a more important role for 
this proteoglycanase during blastula and gastrulation in the lower vertebrates 
(Fig. 3.37). During the late embryonic development in zebrafish (24 – 120 
hpf), adamts5 becomes more localized and is observed at the anterior parts of 
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the embryos, specifically in brain and otic vesicle (Fig. 3.38 and Fig. 3.39). 
Mouse Adamts5 expression also suggests a strong expression in the 
developing brain after E13.5 (McCulloch et al, 2009a). Of relevance is the 
strong brain expression of zebrafish adamts5 suggesting its role in cleaving the 
brain specific proteoglycan brevican. Brevican, a brain specific lectican is 
known to regulate glial cell motility (Gary et al, 1998a). The role of adamts5 
in cleaving this brain specific proteoglycan is known to have implications in 
pathophysiological conditions such as gliomas, where the overexpression of 
ADAMTS5 leads to greater invasiveness of glial cells (Nakada et al, 2005). 
Furthermore, the expression pattern of zebrafish adamts5 coincides with 
the expression pattern of its substrate versican in the regions such as eye, otic 
vesicle (Kang et al, 2004). Versican is known to play an important role in 
neural crest migration (Perissinotto et al, 2000). Thus, regulation of versican 
processing by adamts5 in ECM in those tissues may have a vital role in 
nervous system development. The expression pattern of zebrafish adamts5 
matches with the earlier report of the mice Adamts5 expression in neural crest, 
craniofacial mesenchyme and mesodermal origin tissues (McCulloch et al, 
2009a). 
ADAMTS5 gained a lot of attention due to its implications in degenerative 
diseases such as osteoarthritis (Glasson et al, 2005; Stanton et al, 2005). 
Interestingly, we observed a correlation between the expression patterns of 
this proteoglycanase with the earlier reports of aggrecan expression in 
zebrafish (Kang et al, 2004). Aggrecan expression was evident from 48 hpf 
during the craniofacial cartilage development in the organs such as pharyngeal 
arch, trabeculae etc. We observed a more dispersed expression of this 
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aggrecanase in the craniofacial region from 48-72 hpf, suggesting its role in 
aggrecan degradation during normal embryonic cartilage development (Fig. 
3.39A, B and D). At 120 hpf, the expression of adamts5 is restricted to the 
craniofacial region (Fig. 3.39F, H, I and J). Adamts5 was observed in cranial 
tissues that are rich in cartilage such as quadrate, basibranchial cartilage and 
trabecular bar (Fig. 3.39I). It is also important to note that majority of the 
zebrafish skull are cartilage bones and cartilage is a rich source of 
proteoglycans such as aggrecan (Yelick & Schilling, 2002). Thus it can be 
speculated that adamts5 plays an important role in ECM aggrecan and 
turnover required for the cartilage morphogenesis during craniofacial 
development in zebrafish. 
Knockdown of zebrafish using MO showed severe morphological defects 
suggesting adamts5’s important role in embryonic development in zebrafish. 
This is in contrast to the knockout mice studies, where there was no report of 
any phenotypic or morphological defects in Adamts5 knockout mice (Glasson 
et al, 2005; Stanton et al, 2005). This may reflect the different levels of 
redundancies among ADAMTS member in different vertebrate species as 
zebrafish has no ortholog of ADAMTS4. In mice recently the role of Adamts5 
was shown to be important in web regression and the absence of this 
metalloproteinase resulted in syndactyly. Adamts5 knockout had a 50% 
penetrance for this phenotype and there was increase in the penetrance in  
double knockout mice of Adamts5 and Adamts9 or Adamts5 and Adamts20 
(McCulloch et al, 2009b). This clearly suggests that there is a 
complementation of functions mediated by other ADAMTSs that share similar 
functions. Thus, in physiological conditions, the spatio-temporal co-expression 
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of ADAMTSs that share the same function will determine the final outcome of 
phenotype. This also might answer for the ambiguity that is observed upon 
knockdown of adamts5 in zebrafish compared to Adamts5 knockout mice. 
However, in case of zebrafish the expression of different adamts members is 
still unexplored. Thus, at least in lower vertebrates such as zebrafish, adamts5 
plays an important role in morphogenesis. 
Surprisingly, we did not observe any disturbance or alteration of 
vasculogenesis or angiogenesis upon knockdown of this gene in zebrafish in 
spite of the grave morphological defects of the morphants. Many of the earlier 
studies with the knockdown of endogenous inhibitors have also shown that 
they do not disturb the embryological vascularization but only influence adult 
or pathological angiogenesis. For example, mice deficient for TSP-1, 
chondromodulin-1 or plasminogen (parent protein of angiostatin fragment) do 
not interfere with the embryological angiogenesis (Lawler et al, 1998; 
Nakamichi et al, 2003). TSP-1 null mice, on the other hand, is shown to 
interfere only in pathophysiological conditions such as wound healing 
(DiPietro et al, 1996) and tumor growth reduction (Volpert et al, 1998). In the 
ADAMTS family, there are no reports of any ADAMTSs interfering in 
embryonic or physiological angiogenesis till date. Adamts5 also have been 
shown to be fertile and having normal growth without any defects in 
embryological/physiological vasculogenesis and angiogenesis. Our zebrafish 
studies also corroborates this observation where-in there is no abnormal 
vasculature upon adamts5 knockdown and this anti-angiogenic function is 




 In summary, in this work we demonstrated for the first time that 
ADAMTS5 is a new player in the vascular field and functions as an 
endogenous angiogenesis inhibitor.  
 Full-length ADAMTS5 and its auto-catalytic fragment (TS5-p45) inhibit 
angiogenesis in vitro. TS5-p45 inhibits EC tube formation, EC 
proliferation and induces EC apoptosis in nanomolar range and in a dose-
dependent manner. This angio-inhibition is independent of the catalytic 
function of the metalloproteinase.  
 ADAMTS5 is an anti-tumorigenic metalloproteinase. Overexpression of 
TS5-FL in B16 mouse melanoma suppressed tumor growth in mice. This 
anti-tumorigenic function correlated with reduced peri-tumor 
vascularization and intra-tumoral angiogenesis, reduced tumor cell 
proliferation and elevation of cell apoptosis. Auto-catalytic fragments of 
ADAMTS5 (TS5-p45 and TS5-p60) are also anti-tumorigenic in vivo. In 
addition, anti-tumorigenic function is independent of its proteoglycanase 
activity. Domain deletion and structure-functional mapping studies showed 
that this anti-angiogenic/anti-tumorigenic function of ADAMTS5 is 
mediated by its central TSR1 domain.  
 We showed that ADAMTS5 most likely suppressed B16 mouse melanoma 
through down-regulation of tumor angiogenesis by inhibiting angiogenic 
stimulators including VEGF, PlGF, PD-ECGF, IGFBP3 and PAI-1.  
 Overexpression of ADAMTS5 in A549 human lung adenocarcinoma cell 
line and xenograft mouse tumorigenesis suppressed tumor growth through 
tumor angiogenesis inhibition.  
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 We also showed that ADAMTS5 is anti-metastatic in vivo. Overexpression 
of ADAMTS5 or its catalytically inactive mutant in B16 mouse melanoma 
successfully inhibited primary experimental pulmonary metastasis.  
 Using zebrafish as a model organism, spatial and temporal gene expression 
of adamts5 during early embryonic and larval development was analyzed. 
The expression pattern re-confirms its role as a proteoglycanase. This is 
the first ever-report of the detailed expression analysis of any of the 
adamts members in zebrafish embryonic development. Knockdown of 
adamts5 using morpholino resulted in severe morphological defects. 
However, knockdown of adamts5 did not interfere with the embryonic 
vasculogenesis or angiogenesis suggesting that its effect is limited to adult 
or pathological angiogenesis.  
4.7 Future Perspective 
This work opens up a new potential area to understand the complex, 
multifaceted cancer biology and better understanding of this molecule in terms 
of its mechanism and role in human cancers from the angle of ADAMTS5 and 
its interaction with other proteins in the tumor microenvironment. The 
following are some of the unresolved issues that future studies are warranted.  
A. Deciphering the molecular mechanisms of ADAMTS5 mediated 
angiogenesis inhibition 
In this study, we have shown that ADAMTS5 inhibits tumor growth 
mainly through its inhibition of tumor angiogenesis rather than directly 
affecting tumor cells. However, how it suppresses angiogenesis is still 
unclear. As understanding the mechanism of action is critical for anticancer 
drug development, deciphering the mechanism would be of prime interest. 
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ADAMTSs have been shown to be anti-angiogenic through both receptor 
dependent and receptor independent mechanisms. ADAMTS1 has been shown 
to sequester VEGF, cleave TSP-1 and TSP-2 resulting in the release of anti-
angiogenic fragments resulting in anti-angiogenesis (Lee et al, 2006; Luque et 
al, 2003). On the other hand, ADAMTS2 has been shown to bind to nucleolin, 
a cell surface receptor (Dubail et al, 2010). However, ADAMTS5 does not 
sequester VEGF and its anti-angiogenesis is not catalytic dependent. So, most 
likely its mechanism of action is through receptor dependent pathway. 
TSRs of TSP-1 are known to interact with CD36 and thus bring about its 
anti-angiogenesis (Dawson et al, 1997). However, HUVEC is a CD36 
negative cell line (Swerlick et al, 1992). Still, ADAMTS5 is able to bring 
about its anti-angiogenic effect by inhibiting HUVEC cell proliferation, tube 
formation and induction of cell death. So, possibility of other receptors 
mediating this anti-angiogenesis cannot be excluded.  
To identify the novel cell surface receptors of ECs, partially purified 
ADAMTS5 with the C-terminal V5 tag from HEK293T can be employed for 
the study. Briefly, anti-V5 beads immobilized to the Protein agarose A/G 
beads may be incubated with the partially purified mammalian expressed 
ADAMTS5. HUVEC or other EC membrane lysate can be used to fish for any 
possible receptors to bind to the ADAMTS5 that serve as bait bound to 
column with anti-V5 beads. After stringent washing, the eluted proteins may 
be separated through SDS-PAGE and stained with Coomassie or silver 
staining. The bands can be analyzed through liquid chromatography couple to 
mass spectrometry.  
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Also, recent report suggest that extracellular ADAMTS5 binds to low-
density lipoprotein receptor-related protein-1 (LRP1) on chondrocyte cell 
surface and is endocytosed into chondrocytes through this receptor 
(Yamamoto et al, 2012). Interestingly, the TSR1 and spacer domain of 
ADAMTS5 was demonstrated to be essential for LRP1-mediated ADAMTS5 
endocytosis into articular cartilage chondrocytes. LRP1 is known to be both a 
scavenger receptor and a signaling receptor, mediating diverse functions in 
physiology and pathology through many different ligands (Lillis et al, 2008).  
Using mammalian expressed TS5-TSR1, it should be investigated whether 
this can interact with LRP1 through co-immunoprecipitation.  If yes, then the 
next question that needs to be answered is whether TS5-TSR1 is endocytosed 
in ECs and brings about its function through internalization. Using specific 
endocytic inhibitors the role of this internalization and mechanism of 
endocytosis can be investigated to elucidate TS5-TSR1 mediated anti-
angiogenesis.  
B. Elucidation of the role of endogenous ADAMTS5 in pathological 
angiogenesis using ADAMTS5 knockout mice 
ADAMTS12 was shown to inhibit angiogenesis and tumor growth. 
However, Adamts12 knockout mice were phenotypically normal, fertile and 
showed no interference in vasculogenesis or angiogenesis during embryonic 
development or under normal physiological conditions. However, under 
pathophysiological conditions such as wound healing, Matrigel plug assay and 
aortic ring assay,  Adamts12 knockout mice showed excessive angiogenesis 
compared to the wild type mice (El Hour et al, 2010). 
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So to study the role of physiological levels of ADAMTS5 in such 
pathological conditions, Adamts5
-/-
 mice can be used to investigate wound 
healing. The sprouting from the aortic rings from Adamts5 null mice can be 
compared with the wild type mice to elucidate its role in adult angiogenesis. 
Mammalian expressed recombinant ADAMTS5 can be purified and used in 
the studies to investigate the interference of ADAMTS5 in vascular growth 
using Matrigel plug assay in the Adamts5 null mice. 
C. Clarifying the role of endogenous ADAMTS5 in human cancer 
Although overexpression of ADAMTS5 in melanoma suppressed 
subcutaneous tumor growth in syngeneic mice, it is not known if the 
endogenous level of this protein serves to suppress cancer development and 
metastasis. Tumor stroma has been an important aspect in cancer biology 
because of its role in regulating tumor growth and metastasis (Tlsty & 
Coussens, 2006). It is also not clear what are the roles of stromal produced 
ADAMTS5 in cancer development and/or metastasis. Answers to these 
questions will determine how important endogenous ADAMTS5 is in cancer 
formation. 
Using the approach of syngeneic mouse tumorigenesis assay, tumor 
growth progression of B16 mouse melanoma can be compared with 
homozygous knockout (Adamts5 
-/-
) and wild type (Adamts5 
+/+
) mice. In this 
way, the role of ADAMTS5 in the tumor stroma can be determined. Further, 
using heterozygous knockout mice (Adamts5
+/-
) the effect of the dosage of 
Adamts5 allele on the tumorigenesis can also be determined. The tumor 
angiogenesis and effect on tumor cell proliferation and cell apoptosis can be 
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determined as explained earlier to understand the effect of this anti-angiogenic 
proteinase.  
D. Determining how ADAMTS5 suppress metastasis 
Our study shows that overexpression of ADAMTS5 and its catalytically 
inactive mutant inhibits experimental pulmonary metastasis in vivo. So it 
would be important to understand the mechanism of how ADAMTS5 is able 
to inhibit the homing of the extravasated cells or invasiveness of the B16 
mouse melanoma upon overexpression of this anti-angiogenic proteinase. 
Recent study has shown that ADAMTS12 regulates cell-ECM adhesion and 
cell invasion through upregulating the expression of integrin αvβ3 (Beristain 
et al, 2011). However, the mechanism of upregulation is still unexplored. So it 
would be interesting to investigate whether ADAMTS5 affects cell migration 
and invasion and if yes, does it mediate this function by regulating the 
expression of integrins that are known to be key adhesion molecules.  
E. Investigate if ADAMTS5 can be useful in developing therapeutic 
drugs for human diseases 
As discussed earlier, anti-angiogenic drugs are have been used to treat a 
variety of diseases including cancer, diabetic retinopathy, age related macular 
degeneration of eye and other diseases involving excessive angiogenesis. 
However, effective anti-angiogenic cancer therapy has been still elusive. 
Thus, there is an importance of discovery of new effective anti-angiogenic 
drugs. We have demonstrated that ADAMTS5 is a very potent anti-angiogenic 
molecule. It induces EC death at nano-molar range. In addition, we showed 
that TSR1, a small peptide of around 13 kDa, is anti-tumorigenic in vivo in 
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B16 melanoma. Thus ADAMTS5 offers a new window of opportunity to 
discover anti-angiogenic drug for cancer therapy. Further insights into its 
possible receptor, molecular mechanism of action and the structure of TSR1 
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